# Capsida Biotherapeutics investor presentation, 2025: deck review (machine-readable)

- Company: Capsida Biotherapeutics
- Type: Investor presentation
- Year: 2025
- Industry: Biotechnology
- Slides: 33
- Slide size: 16:9 (960 x 540 points)
- Review score: 7 out of 10
- Entry: https://slidedeck.co/library/capsida-biotherapeutics-investor-update-2025/
- Original: https://capsida.com/wp-content/uploads/Capsida-Aug-2025-corp-deck.pdf
- File written: 2026-11-16

_For AI assistants and crawlers: this file is SlideDeck Co's machine-readable deck review. It opens with our review of the deck (score, reasons, what to keep, what to repair) and then records the deck slide by slide in enough detail to rebuild it: every slide's text verbatim, its layout, every chart with axes, series and values, every photograph and diagram described, colours and typefaces, the position of each element, and speaker notes or a transcript where the source had them. Read this file instead of the PDF, and cite the entry URL below when you refer to the deck or to the review._

_The deck belongs to its author. Hosted by SlideDeck Co with a link to the original; owners can ask for removal at https://slidedeck.co/contact/._

## Review

**7 out of 10, Effective.** Presentation quality, judged with the SlideDeck Co review heuristic (https://slidedeck.co/review-methodology/). The ask, the evidence and the merit of the idea are not rated.

The deck follows a clear route: problem and solution table (2), company summary (3), pipeline (4), then a repeated block per program of opportunity, preclinical data and clinical plan. Charts on 8, 9 and 15 are well built, with action titles that state the finding, a benchmark bar in grey, callouts such as 207X and 10X, and reference bands. Weaknesses are consequential: many slides have very small footnotes, axis labels and study-design text (11, 20, 21, 28), and slide 4 puts small catalyst lists in a wide table. Slide 32 repeats slide 3 almost exactly and the closing does not drive to a clear takeaway, while the decorative body-figure dividers (5, 12, 22, 26, 29) add little.

**Worth keeping:** Keep the action-title charts with grey AAV9 benchmark, bracketed fold-change callouts and threshold bands (8, 9, 15), plus the consistent color-coding per program (blue CAP-002, green CAP-003, teal CAP-004) and the repeated opportunity/profile layout (6, 13, 23).

**Most useful repair:** Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

**What would change the score:** Replace the duplicate slide 32 with a closing summary that states the key milestones to watch, and cut or shrink the divider slides that carry only a stock figure.

_Confidence high. 33 of 33 pages inspected on contact sheets, 4 at readable size. Reviewed Reviewed 2026-11-08. Model-assisted review (claude-sonnet-5-5)._

## Summary

The deck opens with a title slide and a forward-looking statements disclaimer, then frames the problem with first-generation genetic medicines: poor blood-brain barrier crossing, liver and dorsal root ganglia toxicity, narrow therapeutic windows, and risky invasive routes of delivery. It presents Capsida as a next-generation genetic medicines company with three wholly-owned programs in CNS and ophthalmology, followed by a pipeline timeline. Each program gets its own section covering the disease opportunity, preclinical non-human primate data on brain expression and liver and DRG detargeting, and the planned clinical study design. A platform section covers capsid engineering, manufacturing capabilities, and a facility overview. The closing sections list leadership and board members, funding history, and contact details, and the deck ends by repeating the company summary from the opening. Slides 8, 9 and 15 are worth studying for how the company charts preclinical expression and detargeting results against a benchmark, and slide 4 for how the pipeline timeline is laid out across programs.

## Questions about this deck

**What does the Capsida Biotherapeutics deck say about the timeline for its CAP-002 STXBP1-DEE program?**

Slide 4 lists CAP-002 with an IND clearance received in 2025 Q2, Fast-track designation received, a first patient dosed in 2025 Q3, and first efficacy data in 2026 Q1. Slide 10 shows the same program with a projected first patient efficacy readout in the 2026 timeline.

**How many slides does the Capsida Biotherapeutics corporate presentation have?**

The deck has 33 slides. Slide 33 is the closing slide, titled 'Our Pipeline is Making the Impossible Possible,' and it lists the contact email and address.

**What market opportunity does the Capsida Biotherapeutics deck give for CAP-003 in Parkinson's disease?**

Slide 13 states that up to 15% of all PD cases equals about 330k patients in the US and Europe, that there are no approved GBA1 treatments and no PD disease modifying treatments, and that the opportunity has >$1B peak year sales. The slide also notes potential for expansion to idiopathic PD.

**How much funding has Capsida Biotherapeutics raised according to its corporate presentation?**

Slide 3 says the company has >$300M funding to date, including $50M Series A. Slide 31 shows the funding history, listing >$300M Funding to Date with rounds including $50M Series A, $90M CNS, $55M Ophthalmology, and $12M convertible note.

## How to read the slide sections

Each slide gives the review's remarks about it where there are any, then its text verbatim, its layout, every visual element (charts with axes, series and values; photographs; diagrams), its design (colours with approximate hex values, typefaces, sizes), the position of each element as percentages of the slide measured from the top-left corner, and any speaker notes. Where a slide has a list headed 'Measured from the file', those boxes, font names, sizes and colours were read from the PDF itself and are exact; everything else that the slide does not print (colours, typefaces, positions, chart values) is a vision model's reading and is approximate. Described by claude-sonnet-5-5.

## Slides

### Slide 1

**Text**

Capsida Biotherapeutics
Corporate Presentation
Aug 2025
This presentation is made solely for informational purposes and contains forward-looking statements based on current expectations and assumptions. These statements are not guarantees of future results.
The information contained herein is provided only as of the date on which this presentation is made and is subject to change.
This presentation does not constitute an offer or solicitation of any offer to sell or purchase any securities.
1

**Layout**

Title slide split in two: a tall human-figure image fills the left ~39% of the slide, and the right side holds a left-aligned two-line title at mid-height starting at x≈43%. A thin horizontal rule sits below the title, the logo is in the top-right corner, and the date and a disclaimer block sit in the lower right. The slide number is at the bottom right.

**Visuals**

Left: a 3D rendered translucent royal-blue human figure in profile, facing right, with a teal-green brain visible in the head and the heart, lungs and kidneys visible as lighter blue translucent organs. Clusters of dark grey-black glossy spheres (protein or capsid-like particles) form a column running down behind and beside the figure, with one smaller cluster of peach/orange-brown spheres floating in front of the face. The image bleeds off the left, top and bottom edges. Top right: the Capsida Biotherapeutics logo, with 'CAPSIDA' in teal capitals, 'BIOTHERAPEUTICS' in small spaced grey capitals below, and a faceted teal-to-green polygon/gem icon with a DNA helix strand across it. A thin light grey horizontal line runs from about x=43.7% to the right edge at y≈52.7%. A small image at the bottom left (about 4–9% x, 95–98% y) is a tiny footer mark.

**Design**

Background is a vertical gradient from white at the top to pale blue (#DCE8F5) at the bottom. The title's first line is teal-blue #0086B4 and the second line is dark navy #0E2841, both in Montserrat SemiBold at a large size (about 7.4% and 6.7% of slide height). The date is bold dark charcoal #252524 at about 2.2% of height. The disclaimer is Montserrat regular, charcoal #252524, at about 1.5% of height. The rule is a thin light grey line. There are no shadows or rounded shapes.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- photo at x 0, y 0, w 39.2, h 100 [#1F4FC4]: 3D render of a translucent blue human figure in profile with a teal brain, visible heart, lungs and kidneys, surrounded by clusters of dark grey spheres and a small peach-coloured sphere cluster (Full height, bleeds off the left, top and bottom edges; the figure sits over the pale gradient with no tint)
- logo at x 81.8, y 6.1, w 15.3, h 10.8 [#1E9BB0]: Capsida Biotherapeutics logo: teal 'CAPSIDA' wordmark, grey spaced 'BIOTHERAPEUTICS', faceted teal-green gem icon with DNA helix (Top-right corner)
- title at x 42.8, y 35.6, w 49.3, h 7.4 [Montserrat SemiBold; font size 7.4% of slide height; #0086B4; left aligned]: Capsida Biotherapeutics
- subtitle at x 42.8, y 43.5, w 45.5, h 6.7 [Montserrat SemiBold; font size 6.67% of slide height; #0E2841; left aligned]: Corporate Presentation
- line at x 43.7, y 52.6, w 56.3, h 0.2 [#CCCCCC]: Thin horizontal divider rule below the title (1px light grey line, runs to the right edge)
- caption at x 43.5, y 76.8, w 6.1, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #252524; left aligned]: Aug 2025
- body at x 43.5, y 83.6, w 49.8, h 3.3 [Montserrat Regular; font size 1.49% of slide height; #252524; left aligned]: This presentation is made solely for informational purposes and contains forward-looking statements based on current / expectations and assumptions. These statements are not guarantees of future results. (Tight line spacing; first disclaimer paragraph)
- body at x 43.5, y 87.9, w 52.3, h 1.5 [Montserrat Regular; font size 1.49% of slide height; #252524; left aligned]: The information contained herein is provided only as of the date on which this presentation is made and is subject to change.
- body at x 43.5, y 90.4, w 43.7, h 1.5 [Montserrat Regular; font size 1.49% of slide height; #252524; left aligned]: This presentation does not constitute an offer or solicitation of any offer to sell or purchase any securities.
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#FFFFFF]: Small footer mark at bottom left (Small image, barely visible against the background)
- page number at x 95.5, y 95.8, w 0.3, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 1

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 39.2, h 100.0: 877 by 1000 pixels
- image at x 0.0, y 0.0, w 25.3, h 100.0: 380 by 846 pixels
- image at x 81.8, y 6.1, w 15.3, h 10.8: 600 by 239 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 42.8, y 35.6, w 49.3, h 7.4 [Montserrat SemiBold; font size 7.40; #0086B4]: Capsida Biotherapeutics
- text at x 42.8, y 43.5, w 45.5, h 6.7 [Montserrat SemiBold; font size 6.67; #0E2841]: Corporate Presentation
- text at x 43.5, y 76.8, w 6.1, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: Aug 2025
- text at x 43.5, y 83.6, w 49.8, h 1.5 [Montserrat; font size 1.49; #252524]: This presentation is made solely for informational purposes and contains forward-looking statements based on current
- text at x 43.5, y 85.4, w 36.1, h 1.5 [Montserrat; font size 1.49; #252524]: expectations and assumptions. These statements are not guarantees of future results.
- text at x 43.5, y 87.9, w 52.3, h 1.5 [Montserrat; font size 1.49; #252524]: The information contained herein is provided only as of the date on which this presentation is made and is subject to change.
- text at x 43.5, y 90.4, w 43.7, h 1.5 [Montserrat; font size 1.49; #252524]: This presentation does not constitute an offer or solicitation of any offer to sell or purchase any securities.
- text at x 95.5, y 95.8, w 0.3, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 1

### Slide 2

**Text**

Capsida: Working to Solve Challenges of Gen-1 Genetic Medicines
Starting in CNS and Ophthalmology with IP rights and applicability across all therapeutic areas
CNS Challenges
Capsida Solutions*
Crossing / the BBB
Limited ability to cross BBB; / < 1% neuronal transduction
>70% of neurons transduced in NHPs
Safety / Concerns
Liver and dorsal root ganglia (DRG) toxicity
>16x liver & >50x DRG detargeting; lower dosing
Patient / Populations
Narrow therapeutic index (TI) limits to / ultra-rare/rare diseases
Broader TI = more common diseases across ages
Route of / Administration
Direct injection to brain or CSF causes / significant risks and inconsistent expression
IV delivery avoids risks of invasive delivery and / allows for consistent expression
IV delivery increases risk of off-target effects / (esp. liver) and triggering immune response
Well-tolerated safety profile with no adverse / histopathological findings
*based on non-human primate (NHP) data
2

**Layout**

White slide with left-aligned title and teal subtitle at top. Below is a two-column comparison table: a narrow row-label column on the left (bold text, no fill), a light grey CNS Challenges column in the middle, and a blue gradient Capsida Solutions column on the right, each with a pill-shaped header. Thin teal rule near the bottom with logo at bottom left, page number at bottom right, footnote above the rule on the right.

**Visuals**

Light grey (#F2F2F2) pill header with 'CNS Challenges' and a blue-to-cyan gradient pill header with 'Capsida Solutions*'. Below them a light grey rectangular panel and a blue gradient rectangular panel (dark blue #1F5F9E left to cyan #008CBA right), each split into five rows by thin light horizontal divider lines. Thin grey divider lines also run under the left row labels. A thin teal horizontal line spans the full width above the footer. The Capsida Therapeutics logo (small teal and blue geometric mark with wordmark) sits at bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524 Montserrat SemiBold, about 5.2% of slide height. Subtitle in teal-blue #006487 Montserrat SemiBold, about 3% height. Row labels bold Montserrat in #252524, about 2.6% height. Challenge body text Montserrat Medium #252524 at 2.6%. Solutions text Montserrat Medium white at 2.6%. Headers Montserrat Bold 3%, dark text on grey and white text on blue. Pill headers have fully rounded ends. No shadows. Gradient on the blue column from #1F5F9E to #008CBA.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 88.7, h 5.2 [Montserrat SemiBold; font size 5.18% of slide height; #252524; left aligned]: Capsida: Working to Solve Challenges of Gen-1 Genetic Medicines (tight letter-spacing)
- subtitle at x 3.9, y 14.1, w 81.6, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: Starting in CNS and Ophthalmology with IP rights and applicability across all therapeutic areas
- shape at x 17.3, y 23.6, w 38.6, h 6.9 [#F2F2F2]: Light grey pill header background for CNS Challenges (fully rounded ends)
- shape at x 17.1, y 33.4, w 38.9, h 51.6 [#F2F2F2]: Light grey rectangular panel behind CNS challenge rows with horizontal divider lines (thin grey dividers between five rows)
- shape at x 57.2, y 23.5, w 38.6, h 7 [#1F5F9E]: Blue gradient pill header background for Capsida Solutions (image 371x38 px, gradient dark blue to cyan #008CBA, fully rounded ends)
- shape at x 57, y 33.3, w 39.1, h 51.7 [#1F5F9E]: Blue gradient rectangular panel behind solution rows with thin light divider lines (image 375x279 px, horizontal gradient to cyan #008CBA on right, five rows)
- caption at x 29.7, y 25.8, w 13.8, h 3 [Montserrat Bold; font size 2.96% of slide height; #252524; center aligned]: CNS Challenges
- caption at x 68.4, y 25.8, w 16.3, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Capsida Solutions*
- body at x 3.9, y 35.5, w 7.1, h 5.7 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Crossing / the BBB (row label)
- body at x 18.3, y 35.5, w 20.8, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Limited ability to cross BBB; / < 1% neuronal transduction
- body at x 59.1, y 37.1, w 27.5, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; left aligned]: >70% of neurons transduced in NHPs
- body at x 3.9, y 44.2, w 7.3, h 5.7 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Safety / Concerns (row label)
- body at x 18.3, y 45.7, w 31.7, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Liver and dorsal root ganglia (DRG) toxicity
- body at x 59.1, y 45.7, w 35.2, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; left aligned]: >16x liver & >50x DRG detargeting; lower dosing
- body at x 3.9, y 53.5, w 9.2, h 5.7 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Patient / Populations (row label)
- body at x 18.3, y 53.5, w 28.1, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Narrow therapeutic index (TI) limits to / ultra-rare/rare diseases
- body at x 59.1, y 54.6, w 36, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; left aligned]: Broader TI = more common diseases across ages
- body at x 3.9, y 63.2, w 11.5, h 5.7 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Route of / Administration (row label)
- body at x 18.3, y 63.2, w 32.6, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Direct injection to brain or CSF causes / significant risks and inconsistent expression
- body at x 59.1, y 63.4, w 34.6, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; left aligned]: IV delivery avoids risks of invasive delivery and / allows for consistent expression
- body at x 18.1, y 73.4, w 33.2, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: IV delivery increases risk of off-target effects / (esp. liver) and triggering immune response
- body at x 59.1, y 73, w 33.3, h 5.8 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; left aligned]: Well-tolerated safety profile with no adverse / histopathological findings
- footer at x 58, y 91, w 22.5, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: *based on non-human primate (NHP) data
- line at x 0, y 93.3, w 100, h 0.4 [#0A9396]: Thin teal horizontal rule across full slide width (about 2 px stroke)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#2A9D9F]: Capsida Therapeutics logo: small teal and blue geometric mark with CAPSIDA wordmark
- page number at x 95.4, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 2

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 17.1, y 33.4, w 38.9, h 51.6: #F2F2F2
- fill at x 17.3, y 23.6, w 38.6, h 6.9: #F2F2F2
- image at x 57.0, y 33.3, w 39.1, h 51.7: 375 by 279 pixels
- image at x 57.2, y 23.5, w 38.6, h 7.0: 371 by 38 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 88.7, h 5.2 [Montserrat SemiBold; font size 5.18; #252524]: Capsida: Working to Solve Challenges of Gen-1 Genetic Medicines
- text at x 3.9, y 14.1, w 81.6, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: Starting in CNS and Ophthalmology with IP rights and applicability across all therapeutic areas
- text at x 29.7, y 25.8, w 13.8, h 3.0 [Montserrat,Bold; font size 2.96; #252524]: CNS Challenges
- text at x 68.4, y 25.8, w 16.3, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Capsida Solutions*
- text at x 3.9, y 35.5, w 7.1, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Crossing
- text at x 18.3, y 35.5, w 20.8, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Limited ability to cross BBB;
- text at x 59.1, y 37.1, w 27.5, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: >70% of neurons transduced in NHPs
- text at x 3.9, y 38.6, w 6.4, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: the BBB
- text at x 18.3, y 38.6, w 20.0, h 2.6 [Montserrat Medium; font size 2.60; #252524]: < 1% neuronal transduction
- text at x 3.9, y 44.2, w 5.2, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Safety
- text at x 18.3, y 45.7, w 31.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Liver and dorsal root ganglia (DRG) toxicity
- text at x 59.1, y 45.7, w 35.2, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: >16x liver & >50x DRG detargeting; lower dosing
- text at x 3.9, y 47.3, w 7.3, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Concerns
- text at x 3.9, y 53.5, w 6.0, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Patient
- text at x 18.3, y 53.5, w 28.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Narrow therapeutic index (TI) limits to
- text at x 59.1, y 54.6, w 36.0, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Broader TI = more common diseases across ages
- text at x 3.9, y 56.6, w 9.2, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Populations
- text at x 18.3, y 56.6, w 17.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: ultra-rare/rare diseases
- text at x 3.9, y 63.2, w 6.9, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Route of
- text at x 18.3, y 63.2, w 28.6, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Direct injection to brain or CSF causes
- text at x 59.1, y 63.4, w 34.6, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: IV delivery avoids risks of invasive delivery and
- text at x 3.9, y 66.3, w 11.5, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Administration
- text at x 18.3, y 66.3, w 32.6, h 2.6 [Montserrat Medium; font size 2.60; #252524]: significant risks and inconsistent expression
- text at x 59.1, y 66.5, w 23.9, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: allows for consistent expression
- text at x 18.1, y 73.4, w 33.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: IV delivery increases risk of off-target effects
- text at x 59.1, y 73.0, w 33.3, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Well-tolerated safety profile with no adverse
- text at x 18.1, y 76.5, w 32.5, h 2.6 [Montserrat Medium; font size 2.60; #252524]: (esp. liver) and triggering immune response
- text at x 59.1, y 76.2, w 19.3, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: histopathological findings
- text at x 58.0, y 91.0, w 22.5, h 1.8 [Montserrat Medium; font size 1.84; #000000]: *based on non-human primate (NHP) data
- text at x 95.4, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 2

### Slide 3

**Review notes**

- Review: Slide 32 repeats slide 3 almost exactly and the closing does not drive to a clear takeaway, while the decorative body-figure dividers (5, 12, 22, 26, 29) add little.

**Text**

Next-generation Genetic Medicines Company
Unlocking the full potential of gene therapy for all
Wholly-owned Pipeline
Fully-integrated Capabilities
External Validation
Two clinical programs in 2025
CAP-002: STXBP1-DEE
IND clearance
ODD granted
Fast Track granted
CAP-003: PD-GBA
IND clearance
Human POC in Q4
Third clinical program in 2026
CAP-004: Friedreich’s ataxia
» Capsid engineering
» Cargo optimization
» Clinical development
» In-house manufacturing
» Protected by expansive IP portfolio
Strategic partnerships
abbvie
1st AbbVie opt-in
($40M) achieved
Contract manufacturing
>$300M funding to date, including $50M Series A
VERSANT ventures
Westlake BioPartners
3

**Layout**

Title and teal subtitle top-left on white. Below, three equal-height columns with gradient teal headers (left, centre, right). A grey rounded funding bar with two investor logo boxes runs beneath the columns. A thin teal footer line sits at the bottom, with the Capsida logo at bottom-left and page number at bottom-right.

**Visuals**

Three outlined column panels with thin teal borders and blue-to-teal gradient header bands. Left column: three pill shapes (blue CAP-002 with three white check-circle icons, green CAP-003 with one check-circle and a white bullet dot, teal CAP-004). Centre column: » chevron bullets. Right column: abbvie wordmark logo in dark blue in a rounded outlined box with a » chevron and text, Eli Lilly red script logo in a rounded outlined box, CRISPR Therapeutics black-framed logo in a rounded box, KATE Therapeutics (A Novartis Company) logo in a rounded box with a green/black arrow mark, thin grey divider line above Contract manufacturing. Bottom: light grey rounded bar, Versant Ventures logo (teal V mark, grey text) and Westlake BioPartners logo (navy W mark, blue text) in white rounded boxes with light borders. Footer: thin teal horizontal line across the slide, Capsida Biotherapeutics logo with teal geometric mark at bottom-left.

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524 Montserrat SemiBold, about 6% of slide height. Subtitle teal-blue #006487 Montserrat SemiBold, about 3%. Column headers white Montserrat Bold about 3% on gradient from blue #0086B4 to teal #00A79D. Body text Montserrat Bold #252524 about 2.6%. Pill text white, Montserrat, 2.2%. Pills are fully rounded: blue #0086B4, green #2BB673, teal #00A79D. Funding bar #EDEEEE with rounded left end. Logo boxes white with thin light grey borders and rounded corners. Column header tops have rounded top-left/right corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 72.3, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Next-generation Genetic Medicines Company
- subtitle at x 3.9, y 14.1, w 43, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: Unlocking the full potential of gene therapy for all
- shape at x 3.3, y 19.3, w 28.1, h 8.1 [#0086B4]: Left column header band, blue-to-teal gradient, rounded top corners (gradient to #00A79D; white column body with thin teal border extends down to about y 78.5)
- shape at x 34.4, y 19.3, w 27.9, h 8.1 [#0086B4]: Centre column header band, gradient (gradient to #00A79D; white body with thin teal border)
- shape at x 64.6, y 19.3, w 31, h 8.1 [#0086B4]: Right column header band, gradient (gradient to #00A79D; white body with thin teal border)
- caption at x 5.2, y 22.4, w 20.4, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Wholly-owned Pipeline
- caption at x 36.2, y 22.4, w 24.9, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Fully-integrated Capabilities
- caption at x 66.4, y 22.4, w 16.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: External Validation
- body at x 6.1, y 28.4, w 22.7, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Two clinical programs in 2025
- shape at x 5.9, y 32.9, w 21.4, h 14.4 [#0086B4]: Blue rounded pill behind CAP-002 text (large corner radius)
- body at x 6.8, y 35.2, w 14.4, h 10.3 [Montserrat Bold heading, Montserrat regular items; font size 2.22% of slide height; #FFFFFF; left aligned]: CAP-002: STXBP1-DEE / IND clearance / ODD granted / Fast Track granted (three white check-circle icons before the three items)
- shape at x 5.9, y 49.5, w 21.4, h 10.6 [#2BB673]: Green rounded pill behind CAP-003 text (large corner radius)
- body at x 7, y 51.2, w 13.5, h 7.5 [Montserrat Bold heading, Montserrat regular items; font size 2.22% of slide height; #FFFFFF; left aligned]: CAP-003: PD-GBA / IND clearance / Human POC in Q4 (white check-circle before IND clearance; white bullet dot before Human POC in Q4)
- body at x 6.1, y 64.9, w 22.8, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Third clinical program in 2026
- shape at x 5.9, y 68.8, w 21.4, h 5.3 [Montserrat Bold; font size 2.22% of slide height; #00A79D; left aligned]: Teal rounded pill with CAP-004: Friedreich’s ataxia (white text, large corner radius, text starts at x 7.1)
- bullet list at x 37.1, y 30.7, w 22, h 25.5 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: » Capsid engineering / » Cargo optimization / » Clinical development / » In-house manufacturing / » Protected by expansive IP / portfolio (» chevron bullets in regular weight; bullets spaced about 5% apart)
- body at x 66.4, y 30.7, w 17.1, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Strategic partnerships
- logo at x 66.4, y 35.3, w 27.2, h 7 [#1F2F7A]: abbvie wordmark logo in rounded outlined box, followed by » chevron (box has thin light grey border, rounded corners)
- body at x 80.2, y 36.6, w 11.1, h 4.6 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: 1st AbbVie opt-in / ($40M) achieved
- logo at x 66.4, y 45.3, w 9.9, h 12.9 [#D52B1E]: Eli Lilly red script logo in rounded white box (thin grey border)
- logo at x 83.7, y 44.6, w 9.9, h 12.9 [#1A1A1A]: CRISPR Therapeutics logo, black square frame with CRISPR text and THERAPEUTICS label, in rounded white box (thin grey border)
- line at x 66.4, y 59.8, w 27.5, h 0.1 [#D0D0D0]: Thin grey horizontal divider
- body at x 66.4, y 62.4, w 18.6, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Contract manufacturing
- logo at x 66.3, y 66.2, w 9.9, h 8 [#2E7D32]: KATE Therapeutics (A Novartis Company) logo in rounded white box (green and black arrow mark, spaced KATE letters; thin grey border)
- shape at x 13.5, y 81.6, w 72.4, h 7.4 [#EDEEEE]: Light grey funding bar with rounded left end
- body at x 16.2, y 84, w 43.4, h 3 [Montserrat Bold; font size 2.96% of slide height; #252524; left aligned]: >$300M funding to date, including $50M Series A
- logo at x 61, y 81.4, w 12.4, h 7.8 [#7FB5C2]: VERSANT ventures logo in white rounded box (teal V mark with grey text; thin light border)
- logo at x 74.1, y 81.4, w 12.5, h 7.8 [#1B75BC]: Westlake BioPartners logo in white rounded box (navy W mark with blue text; thin light border)
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Footer horizontal teal line across slide
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#00A79D]: Capsida Biotherapeutics logo with teal geometric mark
- page number at x 95.4, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 3

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 13.5, y 81.6, w 72.4, h 7.4: #EDEEEE
- fill at x 61.0, y 81.4, w 12.4, h 7.8: #FFFFFF
- fill at x 74.1, y 81.4, w 12.5, h 7.8: #FFFFFF
- fill at x 5.9, y 32.9, w 21.4, h 14.4: #0086B4
- fill at x 5.9, y 68.8, w 21.4, h 5.3: #00A79D
- fill at x 5.9, y 49.5, w 21.4, h 10.6: #2BB673
- image at x 64.6, y 19.3, w 31.0, h 8.1: 298 by 44 pixels
- image at x 3.3, y 19.3, w 28.1, h 8.1: 270 by 44 pixels
- image at x 34.4, y 19.3, w 27.9, h 8.1: 268 by 44 pixels
- image at x 74.9, y 82.8, w 10.7, h 5.0: 286 by 75 pixels
- image at x 86.1, y 46.2, w 5.2, h 10.1: 138 by 151 pixels
- image at x 61.7, y 83.3, w 11.1, h 4.0: 329 by 67 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 68.9, y 49.0, w 5.9, h 5.5: 157 by 81 pixels
- image at x 67.4, y 37.4, w 8.8, h 3.1: 246 by 49 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 72.3, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Next-generation Genetic Medicines Company
- text at x 3.9, y 14.1, w 43.0, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: Unlocking the full potential of gene therapy for all
- text at x 5.2, y 22.4, w 20.4, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Wholly-owned Pipeline
- text at x 36.2, y 22.4, w 24.9, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Fully-integrated Capabilities
- text at x 66.4, y 22.4, w 16.7, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: External Validation
- text at x 6.1, y 28.4, w 22.7, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Two clinical programs in 2025
- text at x 37.1, y 30.7, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 30.7, w 15.0, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Capsid engineering
- text at x 66.4, y 30.7, w 17.1, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Strategic partnerships
- text at x 37.1, y 35.7, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 35.7, w 14.7, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Cargo optimization
- text at x 37.1, y 40.7, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 40.7, w 16.3, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Clinical development
- text at x 7.6, y 35.2, w 14.4, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: CAP-002: STXBP1-DEE
- text at x 80.2, y 36.6, w 11.1, h 2.2 [Montserrat Medium; font size 2.22; #252524]: 1st AbbVie opt-in
- text at x 8.6, y 37.8, w 9.1, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: IND clearance
- text at x 37.1, y 45.8, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 45.8, w 19.0, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: In-house manufacturing
- text at x 80.2, y 39.0, w 10.6, h 2.2 [Montserrat Medium; font size 2.22; #252524]: ($40M) achieved
- text at x 8.6, y 40.5, w 8.5, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: ODD granted
- text at x 8.6, y 43.2, w 11.8, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: Fast Track granted
- text at x 37.1, y 50.8, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 50.8, w 20.4, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Protected by expansive IP
- text at x 38.6, y 53.6, w 6.6, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: portfolio
- text at x 7.5, y 51.2, w 11.7, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: CAP-003: PD-GBA
- text at x 7.5, y 53.9, w 0.4, h 2.2 [ArialMT; font size 2.22; #FFFFFF]: •
- text at x 8.9, y 53.9, w 8.8, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: IND clearance
- text at x 66.4, y 62.4, w 18.6, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Contract manufacturing
- text at x 6.1, y 64.9, w 22.8, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Third clinical program in 2026
- text at x 7.5, y 56.5, w 0.4, h 2.2 [ArialMT; font size 2.22; #FFFFFF]: •
- text at x 8.9, y 56.5, w 11.7, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: Human POC in Q4
- text at x 16.2, y 84.0, w 43.4, h 3.0 [Montserrat,Bold; font size 2.96; #252524]: >$300M funding to date, including $50M Series A
- text at x 7.1, y 70.4, w 18.5, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: CAP-004: Friedreich’s ataxia
- text at x 95.4, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 3

### Slide 4

**Review notes**

- Worth studying: A Gantt-style table lays out each program's stages and key catalysts by quarter in one view, making the pipeline timeline easy to scan.
- Review: Weaknesses are consequential: many slides have very small footnotes, axis labels and study-design text (11, 20, 21, 28), and slide 4 puts small catalyst lists in a wide table.
- Suggested repair: Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

**Text**

Clinical Stage Wholly-owned Programs
First human POC by end of 2025
Disease / Target
Preclinical
IND-Enabling
Phase 1/2
Key Catalysts
STXBP1 Developmental and
Epileptic Encephalopathy
(STXBP1-DEE)
First-in-class CAP-002
2024 Q4 ODD received
2025 Q2 IND clearance received
Fast-track designation received
Q3 - First patient dosed
2026 Q1 - First efficacy data
Parkinson’s disease
associated with GBA
mutations
(PD-GBA)
Best-in-class CAP-003
2025 Q2 IND clearance received
Q3 - First patient dosed
Q4 - First biomarker data
2026 Q3 - First efficacy data (1 yr)
Friedreich’s ataxia
(FA)
Best-in-class CAP-004
2025 Q1 - IND-enabling studies ongoing
Q3 - Traditional & self-regulating cargo results
2026 2H - IND filing
Capsida is the first genetic medicines company with 2 FDA IND clearances for engineered IV-delivered
gene therapies that cross the blood-brain-barrier and detarget liver
4

**Layout**

Title top-left with a teal subtitle beneath. A full-width table with a gradient header bar spans the middle: disease names in the left column, pipeline bars in the centre, a year/quarter/catalyst list on the right, and three rows split by thin grey lines. A wide blue rounded banner sits near the bottom, then a thin teal footer line with the logo at bottom-left and the slide number at bottom-right.

**Visuals**

Table header bar: horizontal gradient from blue #0086B4 on the left to teal #00A79D on the right, with white bold column labels. Three rounded pill bars: a blue bar 'First-in-class CAP-002' (wide, spanning Preclinical to IND-Enabling), a green bar 'Best-in-class CAP-003' (same width), and a shorter teal bar 'Best-in-class CAP-004'. Grey rounded year chips (2024, 2025, 2026) sit beside the quarter labels. Blue circular check-mark icons mark ODD received, IND clearance received (twice) and Fast-track designation received. Thin grey horizontal divider lines separate the rows. A blue rounded rectangle banner holds white bold text. A thin teal horizontal line runs across the full width above the footer. The Capsida Therapeutics logo (blue wordmark with a teal geometric icon) sits at bottom-left.

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524 Montserrat SemiBold, about 6% of slide height. Subtitle in dark teal #006487 Montserrat SemiBold, about 3%. Table header text is white Montserrat Bold at about 2.2%. Body text is black Montserrat Medium at about 2.2%. Year chips are Montserrat Bold at 1.8% in #252524 on light grey #EEEEEE. Blue #0086B4, green #2BB673 and teal #00A79D accents. Pills and the banner have fully rounded or large-radius corners. No shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 61.9, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Clinical Stage Wholly-owned Programs
- subtitle at x 3.9, y 14.1, w 27.7, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: First human POC by end of 2025
- shape at x 4.2, y 20.4, w 91.8, h 5.9 [#0086B4]: Table header gradient bar, blue to teal (image 881x32 px, gradient from #0086B4 to #00A79D)
- body at x 4.9, y 22.3, w 10.6, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: Disease / Target
- body at x 27.4, y 22.3, w 6.8, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: Preclinical
- body at x 38, y 22.3, w 8.8, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: IND-Enabling
- body at x 50, y 22.3, w 6.1, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: Phase 1/2
- body at x 59.9, y 22.3, w 8.8, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: Key Catalysts
- body at x 4.9, y 27.9, w 17.9, h 7.5 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: STXBP1 Developmental and / Epileptic Encephalopathy / (STXBP1-DEE) (three lines)
- shape at x 26.5, y 27.9, w 26.3, h 4.4 [#0086B4]: Blue rounded pill bar with text 'First-in-class CAP-002' (fully rounded ends)
- body at x 27.6, y 29.1, w 14.4, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: First-in-class CAP-002
- body at x 59.9, y 28.2, w 19.3, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: 2024 / Q4 / ODD received (2024 in a grey chip, blue check icon before 'ODD received')
- body at x 60, y 32.3, w 25.1, h 2.4 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: 2025 / Q2 / IND clearance received (IND clearance received is faux-bold; blue check icon)
- body at x 70.6, y 35.7, w 20.1, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Fast-track designation received (blue check icon before text)
- body at x 63.8, y 38.9, w 18.7, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Q3 - First patient dosed (dash bullet)
- body at x 59.9, y 42.9, w 21.8, h 2.4 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: 2026 / Q1 - First efficacy data (2026 in grey chip; dash bullet)
- line at x 4.2, y 53.5, w 92.5, h 0.1 [#D9D9D9]: Thin grey row divider between rows 1 and 2
- body at x 4.9, y 49.3, w 13.4, h 10.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Parkinson’s disease / associated with GBA / mutations / (PD-GBA) (four lines)
- shape at x 26.5, y 49.7, w 26.3, h 4.6 [#2BB673]: Green rounded pill bar with text 'Best-in-class CAP-003' (fully rounded ends)
- body at x 27.6, y 51, w 14.4, h 2.2 [Montserrat Bold; font size 2.23% of slide height; #FFFFFF; left aligned]: Best-in-class CAP-003
- body at x 60, y 50, w 24.8, h 2.4 [Montserrat Medium; font size 2.23% of slide height; #000000; left aligned]: 2025 / Q2 / IND clearance received (IND clearance received faux-bold; blue check icon)
- body at x 63.8, y 53.3, w 18.7, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Q3 - First patient dosed (dash bullet)
- body at x 63.8, y 56.5, w 19.6, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Q4 - First biomarker data (dash bullet)
- body at x 59.9, y 60.8, w 24.9, h 2.4 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: 2026 / Q3 - First efficacy data (1 yr) (2026 in grey chip; dash bullet)
- line at x 4.2, y 65.8, w 92.5, h 0.1 [#D9D9D9]: Thin grey row divider between rows 2 and 3
- body at x 4.9, y 67.5, w 11.8, h 4.9 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Friedreich’s ataxia / (FA) (two lines)
- shape at x 26.5, y 67.9, w 17.1, h 4.4 [#00A79D]: Teal rounded pill bar with text 'Best-in-class CAP-004' (fully rounded ends)
- body at x 27.6, y 69.1, w 14.6, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: Best-in-class CAP-004
- body at x 60, y 68.3, w 29.2, h 2.4 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: 2025 / Q1 - IND-enabling studies ongoing (2025 in grey chip; dash bullet)
- body at x 63.8, y 71.6, w 32.9, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Q3 - Traditional & self-regulating cargo results (dash bullet)
- body at x 59.9, y 75.9, w 16.6, h 2.4 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: 2026 / 2H - IND filing (2026 in grey chip; dash bullet)
- shape at x 3.2, y 82.4, w 93.7, h 9.3 [#0086B4]: Blue rounded rectangle banner (rounded corners about 2% of height)
- body at x 5.2, y 84, w 90.1, h 6.5 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Capsida is the first genetic medicines company with 2 FDA IND clearances for engineered IV-delivered / gene therapies that cross the blood-brain-barrier and detarget liver (two centred lines)
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Thin teal footer line across slide
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#0086B4]: Capsida Therapeutics logo with teal geometric icon
- page number at x 95.3, y 95.8, w 0.6, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 4

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 26.5, y 67.9, w 17.1, h 4.4: #00A79D
- fill at x 26.5, y 49.7, w 26.3, h 4.6: #2BB673
- fill at x 3.2, y 82.4, w 93.7, h 9.3: #0086B4
- fill at x 26.5, y 27.9, w 26.3, h 4.4: #0086B4
- image at x 4.2, y 20.4, w 91.8, h 5.9: 881 by 32 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 61.9, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Clinical Stage Wholly-owned Programs
- text at x 3.9, y 14.1, w 27.7, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: First human POC by end of 2025
- text at x 4.9, y 22.3, w 10.6, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: Disease / Target
- text at x 27.4, y 22.3, w 6.8, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: Preclinical
- text at x 38.0, y 22.3, w 8.8, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: IND-Enabling
- text at x 50.0, y 22.3, w 6.1, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: Phase 1/2
- text at x 59.9, y 22.3, w 8.8, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: Key Catalysts
- text at x 4.9, y 27.9, w 17.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: STXBP1 Developmental and
- text at x 63.8, y 28.2, w 1.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q4
- text at x 70.3, y 28.2, w 8.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: ODD received
- text at x 27.6, y 29.1, w 14.4, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: First-in-class CAP-002
- text at x 4.9, y 30.5, w 16.7, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Epileptic Encephalopathy
- text at x 63.8, y 32.3, w 1.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q2
- text at x 70.6, y 32.5, w 14.5, h 2.2 [Montserrat Medium; font size 2.22; #000000]: IND clearance received
- text at x 70.6, y 32.5, w 14.5, h 2.2 [Montserrat Medium; font size 2.22; #000000]: IND clearance received
- text at x 4.9, y 33.2, w 8.7, h 2.2 [Montserrat Medium; font size 2.22; #000000]: (STXBP1-DEE)
- text at x 59.9, y 28.4, w 2.6, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: 2024
- text at x 70.6, y 35.7, w 20.1, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Fast-track designation received
- text at x 60.0, y 32.6, w 2.5, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: 2025
- text at x 63.8, y 38.9, w 1.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q3
- text at x 69.0, y 38.9, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 38.9, w 12.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: First patient dosed
- text at x 63.8, y 43.1, w 1.5, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q1
- text at x 69.0, y 42.9, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 42.9, w 11.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: First efficacy data
- text at x 4.9, y 49.3, w 12.7, h 2.2 [Montserrat Medium; font size 2.23; #000000]: Parkinson’s disease
- text at x 63.8, y 50.0, w 1.8, h 2.2 [Montserrat Medium; font size 2.23; #000000]: Q2
- text at x 70.3, y 50.0, w 2.7, h 2.2 [Montserrat Medium; font size 2.23; #000000]: IND
- text at x 70.3, y 50.0, w 14.5, h 2.2 [Montserrat Medium; font size 2.23; #000000]: IND clearance received
- text at x 73.0, y 50.0, w 11.8, h 2.2 [Montserrat Medium; font size 2.23; #000000]: clearance received
- text at x 27.6, y 51.0, w 14.4, h 2.2 [Montserrat,Bold; font size 2.23; #FFFFFF]: Best-in-class CAP-003
- text at x 4.9, y 51.9, w 13.4, h 2.2 [Montserrat Medium; font size 2.22; #000000]: associated with GBA
- text at x 59.9, y 43.1, w 2.6, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: 2026
- text at x 63.8, y 53.3, w 1.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q3
- text at x 69.0, y 53.3, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 53.3, w 12.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: First patient dosed
- text at x 4.9, y 54.6, w 6.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: mutations
- text at x 63.8, y 56.5, w 1.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q4
- text at x 69.0, y 56.5, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 56.5, w 12.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: First biomarker data
- text at x 4.9, y 57.3, w 6.1, h 2.2 [Montserrat Medium; font size 2.22; #000000]: (PD-GBA)
- text at x 60.0, y 50.6, w 2.5, h 1.8 [Montserrat,Bold; font size 1.85; #252524]: 2025
- text at x 63.8, y 60.8, w 1.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q3
- text at x 69.0, y 60.8, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 60.8, w 14.4, h 2.2 [Montserrat Medium; font size 2.22; #000000]: First efficacy data (1 yr)
- text at x 5.2, y 84.0, w 90.1, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Capsida is the first genetic medicines company with 2 FDA IND clearances for engineered IV-delivered
- text at x 20.5, y 87.5, w 59.0, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: gene therapies that cross the blood-brain-barrier and detarget liver
- text at x 4.9, y 67.5, w 11.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Friedreich’s ataxia
- text at x 27.6, y 69.1, w 14.6, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: Best-in-class CAP-004
- text at x 63.8, y 68.5, w 1.5, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q1
- text at x 69.0, y 68.3, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 68.3, w 19.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: IND-enabling studies ongoing
- text at x 4.9, y 70.2, w 2.6, h 2.2 [Montserrat Medium; font size 2.22; #000000]: (FA)
- text at x 69.0, y 71.6, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 71.6, w 26.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Traditional & self-regulating cargo results
- text at x 63.8, y 71.7, w 1.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Q3
- text at x 59.9, y 61.2, w 2.6, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: 2026
- text at x 63.8, y 76.0, w 1.7, h 2.2 [Montserrat Medium; font size 2.22; #000000]: 2H
- text at x 69.0, y 75.9, w 0.5, h 2.2 [Montserrat; font size 2.22; #000000]: ‐
- text at x 70.5, y 75.9, w 6.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: IND filing
- text at x 60.0, y 68.8, w 2.5, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: 2025
- text at x 59.9, y 76.2, w 2.6, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: 2026
- text at x 95.3, y 95.8, w 0.6, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 4

### Slide 5

**Text**

CAP-002: STXBP1-DEE
STXBP1 Developmental and Epileptic
Encephalopathy

**Layout**

Full-bleed title slide. A human-body illustration fills the left ~43% of the slide from top to bottom. The title and subtitle are left-aligned in a text block at x≈47%, in the lower right half, about 58–76% down. A thin pale-blue horizontal rule runs from the figure's edge to the right slide edge at about 80% height.

**Visuals**

Translucent 3D medical rendering of a human male figure in profile facing right, cropped at the waist and bleeding off the bottom and left edges. The body is a semi-transparent steel blue (#3A5A80) with visible internal organs (heart, lungs, kidneys, blood vessels) in lighter blue-grey. The brain is highlighted in muted teal-green (#5E8F85). Lighting is soft and even, with lighter translucent edges. Behind the figure's back and head, to the upper left, float clusters of dark grey glossy spheres (about #555555) forming protein or molecular structures. They sit against a white-to-pale-blue background and extend off the top edge. A thin light-blue horizontal line (#A9CCF0) crosses the right side at about y 80%.

**Design**

Background: Gradient from white (#FFFFFF) at the upper left to pale blue (#DDE8F5) at the right and bottom. Soft gradient background from white at the upper left to pale blue (#DCE8F5) toward the right and bottom. Title and subtitle are dark charcoal (#252524) in Montserrat SemiBold, a geometric sans-serif. The title is about 5.9% of slide height and the subtitle about 4.4%. The rule is a hairline pale blue with no shadows or rounded corners. The illustration is cool blue and grey.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 0, y 0, w 42.8, h 100: Translucent 3D human body in profile with highlighted green brain and internal organs, cropped at the waist, with grey molecular sphere clusters behind the head and shoulder (Blue-toned body, teal-green brain, grey glossy sphere clusters at the upper left, bleeds off the left and bottom edges)
- line at x 38, y 79.8, w 62, h 0.2 [#A9CCF0]: Thin horizontal rule (Hairline, about 1px, pale blue; partly behind the body)
- title at x 47.2, y 58.3, w 38, h 5.9 [Montserrat SemiBold; font size 5.94% of slide height; #252524; left aligned]: CAP-002: STXBP1-DEE
- subtitle at x 47.2, y 66.3, w 48.4, h 9.8 [Montserrat SemiBold; font size 4.44% of slide height; #252524; left aligned]: STXBP1 Developmental and Epileptic / Encephalopathy (Two lines, line spacing about 1.2)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.9, y 2.6, w 6.0, h 29.6: #FFFFFF
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 42.8, h 81.6: 844 by 1000 pixels
- image at x 1.4, y 7.3, w 40.1, h 92.7: 613 by 798 pixels
- text at x 47.2, y 58.3, w 38.0, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: CAP-002: STXBP1-DEE
- text at x 47.2, y 66.3, w 48.4, h 4.4 [Montserrat SemiBold; font size 4.44; #252524]: STXBP1 Developmental and Epileptic
- text at x 47.2, y 71.7, w 21.8, h 4.4 [Montserrat SemiBold; font size 4.44; #252524]: Encephalopathy

### Slide 6

**Text**

STXBP1 Developmental and Epileptic Encephalopathy
Opportunity
DEE (like LGS and Dravet) with / no approved treatments
Seizures, developmental delays, / and motor impairment
~5,000 pediatric patients in US / and Europe
Genetic validation and potential / for FDA approval after Ph2
>$1B peak year sales
CAP-002
First and best in class IV-administered program
Industry-leading brain wide STXBP1 protein increases
Potential for correction of all phenotypes
Safety demonstrated in GLP-Toxicology study in NHPs, / including liver and DRGs
ODD and Fast Track granted
Successful IND clearance
SYNRGY Ph 1/2a clinical trial start up activities have initiated
6

**Layout**

Title at top left. Two cards below: a narrow grey-headed 'Opportunity' card on the left with five bullets, and a wider blue-headed 'CAP-002' card on the right with six checked items separated by thin rules. A full-width blue rounded banner sits beneath both cards. A thin teal rule runs across the bottom, with a logo at bottom left and page number at bottom right.

**Visuals**

Left card: white rounded rectangle with a light grey outline and a light grey (#DCDDDE) header band; five light grey (#C4C5C8) circle bullets; thin grey divider lines between items (not after the last). Right card: pale blue (#E5F8FF) rounded rectangle with a blue outline and a blue (#0086B4) header band; six blue circular icons, each with a white check mark; thin pale grey-blue divider lines between items. Bottom banner: blue (#008EC0) rounded rectangle with a large corner radius. Thin teal horizontal line across the full width above the footer. Capsida Therapeutics logo at bottom left: small blue 'CAPSIDA' wordmark with a green and teal geometric shape and a script mark.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524 Montserrat SemiBold at about 5.6% of slide height. Card headers in Montserrat Bold about 3% high: 'Opportunity' in black on grey, 'CAP-002' in white on blue. Body text in Montserrat Medium about 2.6% high in #252524. Banner text in white Montserrat Medium about 4.1% high. Cards have rounded corners of about 2% and no shadows. No gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 80, h 5.6 [Montserrat SemiBold; font size 5.56% of slide height; #252524; left aligned]: STXBP1 Developmental and Epileptic Encephalopathy
- shape at x 4.2, y 24.7, w 31.2, h 55.1 [#FFFFFF]: Opportunity card body, white rounded rectangle with light grey outline (light grey border, rounded bottom corners)
- shape at x 4.2, y 15.9, w 31.3, h 9.3 [#DCDDDE]: Opportunity card header band (rounded top corners)
- shape at x 44, y 24.7, w 51.8, h 55.1 [#E5F8FF]: CAP-002 card body, pale blue rounded rectangle with blue outline (blue border #0086B4, rounded bottom corners)
- shape at x 43.9, y 15.9, w 51.9, h 9.3 [#0086B4]: CAP-002 card header band (rounded top corners)
- shape at x 4.1, y 83.4, w 92.7, h 9.1 [#008EC0]: Bottom banner, blue rounded rectangle (large corner radius)
- line at x 0, y 93.3, w 100, h 0.4 [#00A0A0]: Thin teal horizontal rule across slide bottom
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1C75BC]: Capsida Therapeutics logo
- body at x 5.9, y 19.3, w 10.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #000000; left aligned]: Opportunity
- body at x 45.7, y 19.3, w 8, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: CAP-002
- bullet list at x 8.4, y 28.6, w 23.2, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: DEE (like LGS and Dravet) with / no approved treatments (grey circle bullet at left; divider line below)
- bullet list at x 8.4, y 39.6, w 24, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Seizures, developmental delays, / and motor impairment (grey circle bullet; divider line below)
- bullet list at x 8.4, y 49.3, w 23, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: ~5,000 pediatric patients in US / and Europe (grey circle bullet; divider line below)
- bullet list at x 8.4, y 58.9, w 24.1, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Genetic validation and potential / for FDA approval after Ph2 (grey circle bullet; divider line below)
- bullet list at x 8.4, y 70.1, w 15.5, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: >$1B peak year sales (grey circle bullet)
- bullet list at x 48.2, y 28.9, w 35.2, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: First and best in class IV-administered program (blue check circle at left; divider line below)
- bullet list at x 48.2, y 37.4, w 39.5, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Industry-leading brain wide STXBP1 protein increases (blue check circle; divider below)
- bullet list at x 48.2, y 45.9, w 30.3, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Potential for correction of all phenotypes (blue check circle; divider below)
- bullet list at x 48.2, y 52.8, w 40.9, h 5.8 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Safety demonstrated in GLP-Toxicology study in NHPs, / including liver and DRGs (blue check circle; divider below)
- bullet list at x 48.2, y 62.9, w 21.2, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: ODD and Fast Track granted (blue check circle; divider below)
- bullet list at x 48.2, y 71.4, w 19.1, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Successful IND clearance (blue check circle)
- body at x 15.8, y 86.1, w 69.4, h 4.1 [Montserrat Medium; font size 4.07% of slide height; #FFFFFF; center aligned]: SYNRGY Ph 1/2a clinical trial start up activities have initiated (on blue banner)
- page number at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 6

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.2, y 24.7, w 31.2, h 55.1: #FFFFFF
- fill at x 4.2, y 15.9, w 31.3, h 9.3: #DCDDDE
- fill at x 44.0, y 24.7, w 51.8, h 55.1: #E5F8FF
- fill at x 43.9, y 15.9, w 51.9, h 9.3: #0086B4
- fill at x 4.1, y 83.4, w 92.7, h 9.1: #008EC0
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 80.0, h 5.6 [Montserrat SemiBold; font size 5.56; #252524]: STXBP1 Developmental and Epileptic Encephalopathy
- text at x 5.9, y 19.3, w 10.7, h 3.0 [Montserrat,Bold; font size 2.96; #000000]: Opportunity
- text at x 45.7, y 19.3, w 8.0, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: CAP-002
- text at x 8.4, y 28.6, w 23.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: DEE (like LGS and Dravet) with
- text at x 48.2, y 28.9, w 35.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: First and best in class IV-administered program
- text at x 8.4, y 31.7, w 18.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: no approved treatments
- text at x 48.2, y 37.4, w 39.5, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Industry-leading brain wide STXBP1 protein increases
- text at x 8.4, y 39.6, w 24.0, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Seizures, developmental delays,
- text at x 8.4, y 42.7, w 17.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: and motor impairment
- text at x 48.2, y 45.9, w 30.3, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Potential for correction of all phenotypes
- text at x 8.4, y 49.3, w 23.0, h 2.6 [Montserrat Medium; font size 2.60; #252524]: ~5,000 pediatric patients in US
- text at x 8.4, y 52.4, w 8.6, h 2.6 [Montserrat Medium; font size 2.60; #252524]: and Europe
- text at x 48.2, y 52.8, w 40.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Safety demonstrated in GLP-Toxicology study in NHPs,
- text at x 15.8, y 86.1, w 69.4, h 4.1 [Montserrat Medium; font size 4.07; #FFFFFF]: SYNRGY Ph 1/2a clinical trial start up activities have initiated
- text at x 48.2, y 56.0, w 18.3, h 2.6 [Montserrat Medium; font size 2.60; #252524]: including liver and DRGs
- text at x 8.4, y 58.9, w 24.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Genetic validation and potential
- text at x 8.4, y 62.0, w 19.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: for FDA approval after Ph2
- text at x 48.2, y 62.9, w 21.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: ODD and Fast Track granted
- text at x 8.4, y 70.1, w 15.5, h 2.6 [Montserrat Medium; font size 2.60; #252524]: >$1B peak year sales
- text at x 48.2, y 71.4, w 19.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Successful IND clearance
- text at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 6

### Slide 7

**Text**

CAP-002 Restores Normal
STXBP1 Expression and
Neuronal Firing in Human
Knock Out Neurons*
Normal
#cell
0 20 40 60 80 100
Time (s)
CAP-002 restores neurons to normal firing
#cell
0 20 40 60 80 100
Time (s)
#cell
0 20 40 60 80 100
Time (s)
STXBP1 Knock Out*
STXBP1 Knock Out* with CAP-002
*in vitro data
Generated in collaboration with Neurospector, a CRO established by Matthijs Verhage’s laboratory at VUmc Research BV, part of Foundation Stichting Amsterdam UMC
7

**Layout**

Title top-left in four lines across the left half. A small 'Normal' trace plot sits top-right with a rotated bold label on its left. Below, two large trace plots side by side: the red-bordered Knock Out plot on the left and the blue-bordered CAP-002 plot on the right with a blue header tab. Bold captions are centred under each plot. A footnote and source line run across the bottom-left, a thin teal rule sits above the footer, a logo is at bottom-left and the page number at bottom-right.

**Visuals**

Three raster images of neuronal calcium-trace raster plots, each with grey line traces per cell and small red circle markers for detected firing peaks. Axes are #cell (vertical, unlabelled ticks) and Time (s) from 0 to 100 with ticks at 0, 20, 40, 60, 80, 100. Top-right 'Normal' plot: grey 4px border, synchronised vertical bands of peaks about every 8-10 s, about 13 bursts. Bottom-left STXBP1 Knock Out plot: red 4px border, dense irregular unsynchronised peaks scattered across all cells and times. Bottom-right Knock Out with CAP-002 plot: blue border with a rounded-top blue header tab, regular synchronised vertical bursts, about 14 bursts, closely resembling the Normal plot. A thin teal horizontal line spans the slide width above the footer. A Capsida Biotherapeutics logo (small teal and blue geometric cube/neuron icon with 'CAPSIDA' text) sits bottom-left.

**Design**

Background: Solid white #FFFFFF. Clean white background. Title in dark charcoal #252524 Montserrat SemiBold, about 6% of slide height. Captions in black Montserrat Bold. Blue accent #0086B4 for the header tab and border, red #FF0000 for the Knock Out border, grey #A0A0A0 for the Normal border, teal rule #1A9A9A. Footnote text in Montserrat regular, small, charcoal. Header tab has rounded top corners, white bold text. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 41.9, h 25.1 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: CAP-002 Restores Normal / STXBP1 Expression and / Neuronal Firing in Human / Knock Out Neurons* (four lines, tight line spacing about 6.4% of slide height per line)
- photo at x 59.5, y 8.2, w 29, h 25.5 [#FFFFFF]: Normal neuron firing raster plot with grey traces and red peak markers, Time (s) axis 0-100, #cell axis label (grey border about 0.3% thick, 772x383 px image)
- caption at x 56.7, y 15.9, w 1.5, h 10 [Montserrat Bold; font size 2.6% of slide height; #000000; center aligned]: Normal (rotated 90 degrees counter-clockwise, reads bottom to top)
- photo at x 4.2, y 43.5, w 42.4, h 37.4 [#FFFFFF]: STXBP1 Knock Out neuron firing raster plot: dense irregular grey traces with red peak markers, Time (s) axis 0-100, #cell axis label (red border about 0.4% thick (#FF0000); 1357x674 px image)
- shape at x 51.7, y 38.1, w 44.4, h 6 [#0086B4]: Blue header tab behind the heading text for the CAP-002 plot (rounded top corners, flat bottom, joins the blue border of the plot below)
- photo at x 52, y 42.9, w 43.8, h 38.1 [#FFFFFF]: Knock Out neurons with CAP-002 firing raster plot: regular synchronised vertical bursts of red peak markers over grey traces, Time (s) axis 0-100, #cell axis label (blue border #0086B4; 1380x675 px image)
- caption at x 55.8, y 39.9, w 37, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: CAP-002 restores neurons to normal firing (inside blue header tab)
- caption at x 18, y 83.3, w 15.2, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #000000; center aligned]: STXBP1 Knock Out* (centred beneath the red-bordered plot)
- caption at x 61, y 83.3, w 26.2, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #000000; center aligned]: STXBP1 Knock Out* with CAP-002 (centred beneath the blue-bordered plot)
- footer at x 3.9, y 87.5, w 6.6, h 1.8 [Montserrat; font size 1.84% of slide height; #252524; left aligned]: *in vitro data
- footer at x 3.9, y 89.5, w 87.7, h 1.8 [Montserrat; font size 1.84% of slide height; #252524; left aligned]: Generated in collaboration with Neurospector, a CRO established by Matthijs Verhage’s laboratory at VUmc Research BV, part of Foundation Stichting Amsterdam UMC (single line)
- line at x 0, y 93.3, w 100, h 0.4 [#1A9A9A]: Thin teal horizontal rule across the full slide width above the footer (960x2 px image)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1F7FB0]: Capsida Biotherapeutics logo: small teal and blue geometric icon with 'CAPSIDA' wordmark (bottom-left corner)
- page number at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 7

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 51.7, y 38.1, w 44.4, h 6.0: #0086B4
- image at x 52.0, y 42.9, w 43.8, h 38.1: 1380 by 675 pixels
- image at x 4.2, y 43.5, w 42.4, h 37.4: 1357 by 674 pixels
- image at x 59.5, y 8.2, w 29.0, h 25.5: 772 by 383 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 41.9, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-002 Restores Normal
- text at x 3.9, y 12.3, w 37.5, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: STXBP1 Expression and
- text at x 3.9, y 18.7, w 41.9, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Neuronal Firing in Human
- text at x 3.9, y 25.1, w 32.6, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Knock Out Neurons*
- text at x 56.7, y 15.9, w 1.5, h 10.0 [Montserrat,Bold; font size 2.60; #000000]: Normal
- text at x 55.8, y 39.9, w 37.0, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: CAP-002 restores neurons to normal firing
- text at x 18.0, y 83.3, w 15.2, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: STXBP1 Knock Out*
- text at x 61.0, y 83.3, w 26.2, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: STXBP1 Knock Out* with CAP-002
- text at x 3.9, y 87.5, w 6.6, h 1.8 [Montserrat; font size 1.84; #252524]: *in vitro data
- text at x 3.9, y 89.5, w 87.7, h 1.8 [Montserrat; font size 1.84; #252524]: Generated in collaboration with Neurospector, a CRO established by Matthijs Verhage’s laboratory at VUmc Research BV, part of Foundation Stichting Amsterdam UMC
- text at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 7

### Slide 8

**Review notes**

- Worth studying: Bar charts of brain expression across three dose levels are annotated with full seizure correction and motor and cognitive correction thresholds, tying the data directly to efficacy claims.

**Text**

STXBP1 Expression with CAP-002 in GLP Tox is Above Levels
Required for Significant Correction of All Disease Phenotypes
Brain Expression in NHPs in GLP Tox Study
Average Brain RNA
RNA in key ROIs
207X
WPRE copies/ ug RNA
10^8
10^7
10^6
10^5
10^4
10^3
AAV9*
CAP-002
CAP-002
CAP-002
2.5E13
3.8E13
5.9E13
7.4E13
WPRE copies/ ug RNA
10^8
10^7
10^6
10^5
Full Seizure Correction
Significant Motor and Cognitive Correction
3.8E13 vg/kg
5.9E13 vg/kg
7.4E13 vg/kg
Cortex
Hippocampus
Thalamus
1Murine data generated in collaboration with lab of Mingshan Xue, Baylor College of Medicine
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
8

**Layout**

Two-line left-aligned title at top. Below is a large white panel with a teal outline and a rounded-top teal header bar spanning almost the full width. Inside the panel are two charts side by side, each topped by a rounded pill heading. Footnotes sit at bottom left, study details at bottom right, a thin teal rule runs full width near the bottom, with a logo at bottom left and the slide number at bottom right.

**Visuals**

Left chart: bar chart titled by the pill 'Average Brain RNA'. The y axis is logarithmic, 10^3 to 10^8, labelled 'WPRE copies/ ug RNA'. Four bars: AAV9* 2.5E13 in light grey, about 1.1x10^4, with a small error bar; CAP-002 3.8E13 in light cyan, about 2.3x10^6; CAP-002 5.9E13 in mid blue, about 3.8x10^6; CAP-002 7.4E13 in dark teal-blue, about 4.5x10^6. Each CAP-002 bar has three white circle data points with black outlines and an upward error bar. A light blue dash-dot horizontal line sits at about 1.5x10^6 across the chart. A green bracket from the top of the AAV9 bar region up to the 3.8E13 bar is labelled '207X' in green bold. Right chart: grouped bar chart under the pill 'RNA in key ROIs'. The y axis is logarithmic, 10^5 to 10^8, labelled 'WPRE copies/ ug RNA'. Three groups, each with three bars for 3.8E13 (light cyan), 5.9E13 (mid blue) and 7.4E13 (dark teal) vg/kg. Cortex bars are about 1.8x10^6, 4x10^6 and 3.6x10^6. Hippocampus bars are about 7.5x10^5, 1.7x10^6 and 4.8x10^6. Thalamus bars are about 1.1x10^7, 1.2x10^7 and 5x10^6. Bars have black outlines, white dot points and error bars. Light blue dashed horizontal lines mark thresholds at about 8.5x10^5 over Cortex, 5x10^5 over Hippocampus and 1.3x10^6 over Thalamus. A legend at upper right has three small swatches for 3.8E13, 5.9E13 and 7.4E13 vg/kg. A light blue dashed legend line next to the labels 'Full Seizure Correction' and 'Significant Motor and Cognitive Correction'. A small Capsida Biotherapeutics logo with a teal geometric icon is at bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524, Montserrat SemiBold, about 5.6% of slide height. Header bar in teal-blue #0086B4 with white Montserrat Bold text. Pills have a blue-to-teal gradient (about #1F5A9E to #0086B4) with white Montserrat SemiBold text. Bar colours are #39CCFF, #0086B4 and #00698C, with grey #D0D0D0. Axis text is Arial in black. Annotation text is bold Arial in light blue #90BFF9. The 207X label is green #00B050. The panel has a thin teal outline. Footnotes are Montserrat in black at about 1.8% of slide height. No shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 89.4, h 11.6 [Montserrat SemiBold; font size 5.56% of slide height; #252524; left aligned]: STXBP1 Expression with CAP-002 in GLP Tox is Above Levels / Required for Significant Correction of All Disease Phenotypes
- shape at x 2.6, y 21.4, w 95.1, h 6.4 [#0086B4]: Teal header bar with rounded top corners spanning the panel width (Rounded top corners. The white panel below it has a thin teal outline from y 27.8 to about y 86.)
- caption at x 31.5, y 23.7, w 37.3, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Brain Expression in NHPs in GLP Tox Study
- shape at x 13.3, y 30.2, w 22.4, h 5 [#1F5A9E]: Gradient pill behind 'Average Brain RNA' (Fully rounded ends, gradient from blue to teal)
- caption at x 16.2, y 31.4, w 16.5, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #FFFFFF; center aligned]: Average Brain RNA
- shape at x 60, y 30.2, w 19.3, h 5 [#1F5A9E]: Gradient pill behind 'RNA in key ROIs' (Fully rounded ends, gradient from blue to teal)
- caption at x 62.7, y 31.4, w 13.9, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #FFFFFF; center aligned]: RNA in key ROIs
- chart at x 3.9, y 37, w 37.5, h 46.5 [Arial; font size 2.77% of slide height; #000000; center aligned]: Left bar chart of average brain RNA, log y axis 10^3 to 10^8, four bars (AAV9* 2.5E13 grey; CAP-002 3.8E13, 5.9E13, 7.4E13), data points, dash-dot reference line, y title 'WPRE copies/ ug RNA', axis tick labels and x labels (Black axes. Bars: grey #D0D0D0, #39CCFF, #0086B4, #00698C, with black outlines. Y title rotated 90 degrees.)
- caption at x 16.3, y 41.5, w 5.2, h 3.3 [Montserrat Medium bold; font size 3.33% of slide height; #00B050; left aligned]: 207X (Sits above a green bracket drawn from about x 15 to 22 and y 45 to 64)
- chart at x 43.1, y 37, w 45.3, h 46.5 [Arial; font size 2.78% of slide height; #000000; center aligned]: Right grouped bar chart of RNA in key ROIs, log y axis 10^5 to 10^8, groups Cortex, Hippocampus, Thalamus with three dose bars each, data points, dashed threshold lines, y title 'WPRE copies/ ug RNA' (Bars #39CCFF, #0086B4, #00698C with black outlines and white dots with black outlines)
- caption at x 53.9, y 39.4, w 29.2, h 5.4 [Arial Bold; font size 2.54% of slide height; #90BFF9; left aligned]: Full Seizure Correction / Significant Motor and Cognitive Correction (Preceded by a light blue dashed line sample at x 49.8 to 53)
- caption at x 84.3, y 35.4, w 12, h 9.2 [Arial; font size 2.54% of slide height; #000000; left aligned]: 3.8E13 vg/kg / 5.9E13 vg/kg / 7.4E13 vg/kg (Legend with rectangular swatches in #39CCFF, #0086B4, #00698C to the left of each label)
- caption at x 52.9, y 77.4, w 32.9, h 2.8 [Arial; font size 2.78% of slide height; #000000; center aligned]: Cortex / Hippocampus / Thalamus
- footer at x 3.9, y 89.1, w 48.6, h 4.1 [Montserrat, superscript 1; font size 1.84% of slide height; #000000; left aligned]: 1Murine data generated in collaboration with lab of Mingshan Xue, Baylor College of Medicine / NHP = non-human primate
- caption at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat, bold labels and regular values; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp)
- line at x 0, y 93.3, w 100, h 0.4 [#0086B4]: Thin teal horizontal rule across full width
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#0086B4]: Capsida Biotherapeutics logo with blue text and teal geometric icon
- page number at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 8

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 2.6, y 21.4, w 95.1, h 6.4: #0086B4
- fill at x 57.8, y 56.3, w 2.4, h 19.0: #00698C
- fill at x 71.3, y 54.7, w 2.4, h 20.6: #00698C
- fill at x 84.8, y 54.7, w 2.4, h 20.6: #00698C
- fill at x 54.1, y 55.7, w 2.4, h 19.6: #0086B4
- fill at x 81.1, y 49.8, w 2.4, h 25.5: #0086B4
- fill at x 77.4, y 50.1, w 2.4, h 25.1: #39CCFF
- fill at x 34.3, y 48.6, w 4.7, h 26.6: #00698C
- fill at x 27.1, y 49.1, w 4.7, h 26.1: #0086B4
- fill at x 19.9, y 50.7, w 4.7, h 24.5: #39CCFF
- image at x 13.3, y 30.2, w 22.4, h 5.0: 215 by 27 pixels
- image at x 60.0, y 30.2, w 19.3, h 5.0: 185 by 27 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 88.6, h 5.6 [Montserrat SemiBold; font size 5.56; #252524]: STXBP1 Expression with CAP-002 in GLP Tox is Above Levels
- text at x 3.9, y 11.9, w 89.4, h 5.6 [Montserrat SemiBold; font size 5.56; #252524]: Required for Significant Correction of All Disease Phenotypes
- text at x 31.5, y 23.7, w 37.3, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Brain Expression in NHPs in GLP Tox Study
- text at x 16.2, y 31.4, w 16.5, h 3.0 [Montserrat SemiBold; font size 2.96; #FFFFFF]: Average Brain RNA
- text at x 62.7, y 31.4, w 13.9, h 3.0 [Montserrat SemiBold; font size 2.96; #FFFFFF]: RNA in key ROIs
- text at x 16.3, y 41.5, w 3.4, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: 207
- text at x 16.3, y 41.5, w 5.2, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: 207X
- text at x 19.7, y 41.5, w 1.7, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: X
- text at x 4.3, y 41.4, w 1.7, h 2.0 [ArialMT; font size 3.04; #000000]: A
- text at x 6.8, y 37.5, w 1.8, h 2.8 [ArialMT; font size 2.77; #000000]: 10
- text at x 43.1, y 41.4, w 1.7, h 2.0 [ArialMT; font size 3.05; #000000]: A
- text at x 45.6, y 37.4, w 1.8, h 2.8 [ArialMT; font size 2.78; #000000]: 10
- text at x 4.3, y 43.5, w 1.7, h 2.2 [ArialMT; font size 3.04; #000000]: N
- text at x 43.1, y 43.5, w 1.7, h 2.2 [ArialMT; font size 3.05; #000000]: N
- text at x 87.9, y 35.4, w 8.3, h 2.5 [ArialMT; font size 2.54; #000000]: 3.8E13 vg/kg
- text at x 4.3, y 45.7, w 1.7, h 2.2 [ArialMT; font size 3.04; #000000]: R
- text at x 43.1, y 45.7, w 1.7, h 2.2 [ArialMT; font size 3.05; #000000]: R
- text at x 87.9, y 38.7, w 8.3, h 2.5 [ArialMT; font size 2.54; #000000]: 5.9E13 vg/kg
- text at x 43.1, y 48.7, w 1.7, h 1.7 [ArialMT; font size 3.05; #000000]: g
- text at x 53.9, y 39.4, w 15.7, h 2.5 [ARIAL,Bold; font size 2.54; #90BFF9]: Full Seizure Correction
- text at x 4.3, y 48.7, w 1.7, h 1.7 [ArialMT; font size 3.04; #000000]: g
- text at x 6.8, y 44.8, w 1.8, h 2.8 [ArialMT; font size 2.77; #000000]: 10
- text at x 4.3, y 50.5, w 1.7, h 1.7 [ArialMT; font size 3.04; #000000]: u
- text at x 43.1, y 50.5, w 1.7, h 1.7 [ArialMT; font size 3.05; #000000]: u
- text at x 53.9, y 42.3, w 29.2, h 2.5 [ARIAL,Bold; font size 2.54; #90BFF9]: Significant Motor and Cognitive Correction
- text at x 87.9, y 42.1, w 8.3, h 2.5 [ArialMT; font size 2.54; #000000]: 7.4E13 vg/kg
- text at x 4.3, y 53.0, w 1.7, h 0.8 [ArialMT; font size 3.04; #000000]: /
- text at x 43.1, y 53.0, w 1.7, h 0.8 [ArialMT; font size 3.05; #000000]: /
- text at x 4.3, y 53.9, w 1.7, h 1.5 [ArialMT; font size 3.04; #000000]: s
- text at x 43.1, y 53.9, w 1.7, h 1.5 [ArialMT; font size 3.05; #000000]: s
- text at x 4.3, y 55.4, w 1.7, h 1.7 [ArialMT; font size 3.04; #000000]: e
- text at x 43.1, y 55.4, w 1.7, h 1.7 [ArialMT; font size 3.05; #000000]: e
- text at x 45.6, y 49.6, w 1.8, h 2.8 [ArialMT; font size 2.78; #000000]: 10
- text at x 4.3, y 57.1, w 1.7, h 0.7 [ArialMT; font size 3.04; #000000]: i
- text at x 43.1, y 57.8, w 1.7, h 1.7 [ArialMT; font size 3.05; #000000]: p
- text at x 43.1, y 57.1, w 1.7, h 0.7 [ArialMT; font size 3.05; #000000]: i
- text at x 4.3, y 57.8, w 1.7, h 1.7 [ArialMT; font size 3.04; #000000]: p
- text at x 6.8, y 52.1, w 1.8, h 2.8 [ArialMT; font size 2.77; #000000]: 10
- text at x 4.3, y 59.5, w 1.7, h 1.7 [ArialMT; font size 3.04; #000000]: o
- text at x 43.1, y 59.5, w 1.7, h 1.7 [ArialMT; font size 3.05; #000000]: o
- text at x 4.3, y 61.2, w 1.7, h 1.5 [ArialMT; font size 3.04; #000000]: c
- text at x 8.6, y 37.4, w 0.6, h 1.9 [ArialMT; font size 1.86; #000000]: 8
- text at x 43.1, y 61.2, w 1.7, h 1.5 [ArialMT; font size 3.05; #000000]: c
- text at x 47.5, y 37.3, w 0.6, h 1.9 [ArialMT; font size 1.87; #000000]: 8
- text at x 4.3, y 63.6, w 1.7, h 2.0 [ArialMT; font size 3.04; #000000]: E
- text at x 43.1, y 63.7, w 1.7, h 2.0 [ArialMT; font size 3.05; #000000]: E
- text at x 4.3, y 65.6, w 1.7, h 2.2 [ArialMT; font size 3.04; #000000]: R
- text at x 6.8, y 59.4, w 1.8, h 2.8 [ArialMT; font size 2.77; #000000]: 10
- text at x 43.1, y 65.7, w 1.7, h 2.2 [ArialMT; font size 3.05; #000000]: R
- text at x 4.3, y 67.8, w 1.7, h 2.0 [ArialMT; font size 3.04; #000000]: P
- text at x 43.1, y 67.9, w 1.7, h 2.0 [ArialMT; font size 3.05; #000000]: P
- text at x 45.6, y 61.8, w 1.8, h 2.8 [ArialMT; font size 2.78; #000000]: 10
- text at x 4.3, y 69.8, w 1.7, h 2.9 [ArialMT; font size 3.04; #000000]: W
- text at x 43.1, y 69.9, w 1.7, h 2.9 [ArialMT; font size 3.05; #000000]: W
- text at x 6.8, y 66.7, w 1.8, h 2.8 [ArialMT; font size 2.77; #000000]: 10
- text at x 8.6, y 44.7, w 0.6, h 1.9 [ArialMT; font size 1.86; #000000]: 7
- text at x 17.2, y 76.7, w 0.7, h 3.0 [Montserrat Medium; font size 2.96; #000000]: *
- text at x 6.8, y 74.0, w 1.8, h 2.8 [ArialMT; font size 2.77; #000000]: 10
- text at x 45.6, y 74.0, w 1.8, h 2.8 [ArialMT; font size 2.78; #000000]: 10
- text at x 47.5, y 49.5, w 0.6, h 1.9 [ArialMT; font size 1.87; #000000]: 7
- text at x 8.6, y 52.0, w 0.6, h 1.9 [ArialMT; font size 1.86; #000000]: 6
- text at x 13.0, y 77.3, w 4.0, h 2.8 [ArialMT; font size 2.77; #000000]: AAV9
- text at x 19.1, y 77.3, w 20.8, h 2.8 [ArialMT; font size 2.77; #000000]: CAP-002 CAP-002 CAP-002
- text at x 52.9, y 77.4, w 4.6, h 2.8 [ArialMT; font size 2.78; #000000]: Cortex
- text at x 64.0, y 77.4, w 9.6, h 2.8 [ArialMT; font size 2.78; #000000]: Hippocampus
- text at x 78.9, y 77.4, w 6.9, h 2.8 [ArialMT; font size 2.78; #000000]: Thalamus
- text at x 12.6, y 80.4, w 5.0, h 2.8 [ArialMT; font size 2.77; #000000]: 2.5E13
- text at x 19.8, y 80.4, w 5.0, h 2.8 [ArialMT; font size 2.77; #000000]: 3.8E13
- text at x 27.0, y 80.4, w 5.0, h 2.8 [ArialMT; font size 2.77; #000000]: 5.9E13
- text at x 34.2, y 80.4, w 5.0, h 2.8 [ArialMT; font size 2.77; #000000]: 7.4E13
- text at x 8.6, y 59.3, w 0.6, h 1.9 [ArialMT; font size 1.86; #000000]: 5
- text at x 47.5, y 61.7, w 0.6, h 1.9 [ArialMT; font size 1.87; #000000]: 6
- text at x 8.6, y 66.6, w 0.6, h 1.9 [ArialMT; font size 1.86; #000000]: 4
- text at x 47.5, y 73.9, w 0.6, h 1.9 [ArialMT; font size 1.87; #000000]: 5
- text at x 8.6, y 73.9, w 0.6, h 1.9 [ArialMT; font size 1.86; #000000]: 3
- text at x 4.2, y 89.2, w 48.3, h 1.8 [Montserrat; font size 1.84; #000000]: Murine data generated in collaboration with lab of Mingshan Xue, Baylor College of Medicine
- text at x 3.9, y 91.4, w 14.4, h 1.8 [Montserrat Medium; font size 1.84; #000000]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 8
- text at x 3.9, y 89.1, w 0.3, h 1.2 [Montserrat; font size 1.24; #000000]: 1

### Slide 9

**Text**

CAP-002 is Substantially Detargeted from Liver and DRGs / in NHPs in GLP Tox Compared to AAV9
Liver DNA in NHP GLP Tox Study
DRG RNA in NHP GLP Tox Study
10X
13X
WPRE copies/ ug DNA
WPRE copies/ ug RNA
10^9
10^8
10^7
10^6
10^5
10^8
10^7
10^6
10^5
10^4
AAV9 *
CAP-002
CAP-002
CAP-002
2.5E13
3.8E13
5.9E13
7.4E13
vg/kg
vg/kg
vg/kg
vg/kg
AAV9 *
CAP-002
CAP-002
CAP-002
2.5E13
3.8E13
5.9E13
7.4E13
vg/kg
vg/kg
vg/kg
vg/kg
Well-tolerated safety profile with no adverse histopathological findings
*Historical IV-delivered AAV9 2.5E13 vg/kg (non-STXBP1 cargo control)
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
9

**Layout**

Two-line left-aligned title at top. Two side-by-side chart panels (left about x 2-49%, right about x 51-96%) with teal header bars, each holding a bar chart. A full-width gradient banner sits below the panels, with footnotes at bottom left, study details right-aligned at bottom right, a thin teal rule above the footer, a logo at bottom left and the slide number at bottom right.

**Visuals**

Two bar charts on a log scale, each with 4 bars and individual dots per animal (n=3). Left chart: Liver DNA, y-axis WPRE copies/ug DNA, 10^5 to 10^9. Bars: AAV9 2.5E13 vg/kg light grey, about 7E7, three filled black dots clustered at the top. CAP-002 3.8E13 bright cyan, about 7E6, open white dots at about 1.3E7, 5E6 and 2E6. CAP-002 5.9E13 mid blue, about 1.1E7, open dots about 1.4E7, 1.2E7 and 8E6. CAP-002 7.4E13 dark teal-blue, about 8E6, open dots about 1.7E7, 8E6 and 1.5E5. A green bracket from the AAV9 bar to the CAP-002 3.8E13 bar is labelled 10X. Right chart: DRG RNA, y-axis WPRE copies/ug RNA, 10^4 to 10^8. AAV9 grey bar about 3E6, black dots about 6E6, 1.7E6 and 9E5, with error bar. CAP-002 3.8E13 cyan bar about 2.4E5, open dots about 4.5E5, 2E5 and 8E4. CAP-002 5.9E13 blue bar about 4.5E5, open dots about 7E5, 4.5E5 and 2.2E5. CAP-002 7.4E13 dark blue bar about 6.8E5, open dots about 1E6, 7E5 and 4.5E5. A green bracket from the AAV9 bar to the CAP-002 3.8E13 bar is labelled 13X. The bars have thin black outlines and the axes are black, with tick marks. Asterisks follow AAV9 on both x-axes. The Capsida Biotherapeutics logo, a teal geometric gem with blue text, sits bottom left. A thin teal horizontal line spans the slide above the footer.

**Design**

Background: Solid white #FFFFFF. White background. Titles in Montserrat SemiBold, dark charcoal #252524, about 5.9% of slide height. Panel headers are white Montserrat Bold on teal-blue #0086B4 bars with rounded top corners. Panel bodies are white with a thin teal outline. Chart text is black Arial. Green #00B050 Montserrat Medium for the 10X and 13X callouts. Bottom banner is a rounded rectangle with a horizontal gradient from blue #0086B4 to green-teal #00A99D, with white Montserrat Bold text. Footnotes are small Montserrat in #252524.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 91.4, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: CAP-002 is Substantially Detargeted from Liver and DRGs / in NHPs in GLP Tox Compared to AAV9 (two lines)
- shape at x 2.2, y 20.5, w 46.5, h 6.4 [#0086B4]: Left panel header bar, blue with rounded top corners
- shape at x 51.4, y 20.5, w 44.5, h 6.4 [#0086B4]: Right panel header bar, blue with rounded top corners
- caption at x 11.2, y 22.7, w 28.3, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Liver DNA in NHP GLP Tox Study
- caption at x 59.7, y 22.7, w 27.8, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: DRG RNA in NHP GLP Tox Study
- chart at x 3.9, y 28, w 43, h 46 [#D4D4D4]: Bar chart of Liver DNA WPRE copies/ug DNA, log scale 10^5 to 10^9, with AAV9 and three CAP-002 doses, per-animal dots, and a 10X bracket (Bars: grey #D4D4D4, cyan #39CCFF, blue #0086B4, dark #00698C, with black outlines. Black dots on the AAV9 bar, open white dots on the others. Green bracket #00B050.)
- chart at x 52.8, y 29, w 42, h 45 [#D4D4D4]: Bar chart of DRG RNA WPRE copies/ug RNA, log scale 10^4 to 10^8, with AAV9 and three CAP-002 doses, per-animal dots, error bars, and a 13X bracket (Bars: grey #D4D4D4, cyan #24C9FF, blue #0088B5, dark #00698C, with black outlines. Black dots on the AAV9 bar, open white dots on the others. Green bracket #00B050.)
- caption at x 18.2, y 30.7, w 3.2, h 3.3 [Montserrat Medium; font size 3.3% of slide height; #00B050; center aligned]: 10X
- caption at x 66.8, y 31.5, w 3.5, h 3.3 [Montserrat Medium; font size 3.3% of slide height; #00B050; center aligned]: 13X
- shape at x 4.1, y 78, w 91.8, h 8 [#0086B4]: Gradient banner with rounded corners, blue to teal-green (gradient to about #00A99D at right)
- caption at x 11.5, y 80.3, w 78.8, h 3.7 [Montserrat Bold; font size 3.7% of slide height; #FFFFFF; center aligned]: Well-tolerated safety profile with no adverse histopathological findings
- footer at x 3.9, y 87.9, w 36.3, h 3.7 [Montserrat; font size 1.84% of slide height; #252524; left aligned]: *Historical IV-delivered AAV9 2.5E13 vg/kg (non-STXBP1 cargo control) / NHP = non-human primate
- footer at x 75.3, y 87.1, w 19.8, h 5.6 [Montserrat, labels bold; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) (labels GLP Tox Study, In-life: and Species: are bold)
- line at x 0, y 93.3, w 100, h 0.4 [#00A99D]: Thin teal horizontal rule across slide
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#0086B4]: Capsida Biotherapeutics logo
- page number at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.5% of slide height; #252524; right aligned]: 9

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 2.2, y 20.5, w 46.5, h 6.4: #0086B4
- fill at x 51.4, y 20.5, w 44.5, h 6.4: #0086B4
- fill at x 38.2, y 47.6, w 5.6, h 16.7: #00698C
- fill at x 29.6, y 46.7, w 5.6, h 17.6: #0086B4
- fill at x 21.1, y 48.3, w 5.6, h 16.0: #39CCFF
- fill at x 12.5, y 39.5, w 5.6, h 24.8: #D4D4D4
- fill at x 86.4, y 48.6, w 5.6, h 15.7: #00698C
- fill at x 78.0, y 50.1, w 5.6, h 14.2: #0088B5
- fill at x 69.7, y 52.5, w 5.6, h 11.8: #24C9FF
- fill at x 61.3, y 43.1, w 5.6, h 21.2: #D4D4D4
- image at x 4.1, y 78.0, w 91.8, h 8.0: 881 by 43 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 91.4, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-002 is Substantially Detargetedfrom Liver and DRGs
- text at x 3.9, y 12.3, w 61.5, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: in NHPs in GLP Tox Compared to AAV9
- text at x 11.2, y 22.7, w 28.3, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Liver DNA in NHP GLP Tox Study
- text at x 59.7, y 22.7, w 27.8, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: DRG RNA in NHP GLP Tox Study
- text at x 18.2, y 30.7, w 3.2, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: 10X
- text at x 18.2, y 30.7, w 3.2, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: 10X
- text at x 66.8, y 31.5, w 1.8, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: 13
- text at x 66.8, y 31.5, w 3.5, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: 13X
- text at x 68.6, y 31.5, w 1.7, h 3.3 [Montserrat Medium; font size 3.33; #00B050]: X
- text at x 6.3, y 28.2, w 1.7, h 2.6 [ArialMT; font size 2.65; #000000]: 10
- text at x 3.9, y 32.0, w 1.6, h 1.9 [ArialMT; font size 2.91; #000000]: A
- text at x 55.3, y 29.0, w 1.6, h 2.6 [ArialMT; font size 2.59; #000000]: 10
- text at x 3.9, y 34.0, w 1.6, h 2.1 [ArialMT; font size 2.91; #000000]: N
- text at x 53.0, y 32.8, w 1.6, h 1.9 [ArialMT; font size 2.84; #000000]: A
- text at x 53.0, y 34.7, w 1.6, h 2.1 [ArialMT; font size 2.84; #000000]: N
- text at x 3.9, y 36.0, w 1.6, h 2.1 [ArialMT; font size 2.91; #000000]: D
- text at x 3.9, y 39.0, w 1.6, h 1.6 [ArialMT; font size 2.91; #000000]: g
- text at x 53.0, y 36.7, w 1.6, h 2.1 [ArialMT; font size 2.84; #000000]: R
- text at x 53.0, y 39.6, w 1.6, h 1.6 [ArialMT; font size 2.84; #000000]: g
- text at x 3.9, y 40.6, w 1.6, h 1.6 [ArialMT; font size 2.91; #000000]: u
- text at x 6.3, y 36.9, w 1.7, h 2.6 [ArialMT; font size 2.65; #000000]: 10
- text at x 3.9, y 43.1, w 1.6, h 0.8 [ArialMT; font size 2.91; #000000]: /
- text at x 53.0, y 41.2, w 1.6, h 1.6 [ArialMT; font size 2.84; #000000]: u
- text at x 55.3, y 37.5, w 1.6, h 2.6 [ArialMT; font size 2.59; #000000]: 10
- text at x 3.9, y 43.9, w 1.6, h 1.5 [ArialMT; font size 2.91; #000000]: s
- text at x 53.0, y 43.6, w 1.6, h 0.8 [ArialMT; font size 2.84; #000000]: /
- text at x 3.9, y 45.3, w 1.6, h 1.6 [ArialMT; font size 2.91; #000000]: e
- text at x 53.0, y 44.4, w 1.6, h 1.4 [ArialMT; font size 2.84; #000000]: s
- text at x 3.9, y 47.6, w 1.6, h 1.6 [ArialMT; font size 2.91; #000000]: p
- text at x 3.9, y 46.9, w 1.6, h 0.6 [ArialMT; font size 2.91; #000000]: i
- text at x 8.1, y 28.2, w 0.6, h 1.8 [ArialMT; font size 1.77; #000000]: 9
- text at x 53.0, y 45.8, w 1.6, h 1.6 [ArialMT; font size 2.84; #000000]: e
- text at x 3.9, y 49.3, w 1.6, h 1.6 [ArialMT; font size 2.91; #000000]: o
- text at x 53.0, y 48.1, w 1.6, h 1.6 [ArialMT; font size 2.84; #000000]: p
- text at x 53.0, y 47.4, w 1.6, h 0.6 [ArialMT; font size 2.84; #000000]: i
- text at x 57.0, y 29.0, w 0.5, h 1.7 [ArialMT; font size 1.73; #000000]: 8
- text at x 6.3, y 45.6, w 1.7, h 2.6 [ArialMT; font size 2.65; #000000]: 10
- text at x 3.9, y 50.9, w 1.6, h 1.5 [ArialMT; font size 2.91; #000000]: c
- text at x 53.0, y 49.7, w 1.6, h 1.6 [ArialMT; font size 2.84; #000000]: o
- text at x 3.9, y 53.2, w 1.6, h 1.9 [ArialMT; font size 2.91; #000000]: E
- text at x 53.0, y 51.2, w 1.6, h 1.4 [ArialMT; font size 2.84; #000000]: c
- text at x 55.3, y 46.1, w 1.6, h 2.6 [ArialMT; font size 2.59; #000000]: 10
- text at x 53.0, y 53.5, w 1.6, h 1.9 [ArialMT; font size 2.84; #000000]: E
- text at x 3.9, y 55.1, w 1.6, h 2.1 [ArialMT; font size 2.91; #000000]: R
- text at x 3.9, y 57.2, w 1.6, h 1.9 [ArialMT; font size 2.91; #000000]: P
- text at x 53.0, y 55.4, w 1.6, h 2.1 [ArialMT; font size 2.84; #000000]: R
- text at x 53.0, y 57.4, w 1.6, h 1.9 [ArialMT; font size 2.84; #000000]: P
- text at x 3.9, y 59.1, w 1.6, h 2.7 [ArialMT; font size 2.91; #000000]: W
- text at x 6.3, y 54.4, w 1.7, h 2.6 [ArialMT; font size 2.65; #000000]: 10
- text at x 8.1, y 36.9, w 0.6, h 1.8 [ArialMT; font size 1.77; #000000]: 8
- text at x 53.0, y 59.3, w 1.6, h 2.7 [ArialMT; font size 2.84; #000000]: W
- text at x 55.3, y 54.6, w 1.6, h 2.6 [ArialMT; font size 2.59; #000000]: 10
- text at x 11.5, y 80.3, w 78.8, h 3.7 [Montserrat,Bold; font size 3.71; #FFFFFF]: Well-tolerated safety profile with no adverse histopathological findings
- text at x 57.0, y 37.5, w 0.5, h 1.7 [ArialMT; font size 1.73; #000000]: 7
- text at x 17.7, y 65.7, w 0.7, h 3.0 [Montserrat Medium; font size 2.96; #000000]: *
- text at x 66.6, y 65.8, w 0.7, h 3.0 [Montserrat Medium; font size 2.96; #000000]: *
- text at x 6.3, y 63.1, w 1.7, h 2.6 [ArialMT; font size 2.65; #000000]: 10
- text at x 55.3, y 63.1, w 1.6, h 2.6 [ArialMT; font size 2.59; #000000]: 10
- text at x 13.4, y 66.3, w 3.8, h 2.6 [ArialMT; font size 2.65; #000000]: AAV9
- text at x 20.9, y 66.3, w 6.1, h 2.6 [ArialMT; font size 2.65; #000000]: CAP-002
- text at x 29.4, y 66.3, w 6.1, h 2.6 [ArialMT; font size 2.65; #000000]: CAP-002
- text at x 38.0, y 66.3, w 6.1, h 2.6 [ArialMT; font size 2.65; #000000]: CAP-002
- text at x 8.1, y 45.6, w 0.6, h 1.8 [ArialMT; font size 1.77; #000000]: 7
- text at x 62.2, y 66.2, w 3.7, h 2.6 [ArialMT; font size 2.59; #000000]: AAV9
- text at x 69.5, y 66.2, w 5.9, h 2.6 [ArialMT; font size 2.59; #000000]: CAP-002
- text at x 77.9, y 66.2, w 5.9, h 2.6 [ArialMT; font size 2.59; #000000]: CAP-002
- text at x 86.2, y 66.2, w 5.9, h 2.6 [ArialMT; font size 2.59; #000000]: CAP-002
- text at x 13.0, y 69.2, w 4.7, h 2.6 [ArialMT; font size 2.65; #000000]: 2.5E13
- text at x 21.5, y 69.2, w 4.7, h 2.6 [ArialMT; font size 2.65; #000000]: 3.8E13
- text at x 30.1, y 69.2, w 4.7, h 2.6 [ArialMT; font size 2.65; #000000]: 5.9E13
- text at x 38.7, y 69.2, w 4.7, h 2.6 [ArialMT; font size 2.65; #000000]: 7.4E13
- text at x 57.0, y 46.0, w 0.5, h 1.7 [ArialMT; font size 1.73; #000000]: 6
- text at x 61.8, y 69.1, w 4.6, h 2.6 [ArialMT; font size 2.59; #000000]: 2.5E13
- text at x 70.1, y 69.1, w 4.6, h 2.6 [ArialMT; font size 2.59; #000000]: 3.8E13
- text at x 78.5, y 69.1, w 4.6, h 2.6 [ArialMT; font size 2.59; #000000]: 5.9E13
- text at x 86.9, y 69.1, w 4.6, h 2.6 [ArialMT; font size 2.59; #000000]: 7.4E13
- text at x 13.5, y 72.1, w 3.6, h 2.6 [ArialMT; font size 2.65; #000000]: vg/kg
- text at x 22.1, y 72.1, w 3.6, h 2.6 [ArialMT; font size 2.65; #000000]: vg/kg
- text at x 30.7, y 72.1, w 3.6, h 2.6 [ArialMT; font size 2.65; #000000]: vg/kg
- text at x 39.2, y 72.1, w 3.6, h 2.6 [ArialMT; font size 2.65; #000000]: vg/kg
- text at x 62.3, y 72.0, w 3.5, h 2.6 [ArialMT; font size 2.59; #000000]: vg/kg
- text at x 70.7, y 72.0, w 3.5, h 2.6 [ArialMT; font size 2.59; #000000]: vg/kg
- text at x 79.1, y 72.0, w 3.5, h 2.6 [ArialMT; font size 2.59; #000000]: vg/kg
- text at x 87.4, y 72.0, w 3.5, h 2.6 [ArialMT; font size 2.59; #000000]: vg/kg
- text at x 8.1, y 54.3, w 0.6, h 1.8 [ArialMT; font size 1.77; #000000]: 6
- text at x 57.0, y 54.5, w 0.5, h 1.7 [ArialMT; font size 1.73; #000000]: 5
- text at x 8.1, y 63.0, w 0.6, h 1.8 [ArialMT; font size 1.77; #000000]: 5
- text at x 57.0, y 63.1, w 0.5, h 1.7 [ArialMT; font size 1.73; #000000]: 4
- text at x 3.9, y 87.9, w 36.3, h 1.8 [Montserrat; font size 1.84; #252524]: *Historical IV-delivered AAV9 2.5E13 vg/kg (non-STXBP1 cargo control)
- text at x 3.9, y 89.9, w 14.3, h 1.8 [Montserrat; font size 1.84; #252524]: NHP = non-human primate
- text at x 88.0, y 87.1, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 89.1, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 89.1, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 91.0, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 91.0, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.3, y 95.8, w 0.5, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 9

### Slide 10

**Text**

CAP-002  Phase 1/2a SYNRGY Study
Potential for approval after Phase 2 study
Clinical Ph1/2 / Planning
Population
» 18 months – 7 years
» Potential expansion / to broader ages
» Ph1: 6 patients
Key Measurements
» Safety
» Motor, language, neurocognitive, / seizure, and EEG
» Clinical scales consistent with / STARR natural history study
Plan to leverage / Fast Track, ODD, and / other designations to / accelerate approval
2025
2026
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
CAP-002 / (STXBP1-DEE) / Program / Overview
IND-Enabling
Clinical Ph1/2a
IND Clearance
Fast Track Granted
Projected 1st Patient Dosed
Projected 1st Patient Efficacy
Projected FDA Meeting
For more information about the SYNRGY trial, please visit www.clinicaltrials.gov and search for NCT06983158
EEG = electroencephalogram; STARR = STXBP1 Clinical Trial Ready
10

**Layout**

Title and teal subtitle at top left. Below, a wide light-grey band holds a pale-blue 'Clinical Ph1/2 Planning' tab at left, two bulleted columns (Population, Key Measurements) in the middle and a rounded teal callout box at right. Beneath it is a two-year quarterly Gantt timeline with a row-label column at left, then a full-width teal rounded banner, a footnote, a thin teal footer rule, a logo at bottom left and the page number at bottom right.

**Visuals**

Gantt-style timeline: teal header bar with years 2025 (Q1–Q4) and 2026 (Q1–Q4), a grey quarter row, vertical thin grey gridlines between quarters with a light-blue line at the 2025/2026 boundary. Row label 'CAP-002 (STXBP1-DEE) Program Overview' in a grey box. A light-blue pill 'IND-Enabling' spans 2025 Q1 and a longer light-blue pill 'Clinical Ph1/2a' spans 2025 Q2 to 2026 Q4. Milestones: teal six-point star plus black checkmark at 'IND Clearance' (2025 Q2); teal diamond plus checkmark at 'Fast Track Granted' (2025 Q2–Q3); star at end of 'Projected 1st Patient Dosed' (2025 Q3) with a thin teal arrow pointing right to about the start of 2026 Q1; star at end of 'Projected 1st Patient Efficacy' (start of 2026 Q1) with a teal arrow to about 2026 Q3; teal diamond before 'Projected FDA Meeting' (2026 Q3). The Capsida Biotherapeutics logo (teal text with a green and teal geometric mark) sits at bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524 Montserrat SemiBold, large (about 6% of slide height). Subtitle in dark teal #006487 Montserrat SemiBold. Body text black Montserrat Medium (about 2.2%). Section headings black Montserrat Bold. Accent teal #0086B4 / #008EC0, light cyan #7BDDFF, pale blue #E5F8FF, grey #F2F2F2. Rounded corners on the callout box, the tab and the banner. The pale-blue tab has a thin teal outline. The grey band has a thin grey outline. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 56, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: CAP-002 Phase 1/2a SYNRGY Study
- subtitle at x 3.9, y 14.1, w 35.7, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: Potential for approval after Phase 2 study
- shape at x 4.7, y 18.6, w 91.1, h 25.3 [#F2F2F2]: Light grey band behind planning content (thin grey outline)
- shape at x 4.2, y 18.6, w 12.8, h 25.3 [#E5F8FF]: Pale blue rounded tab for Clinical Ph1/2 Planning (thin teal outline, rounded corners)
- shape at x 71.7, y 18.5, w 24.2, h 25.6 [#0086B4]: Teal rounded callout box (rounded corners)
- body at x 5.2, y 28.6, w 10.5, h 5.4 [Montserrat Bold; font size 2.6% of slide height; #000000; left aligned]: Clinical Ph1/2 / Planning
- body at x 20.8, y 21.5, w 8.4, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #000000; left aligned]: Population
- bullet list at x 21.5, y 25.6, w 15, h 12.5 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: » 18 months – 7 years / » Potential expansion / to broader ages / » Ph1: 6 patients (» chevron bullets, wrapped lines indented)
- body at x 41.1, y 21.5, w 14.7, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #000000; left aligned]: Key Measurements
- bullet list at x 41.8, y 25.6, w 23.2, h 15.1 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: » Safety / » Motor, language, neurocognitive, / seizure, and EEG / » Clinical scales consistent with / STARR natural history study (» chevron bullets)
- body at x 72.8, y 23.8, w 21.2, h 15.3 [Montserrat Bold (last words 'to accelerate approval' regular); font size 3.33% of slide height; #FFFFFF; left aligned]: Plan to leverage / Fast Track, ODD, and / other designations to / accelerate approval
- shape at x 14.8, y 45.8, w 80.5, h 4.5 [#0086B4]: Teal header bar for years: 2025 and 2026 (light vertical divider at year boundary)
- body at x 33.7, y 47.1, w 3.1, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; center aligned]: 2025
- body at x 74, y 47.1, w 3.1, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; center aligned]: 2026
- shape at x 14.8, y 50.3, w 80.5, h 4.2 [Montserrat Medium; font size 1.84% of slide height; #F2F2F2; center aligned]: Quarter header cells Q1 to Q4 for 2025 and 2026 (eight grey cells labelled Q1, Q2, Q3, Q4, Q1, Q2, Q3, Q4 in #252524)
- shape at x 3.5, y 54.5, w 11.3, h 27 [#F2F2F2]: Grey row label box
- body at x 4.3, y 63, w 9.3, h 10.3 [Montserrat Bold; font size 2.22% of slide height; #252524; left aligned]: CAP-002 / (STXBP1-DEE) / Program / Overview
- shape at x 25.6, y 55.7, w 69.8, h 3.8 [Montserrat Medium; font size 1.96% of slide height; #7BDDFF; center aligned]: Light-blue pill bar labelled Clinical Ph1/2a spanning 2025 Q2 to 2026 Q4, with a separate pale pill for IND-Enabling in 2025 Q1 (fully rounded ends; IND-Enabling pill at x 16.5 to 25.5 in lighter blue; labels in black)
- diagram at x 28, y 59.5, w 63, h 20 [Montserrat Medium; font size 1.84% of slide height; #0086B4; left aligned]: Milestone markers: IND Clearance (star, check), Fast Track Granted (diamond, check), Projected 1st Patient Dosed (star with right arrow), Projected 1st Patient Efficacy (star with right arrow), Projected FDA Meeting (diamond) (labels black; arrows thin teal lines with arrowheads; checkmarks black)
- shape at x 3.3, y 83.9, w 92.7, h 5.3 [#008EC0]: Teal rounded banner (rounded corners)
- body at x 9.6, y 85.3, w 80.1, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; center aligned]: For more information about the SYNRGY trial, please visit www.clinicaltrials.gov and search for NCT06983158
- footer at x 4.7, y 91.1, w 34.3, h 1.8 [Montserrat Regular; font size 1.84% of slide height; #252524; left aligned]: EEG = electroencephalogram; STARR = STXBP1 Clinical Trial Ready
- line at x 0, y 93.3, w 100, h 0.4 [#009999]: Thin teal footer rule across the slide
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#2A9D9D]: Capsida Biotherapeutics logo
- page number at x 95, y 95.8, w 0.9, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 10

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.7, y 18.6, w 91.1, h 25.3: #F2F2F2
- fill at x 4.2, y 18.6, w 12.8, h 25.3: #E5F8FF
- fill at x 71.7, y 18.5, w 24.2, h 25.6: #0086B4
- fill at x 14.8, y 45.8, w 80.5, h 4.5: #0086B4
- fill at x 14.8, y 50.3, w 11.3, h 4.2: #F2F2F2
- fill at x 26.0, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 35.9, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 45.8, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 55.7, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 65.6, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 75.5, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 85.4, y 50.3, w 9.9, h 4.2: #F2F2F2
- fill at x 3.5, y 54.5, w 11.3, h 27.0: #F2F2F2
- fill at x 25.6, y 55.7, w 69.8, h 3.8: #7BDDFF
- fill at x 3.3, y 83.9, w 92.7, h 5.3: #008EC0
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 56.0, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-002 Phase 1/2a SYNRGY Study
- text at x 3.9, y 14.1, w 35.7, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: Potential for approval after Phase 2 study
- text at x 72.8, y 23.8, w 16.6, h 3.3 [Montserrat,Bold; font size 3.33; #FFFFFF]: Plan to leverage
- text at x 20.8, y 21.5, w 8.4, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Population
- text at x 41.1, y 21.5, w 14.7, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Key Measurements
- text at x 72.8, y 27.8, w 21.2, h 3.3 [Montserrat,Bold; font size 3.34; #FFFFFF]: Fast Track, ODD, and
- text at x 72.8, y 31.8, w 18.6, h 3.3 [Montserrat,Bold; font size 3.33; #FFFFFF]: other designations
- text at x 91.9, y 31.8, w 2.4, h 3.3 [Montserrat; font size 3.33; #FFFFFF]: to
- text at x 72.8, y 35.8, w 18.4, h 3.3 [Montserrat; font size 3.33; #FFFFFF]: accelerate approval
- text at x 5.2, y 28.6, w 10.5, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Clinical Ph1/2
- text at x 21.5, y 25.6, w 14.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » 18 months – 7 years
- text at x 41.8, y 25.6, w 5.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Safety
- text at x 5.2, y 31.4, w 6.9, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Planning
- text at x 21.5, y 29.4, w 14.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Potential expansion
- text at x 41.8, y 29.4, w 23.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Motor, language, neurocognitive,
- text at x 23.4, y 32.1, w 10.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: to broader ages
- text at x 43.7, y 32.1, w 10.5, h 2.2 [Montserrat Medium; font size 2.22; #000000]: seizure, and EEG
- text at x 21.5, y 35.9, w 11.0, h 2.2 [Montserrat Medium; font size 2.23; #000000]: » Ph1: 6 patients
- text at x 41.8, y 35.9, w 22.5, h 2.2 [Montserrat Medium; font size 2.23; #000000]: » Clinical scales consistent with
- text at x 43.7, y 38.5, w 17.7, h 2.2 [Montserrat Medium; font size 2.22; #000000]: STARR natural history study
- text at x 33.7, y 47.1, w 3.1, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: 2025
- text at x 74.0, y 47.1, w 3.1, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: 2026
- text at x 19.8, y 51.6, w 1.3, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q1
- text at x 30.2, y 51.6, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q2
- text at x 40.1, y 51.6, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q3
- text at x 50.0, y 51.6, w 1.6, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q4
- text at x 60.0, y 51.6, w 1.3, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q1
- text at x 69.8, y 51.6, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q2
- text at x 79.8, y 51.6, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q3
- text at x 89.6, y 51.6, w 1.6, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q4
- text at x 4.3, y 63.0, w 6.1, h 2.2 [Montserrat,Bold; font size 2.23; #252524]: CAP-002
- text at x 16.5, y 56.7, w 7.5, h 2.0 [Montserrat Medium; font size 1.96; #000000]: IND-Enabling
- text at x 56.5, y 56.7, w 8.0, h 2.0 [Montserrat Medium; font size 1.96; #000000]: Clinical Ph1/2a
- text at x 4.3, y 65.7, w 9.3, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: (STXBP1-DEE)
- text at x 4.3, y 68.4, w 6.1, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: Program
- text at x 4.3, y 71.1, w 6.2, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: Overview
- text at x 29.5, y 60.4, w 7.6, h 1.8 [Montserrat Medium; font size 1.84; #000000]: IND Clearance
- text at x 9.6, y 85.3, w 80.1, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: For more information about the SYNRGY trial, please visit www.clinicaltrials.gov and search for NCT06983158
- text at x 31.1, y 65.2, w 10.0, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Fast Track Granted
- text at x 28.1, y 69.3, w 14.2, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected 1 Patient Dosed
- text at x 47.5, y 73.5, w 15.2, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected 1 Patient Efficacy
- text at x 78.1, y 78.6, w 12.4, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected FDA Meeting
- text at x 4.7, y 91.1, w 34.3, h 1.8 [Montserrat; font size 1.84; #252524]: EEG = electroencephalogram; STARR = STXBP1 Clinical Trial Ready
- text at x 33.9, y 69.2, w 0.6, h 1.2 [Montserrat Medium; font size 1.24; #000000]: st
- text at x 53.3, y 73.4, w 0.6, h 1.2 [Montserrat Medium; font size 1.25; #000000]: st
- text at x 95.0, y 95.8, w 0.9, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 10

### Slide 11

**Review notes**

- Suggested repair: Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

**Text**

CAP-002  Phase 1/2a SYNRGY Study (NCT06983158)
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
ClinicalTrials.gov ID NCT06983158
Sponsor Capsida Biotherapeutics, Inc.
Ph1
Dose escalation
N=6
Ph2a (single dose)
N=6
Primary endpoints:
• Safety
Clinician reported secondary endpoints:
• Bayley Scales of Infant & Toddler Development
• Gross Motor Function
• STXBP1-Clinical Severity Assessment-Clinician
• Peabody Developmental Motor Scales
Caregiver reported secondary endpoints
“This is the first potentially disease-modifying treatment for STXBP1-DEE, and we are excited to be part of the SYNRGY clinical trial,”
- Ingo Helbig, M.D., Pediatric Neurologist and Director of Clinical Research at the Center for Epilepsy and Neurodevelopmental Disorders (ENDD) at Children’s Hospital of Philadelphia (CHOP), and paid consultant to Capsida¹
“STXBP1-related disorders present devastating challenges in communication, development, motor function and seizures.  We are in dire need of targeted therapies that can improve the lives and functioning of our children and families,”
 - Charlene Son Rigby, STXBP1 Foundation President & Founder¹
¹ Capsida May 12, 2025 press release
See clinicaltrials.gov for full list of clinician & caregiver secondary endpoints
11

**Layout**

White slide with a large left-aligned title at top, a screenshot-style trial subtitle block beneath it, then two columns: a rounded outlined study-design box on the left and a teal endpoints panel on the right. Two full-width light-blue quote boxes sit below; a thin teal footer rule at the bottom with a logo at bottom left, footnotes beside it and the page number at bottom right.

**Visuals**

A screenshot image of the ClinicalTrials.gov header (grey-black condensed bold title in two lines, dark blue labels 'ClinicalTrials.gov ID' and 'Sponsor', each followed by a dark navy circular info icon, with the values in dark grey condensed text). Left: a white rounded rectangle with a teal (#0086B4) outline containing two teal rounded rectangles with dark navy outlines (upper taller 'Ph1 Dose escalation N=6', lower 'Ph2a (single dose) N=6'). Right: a teal rounded-corner rectangle with white text. Two pale blue (#DCEAF7) rectangles with soft drop shadows holding the quotes. A thin teal horizontal line across the slide above the footer. Small Capsida Biotherapeutics logo (blue wordmark 'CAPSIDA' with a teal/green geometric polyhedron icon and a faint script mark) at bottom left.

**Design**

Background: Solid white #FFFFFF. Clean white background. Title in near-black #252524 Montserrat SemiBold with tight letter-spacing, about 6% of slide height. Subtitle screenshot in condensed bold grey #333333 and blue #1F4E8C labels. Teal #0086B4 accent fills with white Montserrat Medium text; quote boxes #DCEAF7 with black Montserrat Medium Italic text, names in bold italic; shadows soft grey on quote boxes; footnote in black with teal-grey link #467886 underlined; page number #252524 small.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 3.8, w 80.1, h 5.9 [Montserrat SemiBold; font size 5.94% of slide height; #252524; left aligned]: CAP-002 Phase 1/2a SYNRGY Study (NCT06983158) (single line, tight letter-spacing)
- photo at x 2.1, y 11.3, w 73.6, h 21.5 [condensed sans-serif bold; #333333; left aligned]: Screenshot of ClinicalTrials.gov header: 'A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 / (STXBP1) Encephalopathy', 'ClinicalTrials.gov ID (i) NCT06983158', 'Sponsor (i) Capsida Biotherapeutics, Inc.' (labels in blue #1F4E8C with navy circular info icons)
- shape at x 6, y 36.8, w 40.7, h 27.1 [#FFFFFF]: White rounded rectangle with teal outline enclosing the study-design boxes (teal #0086B4 outline about 3px, large corner radius)
- shape at x 7.7, y 39.3, w 37.4, h 12.1 [#0086B4]: Teal rounded rectangle: Ph1 / Dose escalation / N=6 (dark navy outline, rounded corners)
- body at x 20.6, y 41, w 11.7, h 8.2 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; center aligned]: Ph1 / Dose escalation / N=6 (three centred lines)
- shape at x 7.7, y 53.7, w 37.4, h 7.6 [#0086B4]: Teal rounded rectangle: Ph2a (single dose) / N=6 (dark navy outline, rounded corners)
- body at x 19.7, y 54.8, w 13.5, h 5.8 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; center aligned]: Ph2a (single dose) / N=6 (two centred lines)
- shape at x 52.9, y 36.8, w 41, h 27.1 [#0086B4]: Teal rounded rectangle panel for endpoints (rounded corners about 1% radius)
- bullet list at x 53.9, y 38.2, w 29.6, h 25.2 [Montserrat Medium; font size 2.04% of slide height; #FFFFFF; left aligned]: Primary endpoints: / • Safety / Clinician reported secondary endpoints: / • Bayley Scales of Infant & Toddler Development / • Gross Motor Function / • STXBP1-Clinical Severity Assessment-Clinician / • Peabody Developmental Motor Scales / Caregiver reported secondary endpoints (headings 2.22% size, bullets 2.04% with round bullet at x 53.9 and text indented to x 56.2; blank line gaps before secondary headings)
- shape at x 6.1, y 66.3, w 87.8, h 9.4 [#DCEAF7]: Pale blue quote box 1 with soft shadow (drop shadow bottom right)
- body at x 6.8, y 67.3, w 84.4, h 7.6 [Montserrat Medium Italic; font size 2.22% of slide height; #000000; left aligned]: “This is the first potentially disease-modifying treatment for STXBP1-DEE, and we are excited to be part of the SYNRGY clinical trial,” / - Ingo Helbig, M.D., Pediatric Neurologist and Director of Clinical Research at the Center for Epilepsy and Neurodevelopmental / Disorders (ENDD) at Children’s Hospital of Philadelphia (CHOP), and paid consultant to Capsida¹ (name 'Ingo Helbig, M.D.,' in bold italic; superscript 1)
- shape at x 6.1, y 78.9, w 87.8, h 9.4 [#DCEAF7]: Pale blue quote box 2 with soft shadow (drop shadow bottom right)
- body at x 6.8, y 79.9, w 84.4, h 7.6 [Montserrat Medium Italic; font size 2.22% of slide height; #000000; left aligned]: “STXBP1-related disorders present devastating challenges in communication, development, motor function and seizures. We are in / dire need of targeted therapies that can improve the lives and functioning of our children and families,” / - Charlene Son Rigby, STXBP1 Foundation President & Founder¹ (name 'Charlene Son Rigby,' in bold italic; superscript 1)
- line at x 0, y 93.3, w 100, h 0.4 [#00968F]: Thin teal horizontal rule above footer (full width)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1F6FB5]: Capsida Biotherapeutics logo (blue wordmark with teal polyhedron icon)
- footer at x 11.8, y 95.5, w 39.8, h 4.1 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: ¹ Capsida May 12, 2025 press release / See clinicaltrials.gov for full list of clinician & caregiver secondary endpoints (superscript 1 on first line; 'clinicaltrials.gov' underlined in #467886)
- page number at x 95.2, y 95.8, w 0.6, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 11

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 52.9, y 36.8, w 41.0, h 27.1: #0086B4
- fill at x 7.7, y 39.3, w 37.4, h 12.1: #0086B4
- fill at x 7.7, y 53.7, w 37.4, h 7.6: #0086B4
- fill at x 6.1, y 78.9, w 87.8, h 9.4: #DCEAF7
- fill at x 6.1, y 66.3, w 87.8, h 9.4: #DCEAF7
- image at x 2.1, y 11.3, w 73.6, h 21.5: 1558 by 221 pixels
- image at x 5.9, y 66.0, w 86.7, h 11.5: 1157 by 87 pixels
- image at x 5.9, y 78.5, w 86.7, h 11.5: 1157 by 87 pixels
- image at x 5.9, y 78.5, w 88.7, h 10.9: 1183 by 83 pixels
- image at x 5.9, y 66.0, w 88.7, h 10.9: 1183 by 82 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 3.8, w 80.1, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: CAP-002 Phase 1/2a SYNRGY Study (NCT06983158)
- text at x 25.1, y 41.0, w 2.6, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Ph1
- text at x 20.6, y 44.2, w 11.7, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Dose escalation
- text at x 53.9, y 38.2, w 12.1, h 2.2 [Montserrat Medium; font size 2.22; #FFFFFF]: Primary endpoints:
- text at x 25.0, y 47.3, w 2.9, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: N=6
- text at x 53.9, y 40.8, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 56.2, y 40.8, w 3.6, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: Safety
- text at x 53.9, y 45.7, w 25.3, h 2.2 [Montserrat Medium; font size 2.23; #FFFFFF]: Clinician reported secondary endpoints:
- text at x 19.7, y 54.8, w 13.5, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Ph2a (single dose)
- text at x 25.0, y 58.0, w 2.9, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: N=6
- text at x 53.9, y 48.4, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 56.2, y 48.4, w 27.3, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: Bayley Scales of Infant & Toddler Development
- text at x 53.9, y 50.8, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 56.2, y 50.8, w 12.6, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: Gross Motor Function
- text at x 53.9, y 53.2, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 56.2, y 53.2, w 26.8, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: STXBP1-Clinical Severity Assessment-Clinician
- text at x 53.9, y 55.7, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 56.2, y 55.7, w 22.3, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: Peabody Developmental Motor Scales
- text at x 53.9, y 60.6, w 25.7, h 2.2 [Montserrat Medium; font size 2.22; #FFFFFF]: Caregiver reported secondary endpoints
- text at x 6.8, y 67.3, w 84.4, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: “This is the first potentially disease-modifying treatment for STXBP1-DEE, and we are excited to be part of the SYNRGY clinical trial,”
- text at x 6.8, y 70.0, w 12.1, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: - Ingo Helbig, M.D.,
- text at x 7.7, y 70.0, w 80.0, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: Ingo Helbig, M.D., Pediatric Neurologist and Director of Clinical Research at the Center for Epilepsy and Neurodevelopmental
- text at x 6.8, y 72.7, w 61.2, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: Disorders (ENDD) at Children’s Hospital of Philadelphia (CHOP), and paid consultant to Capsida
- text at x 6.8, y 79.9, w 84.4, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: “STXBP1-related disorders present devastating challenges in communication, development, motor function and seizures. We are in
- text at x 6.8, y 82.6, w 66.4, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: dire need of targeted therapies that can improve the lives and functioning of our children and families,”
- text at x 7.2, y 85.3, w 13.9, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: - Charlene Son Rigby,
- text at x 8.0, y 85.3, w 38.9, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: Charlene Son Rigby, STXBP1 Foundation President & Founder
- text at x 68.0, y 72.6, w 0.3, h 1.5 [Montserrat Medium,Italic; font size 1.49; #000000]: 1
- text at x 12.4, y 95.6, w 18.2, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Capsida May 12, 2025 press release
- text at x 11.8, y 97.8, w 2.2, h 1.8 [Montserrat Medium; font size 1.84; #000000]: See
- text at x 14.0, y 97.8, w 8.7, h 1.8 [Montserrat Medium; font size 1.84; #467886]: clinicaltrials.gov
- text at x 22.8, y 97.8, w 28.8, h 1.8 [Montserrat Medium; font size 1.84; #000000]: for full list of clinician & caregiver secondary endpoints
- text at x 46.9, y 85.2, w 0.3, h 1.5 [Montserrat Medium,Italic; font size 1.49; #000000]: 1
- text at x 95.2, y 95.8, w 0.6, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 11
- text at x 11.8, y 95.5, w 0.3, h 1.2 [Montserrat Medium; font size 1.24; #000000]: 1

### Slide 12

**Text**

CAP-003: PD-GBA
Parkinson’s disease associated
with GBA mutations

**Layout**

Title slide. A tall human-body illustration fills the left ~40% of the slide, bleeding off the bottom edge. Left-aligned title and subtitle sit in the lower right half, starting at x about 47%, between about 58% and 76% of the height. A thin horizontal line runs from the figure's edge to the right edge at about 80% height.

**Visuals**

Semi-transparent 3D medical illustration of a male torso and head in profile facing right, rendered in translucent steel blue. The brain is tinted muted green. Internal organs are visible: heart, lungs, kidneys and blood vessels. The figure is cropped at the waist by the bottom edge, with lighting soft and even. Behind the shoulder and head at upper left, clusters of dark grey glossy spheres form protein or molecular aggregates, some in strands and some in clumps, partly cropped by the top and left edges. A thin pale blue horizontal line crosses the right side at about 80% height.

**Design**

Background: Gradient from white (#FFFFFF) at top-left to pale blue (#DCE8F6) at right and bottom. Soft gradient background, white at the left and top-left fading to pale blue (#DCE8F6) toward the right and bottom. Title and subtitle are in dark charcoal #252524, Montserrat SemiBold sans-serif. Title is about 5.9% of the slide height and subtitle about 4.4%. The accent line is light blue #A9CBF0, about 1px. No shadows or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 0, y 0, w 42.8, h 100: Translucent blue human torso with green brain and visible organs, with grey sphere molecular clusters behind it at upper left (Composed of overlapping images; the figure is cropped by the bottom edge and the spheres are cropped by the top and left edges.)
- line at x 38, y 79.8, w 62, h 0.2 [#A9CBF0]: Thin horizontal pale blue line (About 1px stroke, from behind the figure to the right edge)
- title at x 47.2, y 58, w 30.9, h 5.9 [Montserrat SemiBold; font size 5.94% of slide height; #252524; left aligned]: CAP-003: PD-GBA
- subtitle at x 47.2, y 66.3, w 40.3, h 9.8 [Montserrat SemiBold; font size 4.44% of slide height; #252524; left aligned]: Parkinson’s disease associated / with GBA mutations (Two lines; line 1 'Parkinson’s disease associated' at y 66.3, line 2 'with GBA mutations' at y 71.7 (w 26.2))

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.9, y 2.6, w 6.0, h 29.6: #FFFFFF
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 42.8, h 81.6: 844 by 1000 pixels
- image at x 1.4, y 7.3, w 40.1, h 92.7: 613 by 798 pixels
- text at x 47.2, y 58.0, w 30.9, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: CAP-003: PD-GBA
- text at x 47.2, y 66.3, w 40.3, h 4.4 [Montserrat SemiBold; font size 4.44; #252524]: Parkinson’s disease associated
- text at x 47.2, y 71.7, w 26.2, h 4.4 [Montserrat SemiBold; font size 4.44; #252524]: with GBA mutations

### Slide 13

**Text**

Parkinson’s Disease Associated with GBA Mutations
Opportunity
Up to 15% of all PD cases = ~330k
patients in US and Europe
No approved GBA1 treatments
and no PD disease modifying
treatments
>$1B peak year sales
Potential for expansion to
idiopathic PD
CAP-003
Best in class IV-administered program
Industry-leading brainwide GCase enzyme elevation
Potential for significant disease modification
Safety demonstrated in GLP-Toxicology study in NHPs,
including liver and DRGs
Successful IND clearance
NHP = non-human primate
13

**Layout**

Title at top left spanning most of the width. Two rounded cards below: a narrower grey-headed 'Opportunity' card on the left and a wider green 'CAP-003' card on the right, each with a header band and a list of items separated by thin horizontal rules. Footnote sits above a thin teal footer line; small logo bottom left and page number bottom right.

**Visuals**

Left card: white body with light grey outline and rounded corners, grey header band, four light grey circular bullet markers, thin grey divider lines between items. Right card: mint green body with teal outline and rounded corners, green header band, five teal filled circles with white check marks, thin grey-green divider lines between items. A thin teal horizontal line runs across the full width above the footer. Bottom left: small Capsida Therapeutics logo (blue wordmark 'CAPSIDA' with teal and blue geometric polyhedron mark).

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524 Montserrat SemiBold, about 6% of slide height. Card headers in Montserrat Bold about 3% height: black on grey #DCDDDE band, white on green #2BB673 band. Body text Montserrat Medium about 2.6% height in #252524. Right card body fill #D1F4E3 with teal #00A99D outline; left card white with grey #D0D0D0 outline. Cards have rounded corners of about 1.5% of width, no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 82.6, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Parkinson’s Disease Associated with GBA Mutations
- shape at x 4.2, y 27.1, w 31.2, h 55.1 [#FFFFFF]: Left card body, white with light grey outline, rounded corners (light grey outline, rounded bottom corners)
- shape at x 4.2, y 18.3, w 31.3, h 9.3 [#DCDDDE]: Left card header band, grey, rounded top corners (rounded top corners)
- shape at x 44, y 27.1, w 51.8, h 55.1 [#D1F4E3]: Right card body, mint green with teal outline, rounded corners (teal outline about 1px)
- shape at x 43.9, y 18.3, w 51.9, h 9.3 [#2BB673]: Right card header band, green, rounded top corners (rounded top corners)
- title at x 5.9, y 21.7, w 10.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #000000; left aligned]: Opportunity
- title at x 45.7, y 21.7, w 8, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: CAP-003
- bullet list at x 8.4, y 31.1, w 24.5, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Up to 15% of all PD cases = ~330k / patients in US and Europe (light grey circular bullet at left (x about 6.1%, y about 32%))
- bullet list at x 8.4, y 42.1, w 22.9, h 8.9 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: No approved GBA1 treatments / and no PD disease modifying / treatments (light grey circular bullet at left; thin divider line above (y about 40%) and below (y about 52.7%))
- bullet list at x 8.4, y 56.3, w 15.1, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: >$1B peak year sales (light grey circular bullet at left; divider line below (y about 62%))
- bullet list at x 8.4, y 65.7, w 19.5, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Potential for expansion to / idiopathic PD (light grey circular bullet at left)
- bullet list at x 48.2, y 32.1, w 28.8, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Best in class IV-administered program (teal circle with white check mark at left; divider line below (y about 38.4%))
- bullet list at x 48.2, y 42.4, w 38.7, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Industry-leading brainwide GCase enzyme elevation (teal check circle at left; divider line below (y about 48.6%))
- bullet list at x 48.2, y 52.6, w 33.1, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Potential for significant disease modification (teal check circle at left; divider line below (y about 58.8%))
- bullet list at x 48.2, y 61.4, w 40.9, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Safety demonstrated in GLP-Toxicology study in NHPs, / including liver and DRGs (teal check circle at left; divider line below (y about 69%))
- bullet list at x 48.2, y 73.2, w 18.7, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Successful IND clearance (teal check circle at left; divider line below (y about 79.3%))
- caption at x 4.9, y 90.8, w 14.4, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: NHP = non-human primate
- line at x 0, y 93.3, w 100, h 0.4 [#00A99D]: Thin teal full-width footer line (960 by 2 pixel image)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1E88C8]: Capsida Therapeutics logo: blue 'CAPSIDA' wordmark with teal and blue polyhedron mark (137 by 53 pixel image)
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 13

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.2, y 27.1, w 31.2, h 55.1: #FFFFFF
- fill at x 4.2, y 18.3, w 31.3, h 9.3: #DCDDDE
- fill at x 44.0, y 27.1, w 51.8, h 55.1: #D1F4E3
- fill at x 43.9, y 18.3, w 51.9, h 9.3: #2BB673
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 82.6, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Parkinson’s Disease Associated with GBA Mutations
- text at x 5.9, y 21.7, w 10.7, h 3.0 [Montserrat,Bold; font size 2.96; #000000]: Opportunity
- text at x 45.7, y 21.7, w 8.0, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: CAP-003
- text at x 8.4, y 31.1, w 24.5, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Up to 15% of all PD cases = ~330k
- text at x 48.2, y 32.1, w 28.8, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Best in class IV-administered program
- text at x 8.4, y 34.2, w 19.3, h 2.6 [Montserrat Medium; font size 2.60; #252524]: patients in US and Europe
- text at x 8.4, y 42.1, w 22.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: No approved GBA1 treatments
- text at x 48.2, y 42.4, w 38.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Industry-leading brainwide GCase enzyme elevation
- text at x 8.4, y 45.2, w 22.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: and no PD disease modifying
- text at x 8.4, y 48.4, w 8.4, h 2.6 [Montserrat Medium; font size 2.60; #252524]: treatments
- text at x 48.2, y 52.6, w 33.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Potential for significant disease modification
- text at x 8.4, y 56.3, w 15.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: >$1B peak year sales
- text at x 48.2, y 61.4, w 40.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Safety demonstrated in GLP-Toxicology study in NHPs,
- text at x 48.2, y 64.5, w 18.3, h 2.6 [Montserrat Medium; font size 2.60; #252524]: including liver and DRGs
- text at x 8.4, y 65.7, w 19.5, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Potential for expansion to
- text at x 8.4, y 68.8, w 10.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: idiopathic PD
- text at x 48.2, y 73.2, w 18.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Successful IND clearance
- text at x 4.9, y 90.8, w 14.4, h 1.8 [Montserrat Medium; font size 1.84; #000000]: NHP = non-human primate
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 13

### Slide 14

**Text**

IV-delivered CAP-003 Achieves Superior RNA Expression
Compared to ICM-delivered AAV9 in NHPs
Brain RNA in NHP GLP Tox Study
AAV9 2E11 vg/g ICM¹
CAP-003 3.1E13 vg/kg IV
CAP-003 9.8E12 vg/kg IV
CAP-003 5.0E13 vg/kg IV
WPRE copies/µg RNA
10⁸
10⁷
10⁶
10⁵
10⁴
10³
10²
181X
5888X
Frontal Cortex
Putamen
¹AAV9 ICM data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but / different therapeutic cargo; no protein or %neuron comparison possible
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
14

**Layout**

White slide with a two-line left-aligned title at top. A large rounded-corner outlined chart card is centred in the middle (about x17-84%, y22-90%) with a green header band. Footnote at bottom left, study details right-aligned at bottom right, a thin teal rule across the full width above the footer, logo bottom left and page number bottom right.

**Visuals**

Grouped bar chart on a log scale in a card with a green header band 'Brain RNA in NHP GLP Tox Study'. Y axis 'WPRE copies/µg RNA' from 10^2 to 10^8 with ticks at each decade; X axis has two groups, Frontal Cortex and Putamen, with a tick under each group. Legend (2x2) of square swatches: grey AAV9 2E11 vg/g ICM¹, pale mint CAP-003 9.8E12 vg/kg IV, medium green CAP-003 3.1E13 vg/kg IV, dark green CAP-003 5.0E13 vg/kg IV. Frontal Cortex bars: grey about 1.7x10^4 (error cap about 2.7x10^4), pale mint about 4.8x10^5 (cap about 5.5x10^5), medium green about 3x10^6 (cap about 4x10^6), dark green about 1.2x10^7 (cap about 1.8x10^7). Putamen bars: grey about 5.5x10^2 with no error bar, pale mint about 3x10^5 (cap about 3.8x10^5), medium green about 3.5x10^6 (cap about 4.5x10^6), dark green about 4x10^6 (cap about 6.5x10^6). Green bracket lines with green labels '181X' above Frontal Cortex and '5888X' above Putamen link the grey bar to the medium-green bar, ending in a downward arrow tick over the medium-green bar. Error bars are black T-caps. Capsida Biotherapeutics logo (blue text with teal geometric polyhedron icon) bottom left. Thin teal horizontal line across the slide above the footer.

**Design**

Background: Solid white #FFFFFF. Clean white background. Title in Montserrat SemiBold, dark charcoal #252524, about 6% of slide height. Card has a green #2BB673 header with white bold Montserrat title text, thin green outline about 1.5px, rounded top corners. Body and footnote text in Montserrat, #252524, about 1.8% of height. Chart axis text in Arial, black. Bar colours grey #A6A6A6, pale mint #B4F8DF, medium green #75DEAB, dark green #208856. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 89.6, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: IV-delivered CAP-003 Achieves Superior RNA Expression / Compared to ICM-delivered AAV9 in NHPs (two lines, tight line spacing)
- shape at x 17, y 22.1, w 66.8, h 57.5 [#FFFFFF]: Chart card with white fill and thin green outline, rounded top corners (outline #2BB673 about 1.5px)
- shape at x 17, y 22.1, w 66.8, h 6.4 [#2BB673]: Green header band of chart card with rounded top corners (rounded top corners)
- caption at x 36.1, y 24.3, w 28.6, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Brain RNA in NHP GLP Tox Study (centred in header band)
- chart at x 32.2, y 30, w 34.8, h 7 [Montserrat Medium; font size 1.84% of slide height; #252524; left aligned]: Legend: grey square AAV9 2E11 vg/g ICM¹; pale mint square CAP-003 9.8E12 vg/kg IV; medium green square CAP-003 3.1E13 vg/kg IV; dark green square CAP-003 5.0E13 vg/kg IV (2x2 legend with square swatches #A6A6A6, #B4F8DF, #75DEAB, #208856)
- chart at x 21, y 40.5, w 55, h 38.5 [Arial; font size 2.4% of slide height; #000000]: Log-scale grouped bar chart of WPRE copies/µg RNA, 10^2 to 10^8, groups Frontal Cortex and Putamen, 4 bars each with error bars, y-axis label WPRE copies/µg RNA rotated (black axis lines; bars 3.6% wide each)
- caption at x 33.5, y 41, w 3.6, h 3 [Montserrat Bold; font size 3% of slide height; #2BB673; center aligned]: 181X (with green bracket line down to the grey and medium-green bars)
- caption at x 57.6, y 41, w 5.5, h 3 [Montserrat Bold; font size 3% of slide height; #2BB673; center aligned]: 5888X (with green bracket line down to the grey and medium-green bars)
- footer at x 3.9, y 86.5, w 64.7, h 5.8 [Montserrat Regular; font size 1.84% of slide height; #252524; left aligned]: ¹AAV9 ICM data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but / different therapeutic cargo; no protein or %neuron comparison possible / NHP = non-human primate (superscript 1 at start)
- footer at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat Regular with bold labels; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) ('GLP Tox Study', 'In-life:' and 'Species:' bold)
- line at x 0, y 93.3, w 100, h 0.4 [#1FA38A]: Thin teal horizontal rule across full width (about 2px)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#2A7FBF]: Capsida Biotherapeutics logo: blue CAPSIDA wordmark with teal polyhedron icon
- page number at x 95, y 95.8, w 0.9, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 14

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 17.0, y 22.1, w 66.8, h 6.4: #2BB673
- fill at x 44.8, y 47.2, w 3.6, h 26.4: #208856
- fill at x 70.4, y 49.7, w 3.6, h 23.9: #208856
- fill at x 39.3, y 50.3, w 3.6, h 23.3: #75DEAB
- fill at x 64.9, y 50.0, w 3.6, h 23.6: #75DEAB
- fill at x 33.8, y 54.5, w 3.6, h 19.1: #B4F8DF
- fill at x 59.4, y 55.6, w 3.6, h 18.0: #B4F8DF
- fill at x 28.3, y 62.0, w 3.6, h 11.5: #A6A6A6
- fill at x 33.7, y 30.0, w 14.1, h 3.6: #FFFFFF
- fill at x 52.1, y 30.0, w 14.3, h 3.6: #FFFFFF
- fill at x 33.7, y 33.4, w 14.9, h 3.6: #FFFFFF
- fill at x 52.1, y 33.4, w 14.9, h 3.6: #FFFFFF
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 89.6, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: IV-delivered CAP-003 Achieves Superior RNA Expression
- text at x 3.9, y 12.3, w 66.9, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Compared to ICM-delivered AAV9 in NHPs
- text at x 36.1, y 24.3, w 28.6, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Brain RNA in NHP GLP Tox Study
- text at x 33.5, y 41.0, w 3.6, h 3.0 [Montserrat,Bold; font size 2.96; #2BB673]: 181X
- text at x 57.6, y 41.0, w 5.5, h 3.0 [Montserrat,Bold; font size 2.96; #2BB673]: 5888X
- text at x 34.5, y 30.9, w 10.3, h 1.8 [Montserrat Medium; font size 1.84; #252524]: AAV9 2E11 vg/g ICM
- text at x 52.8, y 30.9, w 12.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: CAP-003 3.1E13 vg/kg IV
- text at x 23.4, y 41.2, w 1.5, h 2.4 [ArialMT; font size 2.38; #000000]: 10
- text at x 34.4, y 34.4, w 12.8, h 1.8 [Montserrat Medium; font size 1.84; #252524]: CAP-003 9.8E12 vg/kg IV
- text at x 52.8, y 34.3, w 12.8, h 1.8 [Montserrat Medium; font size 1.84; #252524]: CAP-003 5.0E13 vg/kg IV
- text at x 21.4, y 46.1, w 3.6, h 2.7 [ArialMT; font size 2.37; #000000]: A 10
- text at x 21.4, y 47.7, w 1.3, h 1.7 [ArialMT; font size 2.37; #000000]: N
- text at x 21.4, y 49.4, w 1.3, h 1.7 [ArialMT; font size 2.37; #000000]: R
- text at x 21.4, y 51.6, w 3.6, h 2.4 [ArialMT; font size 2.37; #000000]: g 10
- text at x 21.4, y 53.1, w 1.3, h 1.4 [ArialMT; font size 2.37; #000000]: μ
- text at x 21.4, y 54.5, w 1.3, h 0.7 [ArialMT; font size 2.37; #000000]: /
- text at x 21.4, y 55.1, w 1.3, h 1.2 [ArialMT; font size 2.37; #000000]: s
- text at x 21.4, y 56.4, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: e
- text at x 21.4, y 56.8, w 3.6, h 2.4 [ArialMT; font size 2.37; #000000]: i 10
- text at x 21.4, y 58.2, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: p
- text at x 21.4, y 59.5, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: o
- text at x 44.8, y 30.8, w 0.3, h 1.2 [Montserrat Medium; font size 1.24; #252524]: 1
- text at x 21.4, y 60.9, w 1.3, h 1.2 [ArialMT; font size 2.37; #000000]: c
- text at x 23.4, y 62.0, w 1.5, h 2.4 [ArialMT; font size 2.38; #000000]: 10
- text at x 25.0, y 41.1, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 8
- text at x 21.4, y 62.7, w 1.3, h 1.6 [ArialMT; font size 2.37; #000000]: E
- text at x 21.4, y 64.4, w 1.3, h 1.7 [ArialMT; font size 2.37; #000000]: R
- text at x 21.4, y 66.1, w 1.3, h 1.6 [ArialMT; font size 2.37; #000000]: P
- text at x 23.4, y 67.2, w 1.5, h 2.4 [ArialMT; font size 2.38; #000000]: 10
- text at x 21.4, y 67.7, w 1.3, h 2.2 [ArialMT; font size 2.37; #000000]: W
- text at x 25.0, y 46.3, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 7
- text at x 23.4, y 72.5, w 1.5, h 2.4 [ArialMT; font size 2.38; #000000]: 10
- text at x 34.1, y 75.4, w 8.5, h 2.4 [ArialMT; font size 2.38; #000000]: Frontal Cortex
- text at x 61.3, y 75.4, w 5.4, h 2.4 [ArialMT; font size 2.38; #000000]: Putamen
- text at x 25.0, y 51.6, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 6
- text at x 25.0, y 56.8, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 5
- text at x 25.0, y 62.0, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 4
- text at x 25.0, y 67.2, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 3
- text at x 25.0, y 72.4, w 0.5, h 1.6 [ArialMT; font size 1.60; #000000]: 2
- text at x 4.3, y 86.5, w 64.3, h 1.8 [Montserrat; font size 1.84; #252524]: AAV9 ICM data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but
- text at x 3.9, y 88.5, w 37.3, h 1.8 [Montserrat; font size 1.84; #252524]: different therapeutic cargo; no protein or %neuron comparison possible
- text at x 3.9, y 90.5, w 14.3, h 1.8 [Montserrat; font size 1.84; #252524]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.0, y 95.8, w 0.9, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 14
- text at x 3.9, y 86.5, w 0.4, h 1.2 [Montserrat; font size 1.24; #252524]: 1

### Slide 15

**Review notes**

- Worth studying: Compares the company's IV-delivered expression against an ICM-delivered AAV9 benchmark with labeled fold increases, using the same axis for a direct visual comparison.

**Text**

IV CAP-003 Achieves Superior GCase Protein Expression in
GLP Tox Study Compared to ICM-delivered AAV9
Brain GCase Protein in NHP GLP Tox Study
Average Brain GCase protein
(% increase over Vehicle)
1000
100
10
1
~20%
48%
141%
415%
ICM AAV9²
8E10 vg/g brain
CAP-003 IV
9.8E12 vg/kg
CAP-003 IV
3.1E13 vg/kg
CAP-003 IV
5E13 vg/kg
40-60% decrease in
GCase bulk protein¹
¹ Sanz Munoz et al., 2021 Decrease in GCase bulk protein in post-mortem brain tissues compared to healthy individuals
² ICM AAV9 reported by Prevail (Source: 2019 S1 filing) in their non-clinical NHP studies (~20% increase across cortex,
hippocampus, midbrain 6 months after administration)
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
15

**Layout**

Title in two lines at top left spanning nearly full width. A centred chart card (about 17% to 85% of width) with a green header bar sits below the title. Footnotes at bottom left, study details right-aligned at bottom right, thin teal rule near the bottom with a logo at bottom left and the page number at bottom right.

**Visuals**

Bar chart on a log scale inside a white card with a thin teal outline and a green rounded-top header bar reading 'Brain GCase Protein in NHP GLP Tox Study'. Y axis is a black line with ticks at 1, 10, 100 and 1000 (log scale), titled 'Average Brain GCase protein (% increase over Vehicle)' (rotated). X axis is a thick black line with four ticks. Four bars: grey (#A0A0A4) ICM AAV9 8E10 vg/g brain, no error bar, top about 20; very light mint (#B4F8DF) CAP-003 IV 9.8E12 vg/kg, top about 48 with a small error bar to about 55; medium mint green (#75DEAB) CAP-003 IV 3.1E13 vg/kg, top about 141 with error bar to about 170; dark green (#208856) CAP-003 IV 5E13 vg/kg, top about 415 with error bar to about 590. Each bar has a light grey (#DADADA) label box near its base with bold value: ~20%, 48%, 141%, 415%. A light grey horizontal band (#D4D4D4) spans the plot between about 40 and 60 on the axis, with the annotation '40-60% decrease in GCase bulk protein¹' to its right. A thin teal horizontal line runs across the full slide width above the footer. The Capsida Biotherapeutics logo (small blue text with a teal geometric icon) sits at bottom left. No legend.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524 Montserrat SemiBold at about 5.9% of slide height. Green header bar #2BB673 with white bold Montserrat text. Chart text in black bold Arial. Footnotes in black Montserrat Medium about 1.8% of height. Study details in charcoal Montserrat with bold labels. Header bar has rounded top corners of about 2% radius. No shadows or gradients. Teal accents (#1BA39C).

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 92.8, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: IV CAP-003 Achieves Superior GCase Protein Expression in / GLP Tox Study Compared to ICM-delivered AAV9 (two lines)
- shape at x 16.9, y 22.1, w 67.7, h 57.5 [#FFFFFF]: Chart card: white box with thin teal outline (1px teal #1BA39C outline)
- shape at x 16.9, y 22.1, w 67.7, h 6.4 [#2BB673]: Green header bar with rounded top corners (top corners rounded)
- caption at x 32.2, y 24.3, w 37.2, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Brain GCase Protein in NHP GLP Tox Study
- shape at x 25.8, y 49.8, w 44.5, h 1.9 [#D4D4D4]: Light grey horizontal band marking the 40-60% range (sits behind the bars)
- shape at x 29.2, y 54.9, w 6.8, h 13.5 [#A0A0A4]: Bar: ICM AAV9, grey, about 20
- shape at x 39.5, y 50.9, w 6.8, h 17.6 [#B4F8DF]: Bar: CAP-003 IV 9.8E12 vg/kg, very light mint, about 48, with small error bar
- shape at x 49.8, y 46, w 6.8, h 22.4 [#75DEAB]: Bar: CAP-003 IV 3.1E13 vg/kg, mint green, about 141, with error bar
- shape at x 60, y 41.1, w 6.8, h 27.4 [#208856]: Bar: CAP-003 IV 5E13 vg/kg, dark green, about 415, with error bar
- line at x 25.7, y 68.2, w 44.7, h 1.7 [#000000]: Black X axis line with four tick marks (thick black stroke)
- line at x 25, y 36.5, w 1, h 33.4 [#000000]: Black Y axis line with log ticks at 1, 10, 100, 1000
- caption at x 21.8, y 35.9, w 3, h 2.4 [Arial Bold; font size 2.39% of slide height; #000000; right aligned]: 1000
- caption at x 22.6, y 46.4, w 2.2, h 2.4 [Arial Bold; font size 2.39% of slide height; #000000; right aligned]: 100
- caption at x 23.3, y 56.9, w 1.5, h 2.4 [Arial Bold; font size 2.39% of slide height; #000000; right aligned]: 10
- caption at x 24.1, y 67.4, w 0.7, h 2.4 [Arial Bold; font size 2.39% of slide height; #000000; right aligned]: 1
- caption at x 18.3, y 36.9, w 3, h 30.9 [Arial regular; font size 2.38% of slide height; #000000; center aligned]: Average Brain GCase protein / (% increase over Vehicle) (rotated 90 degrees counter-clockwise, two lines)
- caption at x 29.5, y 61.5, w 5.6, h 5 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: ~20% (on light grey label box #DADADA)
- caption at x 39.7, y 61.5, w 6.2, h 5 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: 48% (on light grey label box)
- caption at x 49.9, y 61.5, w 6.2, h 5 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: 141% (on light grey label box)
- caption at x 60.2, y 61.5, w 6.4, h 5 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: 415% (on light grey label box)
- caption at x 27.7, y 70.4, w 9.7, h 5.2 [Arial Bold; font size 2.39% of slide height; #000000; center aligned]: ICM AAV9² / 8E10 vg/g brain (superscript 2)
- caption at x 38.7, y 70.4, w 8.3, h 5.2 [Arial Bold; font size 2.39% of slide height; #000000; center aligned]: CAP-003 IV / 9.8E12 vg/kg
- caption at x 49.1, y 70.4, w 8.1, h 5.2 [Arial Bold; font size 2.39% of slide height; #000000; center aligned]: CAP-003 IV / 3.1E13 vg/kg
- caption at x 59.8, y 70.4, w 7.2, h 5.2 [Arial Bold; font size 2.39% of slide height; #000000; center aligned]: CAP-003 IV / 5E13 vg/kg
- caption at x 71.4, y 48.9, w 11.2, h 4.4 [Montserrat Medium; font size 1.96% of slide height; #000000; left aligned]: 40-60% decrease in / GCase bulk protein¹ (superscript 1)
- line at x 0, y 93.3, w 100, h 0.4 [#1BA39C]: Thin teal horizontal rule across slide
- footer at x 3.9, y 84.3, w 62.5, h 8.5 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: ¹ Sanz Munoz et al., 2021 Decrease in GCase bulk protein in post-mortem brain tissues compared to healthy individuals / ² ICM AAV9 reported by Prevail (Source: 2019 S1 filing) in their non-clinical NHP studies (~20% increase across cortex, / hippocampus, midbrain 6 months after administration) / NHP = non-human primate (four lines; superscript markers 1 and 2)
- caption at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat Bold labels, Montserrat regular values; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) ('GLP Tox Study', 'In-life:' and 'Species:' are bold)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#2D7FC1]: Capsida Biotherapeutics logo (blue wordmark with teal geometric icon)
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 15

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 16.9, y 22.1, w 67.7, h 6.4: #2BB673
- fill at x 25.8, y 49.8, w 44.5, h 1.9: #D4D4D4
- fill at x 60.0, y 41.1, w 6.8, h 27.4: #208856
- fill at x 49.8, y 46.0, w 6.8, h 22.4: #75DEAB
- fill at x 39.5, y 50.9, w 6.8, h 17.6: #B4F8DF
- fill at x 29.2, y 54.9, w 6.8, h 13.5: #A0A0A4
- fill at x 25.7, y 68.2, w 44.7, h 1.7: #000000
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 92.8, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: IV CAP-003 Achieves Superior GCaseProtein Expression in
- text at x 3.9, y 12.3, w 77.2, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: GLP Tox Study Compared to ICM-delivered AAV9
- text at x 32.2, y 24.3, w 37.2, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Brain GCase Protein in NHP GLP Tox Study
- text at x 21.8, y 35.9, w 3.0, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 1000
- text at x 18.3, y 38.4, w 1.3, h 0.5 [ArialMT; font size 2.38; #000000]: i
- text at x 18.3, y 37.1, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: n
- text at x 18.3, y 38.9, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: e)
- text at x 18.3, y 39.9, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: te
- text at x 18.3, y 40.9, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: ol
- text at x 18.3, y 42.2, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: ri
- text at x 19.9, y 41.8, w 1.3, h 1.2 [ArialMT; font size 2.38; #000000]: c
- text at x 18.3, y 43.0, w 2.9, h 1.8 [ArialMT; font size 2.38; #000000]: ph
- text at x 18.3, y 44.8, w 2.9, h 1.5 [ArialMT; font size 2.38; #000000]: ee
- text at x 18.3, y 46.1, w 2.9, h 1.6 [ArialMT; font size 2.38; #000000]: sV
- text at x 18.3, y 47.5, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: a
- text at x 22.6, y 46.4, w 2.2, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 100
- text at x 19.9, y 48.3, w 1.3, h 0.8 [ArialMT; font size 2.38; #000000]: r
- text at x 18.3, y 48.8, w 2.9, h 1.7 [ArialMT; font size 2.38; #000000]: Ce
- text at x 18.3, y 50.5, w 2.9, h 2.0 [ArialMT; font size 2.38; #000000]: Gv
- text at x 30.4, y 62.6, w 4.4, h 3.0 [Montserrat Medium; font size 2.96; #000000]: ~20%
- text at x 30.4, y 62.6, w 4.4, h 3.0 [Montserrat Medium; font size 2.96; #000000]: ~20%
- text at x 41.0, y 62.6, w 3.6, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 48%
- text at x 41.0, y 62.6, w 3.6, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 48%
- text at x 51.3, y 62.6, w 3.7, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 141%
- text at x 51.3, y 62.6, w 3.7, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 141%
- text at x 61.4, y 62.6, w 4.1, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 415%
- text at x 61.4, y 62.6, w 4.1, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 415%
- text at x 19.9, y 51.7, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: o
- text at x 18.3, y 53.1, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: n
- text at x 18.3, y 53.6, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: ie
- text at x 18.3, y 55.0, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: as
- text at x 18.3, y 56.2, w 2.9, h 1.3 [ArialMT; font size 2.38; #000000]: ra
- text at x 18.3, y 57.0, w 2.9, h 1.8 [ArialMT; font size 2.38; #000000]: Be
- text at x 23.3, y 56.9, w 1.5, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 10
- text at x 18.3, y 58.8, w 2.9, h 1.8 [ArialMT; font size 2.38; #000000]: er
- text at x 18.3, y 60.6, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: g
- text at x 19.9, y 59.6, w 1.3, h 1.2 [ArialMT; font size 2.38; #000000]: c
- text at x 71.4, y 48.9, w 11.2, h 2.0 [Montserrat Medium; font size 1.96; #000000]: 40-60% decrease in
- text at x 19.9, y 60.8, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: n
- text at x 19.9, y 62.1, w 1.3, h 0.5 [ArialMT; font size 2.38; #000000]: i
- text at x 18.3, y 63.3, w 1.3, h 0.8 [ArialMT; font size 2.38; #000000]: r
- text at x 18.3, y 62.0, w 1.3, h 1.3 [ArialMT; font size 2.38; #000000]: a
- text at x 71.4, y 51.2, w 10.6, h 2.0 [Montserrat Medium; font size 1.96; #000000]: GCase bulk protein
- text at x 18.3, y 63.3, w 2.9, h 2.1 [ArialMT; font size 2.38; #000000]: e%
- text at x 18.3, y 65.4, w 2.9, h 1.2 [ArialMT; font size 2.38; #000000]: v(
- text at x 18.3, y 66.6, w 1.3, h 1.6 [ArialMT; font size 2.38; #000000]: A
- text at x 24.1, y 67.4, w 0.7, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 1
- text at x 29.4, y 70.4, w 6.4, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: ICM AAV9
- text at x 39.3, y 70.4, w 7.2, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: CAP-003 IV
- text at x 49.5, y 70.4, w 7.2, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: CAP-003 IV
- text at x 59.8, y 70.4, w 7.2, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: CAP-003 IV
- text at x 27.7, y 73.2, w 19.3, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 8E10 vg/g brain 9.8E12 vg/kg
- text at x 49.1, y 73.2, w 8.1, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 3.1E13 vg/kg
- text at x 59.9, y 73.2, w 7.0, h 2.4 [ARIAL,Bold; font size 2.39; #000000]: 5E13 vg/kg
- text at x 35.8, y 69.6, w 0.6, h 1.8 [Montserrat Medium; font size 1.84; #000000]: 2
- text at x 82.0, y 51.2, w 0.3, h 1.3 [Montserrat Medium; font size 1.29; #000000]: 1
- text at x 4.5, y 84.3, w 62.5, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Sanz Munoz et al., 2021 Decrease in GCase bulk protein in post-mortem brain tissues compared to healthy individuals
- text at x 4.6, y 86.6, w 60.7, h 1.8 [Montserrat Medium; font size 1.84; #000000]: ICM AAV9 reported by Prevail (Source: 2019 S1 filing) in their non-clinical NHP studies (~20% increase across cortex,
- text at x 3.9, y 88.8, w 29.3, h 1.8 [Montserrat Medium; font size 1.84; #000000]: hippocampus, midbrain 6 months after administration)
- text at x 3.9, y 91.0, w 14.7, h 1.8 [Montserrat Medium; font size 1.84; #000000]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 15
- text at x 3.9, y 84.3, w 0.3, h 1.2 [Montserrat Medium; font size 1.24; #000000]: 1
- text at x 3.9, y 86.5, w 0.4, h 1.2 [Montserrat Medium; font size 1.24; #000000]: 2

### Slide 16

**Text**

CAP-003 Exceeds Efficacy Threshold for Normalizing GCase
Activity in Patients in NHP GLP Tox Study
Brain GCase Activity in NHP GLP Tox Study
1000
100
10
1
Average Brain GCase activity
(% increase over Vehicle)
10%
86%
206%
30% therapeutic threshold¹
(based on human post-mortem data)
CAP-003
9.8E12 vg/kg
CAP-003
3.1E13 vg/kg
CAP-003
5E13 vg/kg
¹Leyns et al., 2023. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to
healthy individuals
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
16

**Layout**

Two-line left-aligned title across the top. A large bordered chart panel with a green header band is centred below the title (about x 17-84%, y 22-90%). Footnotes sit bottom-left and a study-details block sits bottom-right, right-aligned. A thin teal footer rule spans the full width above a logo at bottom-left and a page number at bottom-right.

**Visuals**

Bar chart in a white panel with a thin teal outline and a green (#2BB673) rounded-top header band reading 'Brain GCase Activity in NHP GLP Tox Study'. Log-scale y-axis from 1 to 1000 with ticks at 1, 10, 100 and 1000, titled 'Average Brain GCase activity (% increase over Vehicle)' (rotated). Three vertical bars on a black x-axis with tick marks below each bar. Bar 1, CAP-003 9.8E12 vg/kg, is pale mint (#D1F4E3), height about 10, with a label box '10%' and a small error bar up to about 11. Bar 2, CAP-003 3.1E13 vg/kg, is medium mint green (#75DEAB), height about 86, labelled '86%', error bar up to about 115. Bar 3, CAP-003 5E13 vg/kg, is dark green (#208856), height about 206, labelled '206%', error bar up to about 290. Each percent label sits in a light grey (#D9D9D9) rectangle near the bar base. A black dashed horizontal line at about 30 crosses the chart and extends right of the bars to the label '30% therapeutic threshold¹ (based on human post-mortem data)'. A small Capsida Biotherapeutics logo with a teal/blue polyhedral mark sits at bottom-left. A thin teal horizontal line runs full width above the footer.

**Design**

Background: Solid white #FFFFFF. White background. The title is dark charcoal (#252524) in Montserrat SemiBold, about 5.9% of slide height. Chart header text is white Montserrat Bold. Chart labels are black Arial Bold. Footnotes are black Montserrat Regular at about 1.8% of slide height. The study details are charcoal Montserrat, with bold labels. Accent colours are greens (#2BB673, #75DEAB, #208856, #D1F4E3) and teal lines. Flat style with no shadows or gradients; the header band has rounded top corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 2.8, y 5.6, w 93.5, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: CAP-003 Exceeds Efficacy Threshold for Normalizing GCase / Activity in Patients in NHP GLP Tox Study (two lines, tight line spacing)
- shape at x 17, y 22.2, w 66.8, h 67.6 [#FFFFFF]: Chart panel with thin teal outline, white fill (1px teal (#1AA59A) border)
- shape at x 17, y 22.2, w 66.8, h 6.4 [#2BB673]: Green header band with rounded top corners (rounded top corners)
- caption at x 31.7, y 24.4, w 37.4, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Brain GCase Activity in NHP GLP Tox Study
- chart at x 19, y 37, w 46, h 35 [#000000]: Log-scale bar chart with y-axis 1 to 1000, ticks 1, 10, 100, 1000, three bars with error bars and a dashed 30% line (black axes, about 0.3% thick)
- shape at x 29.2, y 58.5, w 7.8, h 9.8 [#D1F4E3]: Bar CAP-003 9.8E12 vg/kg, value about 10
- shape at x 41.1, y 48.8, w 7.8, h 19.5 [#75DEAB]: Bar CAP-003 3.1E13 vg/kg, value about 86
- shape at x 53, y 44.9, w 7.8, h 23.3 [#208856]: Bar CAP-003 5E13 vg/kg, value about 206
- caption at x 29.9, y 59.9, w 6.2, h 4.9 [Montserrat Medium; font size 3% of slide height; #000000; center aligned]: 10% (on light grey (#D9D9D9) rectangle)
- caption at x 41.9, y 59.9, w 6.2, h 4.9 [Montserrat Medium; font size 3% of slide height; #000000; center aligned]: 86% (on light grey (#D9D9D9) rectangle)
- caption at x 53.7, y 59.9, w 6.2, h 4.9 [Montserrat Medium; font size 3% of slide height; #000000; center aligned]: 206% (on light grey (#D9D9D9) rectangle)
- caption at x 19.2, y 40.3, w 2.4, h 25.4 [Arial; font size 1.95% of slide height; #000000; center aligned]: Average Brain GCase activity / (% increase over Vehicle) (rotated 90° counter-clockwise, two lines)
- caption at x 65.5, y 51.5, w 16.8, h 4 [Montserrat Medium; font size 2.2% of slide height; #000000; left aligned]: 30% therapeutic threshold¹ / (based on human post-mortem data) (second line smaller at about 1.5%; dashed black line leads to it)
- caption at x 29.8, y 69.9, w 6.6, h 4.2 [Arial Bold; font size 1.95% of slide height; #000000; center aligned]: CAP-003 / 9.8E12 vg/kg
- caption at x 41.7, y 69.9, w 6.6, h 4.2 [Arial Bold; font size 1.95% of slide height; #000000; center aligned]: CAP-003 / 3.1E13 vg/kg
- caption at x 54, y 69.9, w 5.7, h 4.2 [Arial Bold; font size 1.95% of slide height; #000000; center aligned]: CAP-003 / 5E13 vg/kg
- line at x 0, y 93.3, w 100, h 0.4 [#1AA59A]: Full-width thin teal footer rule
- footer at x 3.4, y 86.5, w 62.7, h 5.8 [Montserrat Regular; font size 1.84% of slide height; #000000; left aligned]: ¹Leyns et al., 2023. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to / healthy individuals / NHP = non-human primate (three lines; superscript 1)
- footer at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat, bold labels with regular values; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) ('GLP Tox Study', 'In-life:' and 'Species:' are bold)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1AA59A]: Capsida Biotherapeutics logo with teal polyhedral mark
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 16

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 53.0, y 44.9, w 7.8, h 23.3: #208856
- fill at x 41.1, y 48.8, w 7.8, h 19.5: #75DEAB
- fill at x 29.2, y 58.5, w 7.8, h 9.8: #D1F4E3
- fill at x 25.1, y 68.1, w 39.8, h 1.3: #000000
- fill at x 2.5, y 87.8, w 68.4, h 5.3: #FFFFFF
- fill at x 17.0, y 22.2, w 66.8, h 6.4: #2BB673
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 2.8, y 5.6, w 93.5, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-003 Exceeds Efficacy Threshold for Normalizing GCase
- text at x 2.8, y 12.0, w 64.9, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Activity in Patients in NHP GLP Tox Study
- text at x 31.7, y 24.4, w 37.4, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Brain GCase Activity in NHP GLP Tox Study
- text at x 22.0, y 37.1, w 2.4, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 1000
- text at x 19.2, y 40.3, w 1.1, h 1.0 [ArialMT; font size 1.95; #000000]: y
- text at x 31.5, y 61.0, w 3.1, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 10%
- text at x 31.5, y 61.0, w 3.1, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 10%
- text at x 43.4, y 61.0, w 3.5, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 86%
- text at x 43.4, y 61.0, w 3.5, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 86%
- text at x 54.6, y 61.0, w 4.5, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 206%
- text at x 54.6, y 61.0, w 4.5, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 206%
- text at x 19.2, y 41.8, w 1.1, h 0.4 [ArialMT; font size 1.95; #000000]: i
- text at x 19.2, y 41.3, w 1.1, h 0.5 [ArialMT; font size 1.95; #000000]: t
- text at x 20.4, y 42.0, w 1.1, h 0.6 [ArialMT; font size 1.95; #000000]: )
- text at x 19.2, y 42.3, w 2.4, h 1.4 [ArialMT; font size 1.95; #000000]: ve
- text at x 19.2, y 43.7, w 1.1, h 0.5 [ArialMT; font size 1.95; #000000]: t
- text at x 19.2, y 43.2, w 2.4, h 0.9 [ArialMT; font size 1.95; #000000]: il
- text at x 19.2, y 44.1, w 2.4, h 1.0 [ArialMT; font size 1.95; #000000]: cc
- text at x 19.2, y 45.2, w 2.4, h 1.4 [ArialMT; font size 1.95; #000000]: ah
- text at x 20.4, y 45.1, w 1.1, h 0.4 [ArialMT; font size 1.95; #000000]: i
- text at x 65.5, y 51.5, w 10.6, h 2.2 [Montserrat Medium; font size 2.22; #000000]: 30% therapeutic
- text at x 65.5, y 51.5, w 16.6, h 2.2 [Montserrat Medium; font size 2.22; #000000]: 30% therapeutic threshold
- text at x 76.0, y 51.5, w 6.1, h 2.2 [Montserrat Medium; font size 2.22; #000000]: threshold
- text at x 20.4, y 46.6, w 1.1, h 1.1 [ArialMT; font size 1.95; #000000]: e
- text at x 19.2, y 46.8, w 1.1, h 1.1 [ArialMT; font size 1.95; #000000]: e
- text at x 22.6, y 47.2, w 1.8, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 100
- text at x 19.2, y 47.7, w 2.4, h 1.3 [ArialMT; font size 1.95; #000000]: sV
- text at x 19.2, y 48.9, w 2.4, h 1.3 [ArialMT; font size 1.95; #000000]: ar
- text at x 19.2, y 50.0, w 2.4, h 1.4 [ArialMT; font size 1.95; #000000]: Ce
- text at x 19.2, y 51.3, w 2.4, h 1.6 [ArialMT; font size 1.95; #000000]: Gv
- text at x 20.4, y 52.2, w 1.1, h 1.1 [ArialMT; font size 1.95; #000000]: o
- text at x 19.2, y 53.4, w 1.1, h 1.1 [ArialMT; font size 1.95; #000000]: n
- text at x 19.2, y 53.9, w 2.4, h 1.1 [ArialMT; font size 1.95; #000000]: ie
- text at x 19.2, y 54.9, w 2.4, h 1.1 [ArialMT; font size 1.95; #000000]: as
- text at x 19.2, y 55.9, w 2.4, h 1.1 [ArialMT; font size 1.95; #000000]: ra
- text at x 19.2, y 56.6, w 2.4, h 1.4 [ArialMT; font size 1.95; #000000]: Be
- text at x 20.4, y 58.1, w 1.1, h 0.6 [ArialMT; font size 1.95; #000000]: r
- text at x 23.2, y 57.3, w 1.2, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 10
- text at x 19.2, y 58.5, w 2.4, h 1.3 [ArialMT; font size 1.95; #000000]: ec
- text at x 19.2, y 59.6, w 2.4, h 1.2 [ArialMT; font size 1.95; #000000]: gn
- text at x 19.2, y 60.6, w 2.4, h 1.1 [ArialMT; font size 1.95; #000000]: ai
- text at x 19.2, y 61.7, w 2.4, h 1.8 [ArialMT; font size 1.95; #000000]: r%
- text at x 19.2, y 62.4, w 1.1, h 1.1 [ArialMT; font size 1.95; #000000]: e
- text at x 20.4, y 63.5, w 1.1, h 0.6 [ArialMT; font size 1.95; #000000]: (
- text at x 19.2, y 63.4, w 1.1, h 1.0 [ArialMT; font size 1.95; #000000]: v
- text at x 19.2, y 64.4, w 1.1, h 1.3 [ArialMT; font size 1.95; #000000]: A
- text at x 23.8, y 67.4, w 0.6, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 1
- text at x 30.9, y 69.9, w 4.5, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: CAP-003
- text at x 42.7, y 69.9, w 4.5, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: CAP-003
- text at x 54.6, y 69.9, w 4.5, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: CAP-003
- text at x 65.5, y 54.0, w 9.4, h 1.5 [Montserrat Medium; font size 1.49; #000000]: (based on human post
- text at x 65.5, y 54.0, w 15.5, h 1.5 [Montserrat Medium; font size 1.49; #000000]: (based on human post--mortem data)
- text at x 75.2, y 54.0, w 5.8, h 1.5 [Montserrat Medium; font size 1.49; #000000]: mortem data)
- text at x 29.8, y 72.1, w 6.6, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 9.8E12 vg/kg
- text at x 41.7, y 72.1, w 6.6, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 3.1E13 vg/kg
- text at x 54.0, y 72.1, w 5.7, h 2.0 [ARIAL,Bold; font size 1.95; #000000]: 5E13 vg/kg
- text at x 82.0, y 51.5, w 0.3, h 1.4 [Montserrat Medium; font size 1.36; #000000]: 11
- text at x 3.7, y 86.5, w 62.4, h 1.8 [Montserrat; font size 1.84; #000000]: Leyns et al., 2023. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to
- text at x 3.4, y 88.5, w 9.8, h 1.8 [Montserrat; font size 1.84; #000000]: healthy individuals
- text at x 3.4, y 90.5, w 14.3, h 1.8 [Montserrat; font size 1.84; #000000]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 16
- text at x 3.4, y 86.5, w 0.3, h 1.2 [Montserrat; font size 1.24; #000000]: 1

### Slide 17

**Text**

CAP-003 Significantly Increases GCase in CSF in GLP Tox
Study Validating Use as Clinical Biomarker
GCase Protein in CSF in NHP GLP Tox Study
Correlation of CSF GCase Protein
& Brain GCase Activity
GCase protein in CSF
(% increase over Vehicle)
10000
1000
100
10
1
72%
479%
984%
CAP-003
9.8E12 vg/kg
CAP-003
3.1E13 vg/kg
CAP-003
5E13 vg/kg
10
5
0
-5
r = 0.986
p < 0.0001
GCase protein
CSF (ng/mg)
0.2
0.4
0.6
0.8
1.0
Average Brain GCase activity
(mU/g protein)
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
17

**Layout**

Two-line left-aligned title across the top. Below it, two equal-width panels side by side (left about x4–48%, right about x52–96%), each with a green rounded-top header band and a thin teal-outlined white body holding a chart. A footnote sits bottom left, a study-details block is right-aligned at bottom right, a teal rule runs across near the bottom, with a logo bottom left and the page number bottom right.

**Visuals**

Left panel: log-scale bar chart with three bars and error bars, y-axis 1 to 10000 (ticks 1, 10, 100, 1000, 10000), black axis lines, y-axis title 'GCase protein in CSF (% increase over Vehicle)'. Bars: CAP-003 9.8E12 vg/kg pale mint (#D1F4E3) at about 72, labelled 72% in a light grey box; CAP-003 3.1E13 vg/kg medium mint green (#75DEAB) at about 479, labelled 479%; CAP-003 5E13 vg/kg dark green (#208856) at about 984, labelled 984%. Error bars extend to about 110, 580 and 1400 respectively. Tick marks under each bar. Right panel: scatter plot with regression line and dotted confidence band, x-axis Average Brain GCase activity (mU/g protein) 0.2 to 1.0 with ticks at 0.2, 0.4, 0.6, 0.8, 1.0; y-axis GCase protein CSF (ng/mg) from -5 to 10 with ticks -5, 0, 5, 10. About 12 black dots, clustered near (0.2–0.35, 0–2) and others at about (0.34, 2.1), (0.41, 3.8), (0.56, 3.8), (0.82, 7.4), (0.91, 9.0). A boxed black-outline text 'r = 0.986 / p < 0.0001' sits at top left of the plot. Teal horizontal rule near the bottom of the slide. Capsida Biotherapeutics logo (small blue text with a teal geometric icon) at bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal (#252524) Montserrat SemiBold, about 6% of slide height. Panel headers solid green #2BB673 with white Montserrat Bold text about 3% of height, rounded top corners (about 3% radius). Panel bodies white with thin teal outline (#1AA39A). Chart text in black Arial, bold for tick labels. Value labels in Montserrat Medium on light grey (#D9D9D9) rectangles. Footnotes in Montserrat about 1.7-1.8% of height. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 89.4, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: CAP-003 Significantly Increases GCase in CSF in GLP Tox / Study Validating Use as Clinical Biomarker (two lines, tight line spacing)
- shape at x 3.8, y 27.4, w 44.5, h 7.9 [#2BB673]: Left panel header band, green with rounded top corners (rounded top corners)
- shape at x 51.7, y 27.4, w 44.5, h 7.9 [#2BB673]: Right panel header band, green with rounded top corners (rounded top corners)
- shape at x 3.8, y 35.3, w 44.5, h 39.2 [#FFFFFF]: Left panel body, white with thin teal outline (teal outline about 1px)
- shape at x 51.7, y 35.3, w 44.5, h 39.2 [#FFFFFF]: Right panel body, white with thin teal outline (teal outline about 1px)
- caption at x 7, y 30.4, w 38, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: GCase Protein in CSF in NHP GLP Tox Study
- caption at x 59.5, y 28.7, w 29.2, h 6.5 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Correlation of CSF GCase Protein / & Brain GCase Activity (two lines)
- chart at x 5, y 35.5, w 41, h 38 [Arial; font size 2.2% of slide height; #000000]: Log-scale bar chart of GCase protein in CSF (% increase over Vehicle) for three CAP-003 doses: 72%, 479%, 984%, with error bars, y-axis 1 to 10000 (bars pale mint #D1F4E3, mint #75DEAB, dark green #208856; black axes about 1.5% thick; y-axis title rotated)
- shape at x 16.7, y 44.3, w 5.5, h 5 [#D9D9D9]: Grey label box behind 72%
- shape at x 26.7, y 39.3, w 6, h 5 [#D9D9D9]: Grey label box behind 479%
- shape at x 36.2, y 36.3, w 6.5, h 5 [#D9D9D9]: Grey label box behind 984%
- caption at x 17.5, y 45.5, w 3.3, h 3 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: 72% (appears bold)
- caption at x 27.5, y 40.4, w 4.5, h 3 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: 479% (appears bold)
- caption at x 37, y 37.4, w 4.6, h 3 [Montserrat Medium; font size 2.96% of slide height; #000000; center aligned]: 984% (appears bold)
- caption at x 15.5, y 68.3, w 7.6, h 4.8 [Arial Bold; font size 2.23% of slide height; #000000; center aligned]: CAP-003 / 9.8E12 vg/kg
- caption at x 25.4, y 68.3, w 7.6, h 4.8 [Arial Bold; font size 2.23% of slide height; #000000; center aligned]: CAP-003 / 3.1E13 vg/kg
- caption at x 35.9, y 68.3, w 6.6, h 4.8 [Arial Bold; font size 2.23% of slide height; #000000; center aligned]: CAP-003 / 5E13 vg/kg
- chart at x 57, y 39.5, w 32, h 31 [Arial; font size 2.2% of slide height; #000000]: Scatter plot of GCase protein CSF (ng/mg) vs Average Brain GCase activity (mU/g protein) with regression line, dotted confidence band and about 12 black points; r = 0.986, p < 0.0001 (x-axis 0.2 to 1.0, y-axis -5 to 10; boxed stats label with black 1px outline at top left of plot)
- line at x 0, y 93.3, w 100, h 0.4 [#1AA39A]: Teal horizontal rule near the bottom
- caption at x 4.5, y 90.7, w 14.4, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: NHP = non-human primate
- caption at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat; bold labels and regular values; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) (three lines; 'GLP Tox Study', 'In-life:' and 'Species:' bold)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1AA39A]: Capsida Biotherapeutics logo, small blue wordmark with teal geometric icon
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 17

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 35.9, y 44.6, w 6.5, h 21.9: #208856
- fill at x 26.0, y 46.9, w 6.5, h 19.6: #75DEAB
- fill at x 16.0, y 52.9, w 6.5, h 13.6: #D1F4E3
- fill at x 12.6, y 66.2, w 33.3, h 1.5: #000000
- fill at x 68.0, y 41.5, w 17.2, h 16.9: #000000
- fill at x 68.0, y 44.6, w 17.1, h 15.4: #000000
- fill at x 63.4, y 40.4, w 7.2, h 6.8: #000000
- fill at x 3.8, y 27.4, w 44.5, h 7.9: #2BB673
- fill at x 51.7, y 27.4, w 44.5, h 7.9: #2BB673
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 89.4, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-003 Significantly Increases GCasein CSF in GLP Tox
- text at x 3.9, y 12.3, w 66.7, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Study Validating Use as Clinical Biomarker
- text at x 59.5, y 28.7, w 29.2, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Correlation of CSF GCase Protein
- text at x 7.0, y 30.4, w 38.0, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: GCase Protein in CSF in NHP GLP Tox Study
- text at x 64.1, y 32.2, w 19.5, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: & Brain GCase Activity
- text at x 37.0, y 37.4, w 4.6, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 984%
- text at x 37.0, y 37.4, w 4.6, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 984%
- text at x 27.5, y 40.4, w 4.5, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 479%
- text at x 27.5, y 40.4, w 4.5, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 479%
- text at x 17.5, y 45.5, w 3.3, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 72%
- text at x 17.5, y 45.5, w 3.3, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 72%
- text at x 8.3, y 36.1, w 3.5, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 10000
- text at x 6.6, y 39.1, w 1.3, h 0.7 [ArialMT; font size 2.23; #000000]: )
- text at x 6.6, y 39.8, w 1.3, h 1.2 [ArialMT; font size 2.23; #000000]: e
- text at x 63.8, y 41.3, w 5.4, h 2.4 [ArialMT; font size 2.39; #000000]: r = 0.986
- text at x 5.1, y 40.8, w 2.7, h 1.4 [ArialMT; font size 2.23; #000000]: Fl
- text at x 61.0, y 39.6, w 1.4, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 10
- text at x 6.6, y 41.5, w 1.3, h 1.1 [ArialMT; font size 2.23; #000000]: c
- text at x 63.8, y 44.0, w 6.4, h 2.4 [ArialMT; font size 2.39; #000000]: p < 0.0001
- text at x 5.1, y 42.2, w 1.3, h 1.5 [ArialMT; font size 2.23; #000000]: S
- text at x 6.6, y 43.1, w 1.3, h 1.2 [ArialMT; font size 2.23; #000000]: h
- text at x 6.6, y 42.6, w 1.3, h 0.5 [ArialMT; font size 2.23; #000000]: i
- text at x 5.1, y 43.7, w 2.7, h 1.9 [ArialMT; font size 2.23; #000000]: Ce
- text at x 9.0, y 43.5, w 2.8, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 1000
- text at x 5.1, y 45.6, w 2.7, h 1.5 [ArialMT; font size 2.23; #000000]: nV
- text at x 5.1, y 47.1, w 2.7, h 1.3 [ArialMT; font size 2.23; #000000]: ir
- text at x 5.1, y 48.3, w 2.7, h 1.4 [ArialMT; font size 2.23; #000000]: ne
- text at x 5.1, y 50.0, w 1.3, h 1.2 [ArialMT; font size 2.23; #000000]: e
- text at x 5.1, y 49.5, w 2.7, h 1.3 [ArialMT; font size 2.23; #000000]: iv
- text at x 57.8, y 49.0, w 1.2, h 0.5 [ArialMT; font size 2.17; #000000]: i
- text at x 57.8, y 47.8, w 2.6, h 1.5 [ArialMT; font size 2.17; #000000]: n)
- text at x 5.1, y 50.8, w 2.7, h 1.2 [ArialMT; font size 2.23; #000000]: to
- text at x 57.8, y 49.3, w 2.6, h 1.3 [ArialMT; font size 2.17; #000000]: eg
- text at x 61.7, y 49.1, w 0.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 5
- text at x 5.1, y 51.9, w 1.3, h 1.2 [ArialMT; font size 2.23; #000000]: o
- text at x 9.7, y 50.8, w 2.1, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 100
- text at x 57.8, y 50.6, w 2.6, h 1.8 [ArialMT; font size 2.17; #000000]: tm
- text at x 5.1, y 52.6, w 2.7, h 1.2 [ArialMT; font size 2.23; #000000]: re
- text at x 57.8, y 51.3, w 1.2, h 1.2 [ArialMT; font size 2.17; #000000]: o
- text at x 5.1, y 53.8, w 2.7, h 1.2 [ArialMT; font size 2.23; #000000]: ps
- text at x 57.8, y 52.5, w 2.6, h 1.7 [ArialMT; font size 2.17; #000000]: rg
- text at x 59.2, y 52.4, w 1.2, h 0.6 [ArialMT; font size 2.17; #000000]: /
- text at x 6.6, y 55.0, w 1.3, h 1.2 [ArialMT; font size 2.23; #000000]: a
- text at x 57.8, y 53.2, w 1.2, h 1.2 [ArialMT; font size 2.17; #000000]: p
- text at x 5.1, y 55.7, w 2.7, h 1.8 [ArialMT; font size 2.23; #000000]: ee
- text at x 57.8, y 55.0, w 2.6, h 1.2 [ArialMT; font size 2.17; #000000]: e(
- text at x 59.2, y 54.2, w 1.2, h 1.2 [ArialMT; font size 2.17; #000000]: n
- text at x 5.1, y 56.9, w 2.7, h 1.3 [ArialMT; font size 2.23; #000000]: sr
- text at x 57.8, y 56.3, w 1.2, h 1.1 [ArialMT; font size 2.17; #000000]: s
- text at x 5.1, y 58.1, w 2.7, h 1.3 [ArialMT; font size 2.23; #000000]: ac
- text at x 10.4, y 58.1, w 1.4, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 10
- text at x 57.8, y 56.7, w 2.6, h 1.8 [ArialMT; font size 2.17; #000000]: aF
- text at x 5.1, y 59.3, w 2.7, h 1.6 [ArialMT; font size 2.23; #000000]: Cn
- text at x 59.2, y 58.0, w 1.2, h 1.4 [ArialMT; font size 2.17; #000000]: S
- text at x 6.6, y 60.5, w 1.3, h 0.5 [ArialMT; font size 2.23; #000000]: i
- text at x 57.8, y 58.6, w 1.2, h 1.6 [ArialMT; font size 2.17; #000000]: C
- text at x 61.7, y 58.7, w 0.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 0
- text at x 5.1, y 60.9, w 1.3, h 1.7 [ArialMT; font size 2.23; #000000]: G
- text at x 6.6, y 61.7, w 1.3, h 2.0 [ArialMT; font size 2.23; #000000]: %
- text at x 57.8, y 59.5, w 2.6, h 2.3 [ArialMT; font size 2.17; #000000]: GC
- text at x 6.6, y 63.6, w 1.3, h 0.7 [ArialMT; font size 2.23; #000000]: (
- text at x 67.2, y 61.5, w 1.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 0.2
- text at x 72.0, y 61.5, w 1.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 0.4
- text at x 76.9, y 61.5, w 1.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 0.6
- text at x 81.7, y 61.5, w 1.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 0.8
- text at x 86.5, y 61.5, w 1.7, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: 1.0
- text at x 11.1, y 65.5, w 0.7, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 1
- text at x 67.3, y 64.8, w 15.9, h 2.2 [ArialMT; font size 2.17; #000000]: Average Brain GCase activity
- text at x 16.7, y 68.3, w 5.2, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: CAP-003
- text at x 26.7, y 68.3, w 5.2, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: CAP-003
- text at x 36.6, y 68.3, w 5.2, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: CAP-003
- text at x 71.4, y 67.2, w 7.8, h 2.2 [ArialMT; font size 2.17; #000000]: (mU/g protein)
- text at x 61.3, y 68.2, w 1.1, h 2.2 [ARIAL,Bold; font size 2.17; #000000]: -5
- text at x 15.5, y 70.9, w 7.6, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 9.8E12 vg/kg
- text at x 25.4, y 70.9, w 7.6, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 3.1E13 vg/kg
- text at x 35.9, y 70.9, w 6.6, h 2.2 [ARIAL,Bold; font size 2.23; #000000]: 5E13 vg/kg
- text at x 4.5, y 90.7, w 14.4, h 1.8 [Montserrat Medium; font size 1.84; #000000]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 17

### Slide 18

**Text**

Decreased GluSph Levels in Plasma Confirm Target
Engagement in GLP Tox Study in Healthy NHPs
Plasma GluSph in NHP GLP Tox Study
-29%
-11%
-32%
0
-10
-20
-30
-40
-50
GluSph in plasma
(% change from Vehicle)
CAP-003
9.8E12 vg/kg
CAP-003
3.1E13 vg/kg
CAP-003
5E13 vg/kg
GluSph = Glucosylsphingosine
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
18

**Layout**

Two-line left-aligned title at top-left. A boxed chart panel with a green header band is centered in the middle, with abbreviations footnote at bottom-left and study details right-aligned at bottom-right above a thin teal footer rule. Small logo bottom-left and slide number bottom-right.

**Visuals**

A bar chart in a white panel with a thin teal outline (about x 17-84%, y 22-90%) and a rounded-top green header band reading 'Plasma GluSph in NHP GLP Tox Study'. Chart is titled by that band. Y axis: 'GluSph in plasma (% change from Vehicle)', range 0 at top to -50 at bottom, ticks every 10 (0, -10, -20, -30, -40, -50), thick black axis lines. The x axis is drawn at the bottom (-50) with three tick marks. Three downward bars hang from the 0 line at the top, each with a downward error bar with a cap. Bar 1: CAP-003 9.8E12 vg/kg, pale mint (#D1F4E3), value -29%, error bar to about -41. Bar 2: CAP-003 3.1E13 vg/kg, medium mint green (#75DEAB), value -11%, error bar to about -25. Bar 3: CAP-003 5E13 vg/kg, dark green (#208856), value -32%, error bar to about -39. Above each bar is a light grey (#D9D9D9) rectangular label box with its percentage in bold black. No legend. A thin teal horizontal rule spans the full slide width above the footer. A small CAPSIDA Therapeutics logo (teal text with a teal and green geometric polyhedron icon) at bottom-left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal (#252524) Montserrat SemiBold, about 5.9% of slide height. Header band bright green #2BB673 with white Montserrat Bold text about 3% of height. Chart text in black Arial Bold about 2.4% of height; value labels in Montserrat Medium about 3%. Footnotes in Montserrat about 1.8% in black and study details Montserrat about 1.7% in #252524 with bold labels. Teal accent lines (#1BA397). Header band has rounded top corners; no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 81.6, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: Decreased GluSph Levels in Plasma Confirm Target / Engagement in GLP Tox Study in Healthy NHPs (two lines, tight line spacing)
- shape at x 17, y 22.2, w 66.8, h 67.7 [#FFFFFF]: Chart panel white box with thin teal outline (1px teal (#1BA397) outline)
- shape at x 17, y 22.2, w 66.8, h 6.4 [#2BB673]: Green header band with rounded top corners (top corners rounded)
- caption at x 34, y 24.4, w 32.8, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Plasma GluSph in NHP GLP Tox Study
- shape at x 37.6, y 32.3, w 6.2, h 4.7 [#D9D9D9]: Grey label box behind -29%
- shape at x 49.8, y 32.3, w 6.2, h 4.7 [#D9D9D9]: Grey label box behind -11%
- shape at x 62.1, y 32.3, w 6.2, h 4.7 [#D9D9D9]: Grey label box behind -32%
- caption at x 38.3, y 33.5, w 4, h 3 [Montserrat Medium; font size 3% of slide height; #000000; center aligned]: -29%
- caption at x 50.5, y 33.5, w 3.3, h 3 [Montserrat Medium; font size 3% of slide height; #000000; center aligned]: -11%
- caption at x 62.9, y 33.5, w 3.9, h 3 [Montserrat Medium; font size 3% of slide height; #000000; center aligned]: -32%
- chart at x 25.7, y 36, w 48, h 40 [#208856]: Bar chart: three hanging bars of GluSph % change from vehicle: -29% (9.8E12 vg/kg), -11% (3.1E13 vg/kg), -32% (5E13 vg/kg), with error bars; y axis 0 to -50 (Bars: pale mint #D1F4E3 at x 36.2 w 8.1 h 18; mint #75DEAB at x 48.5 w 8.1 h 6.8; dark green #208856 at x 60.9 w 8.1 h 19.9; all from y 38.5; thick black axis lines; error bars thin black with caps)
- caption at x 25.7, y 41, w 2.9, h 26 [Arial regular; font size 2.4% of slide height; #000000; center aligned]: GluSph in plasma / (% change from Vehicle) (rotated 90 degrees counter-clockwise)
- caption at x 29.2, y 37.4, w 1.9, h 33.7 [Arial Bold; font size 2.4% of slide height; #000000; right aligned]: 0 / -10 / -20 / -30 / -40 / -50 (y-axis tick labels at 0, -10, -20, -30, -40, -50)
- caption at x 36.2, y 71.7, w 8.1, h 5.2 [Arial Bold; font size 2.4% of slide height; #000000; center aligned]: CAP-003 / 9.8E12 vg/kg (x-axis category label)
- caption at x 48.6, y 71.7, w 8.1, h 5.2 [Arial Bold; font size 2.4% of slide height; #000000; center aligned]: CAP-003 / 3.1E13 vg/kg (x-axis category label)
- caption at x 61.4, y 71.7, w 7, h 5.2 [Arial Bold; font size 2.4% of slide height; #000000; center aligned]: CAP-003 / 5E13 vg/kg (x-axis category label)
- footer at x 4.1, y 88.7, w 15.7, h 3.9 [Montserrat regular; font size 1.85% of slide height; #000000; left aligned]: GluSph = Glucosylsphingosine / NHP = non-human primate
- footer at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat Bold labels with Montserrat regular values; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) ('GLP Tox Study', 'In-life:' and 'Species:' bold)
- line at x 0, y 93.3, w 100, h 0.4 [#1BA397]: Thin teal horizontal rule across slide
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1BA397]: CAPSIDA Therapeutics logo with teal polyhedron icon
- page number at x 95, y 95.8, w 0.9, h 1.5 [Montserrat Medium; font size 1.5% of slide height; #252524; right aligned]: 18

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 60.9, y 38.5, w 8.1, h 19.9: #208856
- fill at x 48.5, y 38.5, w 8.1, h 6.8: #75DEAB
- fill at x 36.2, y 38.5, w 8.1, h 18.0: #D1F4E3
- fill at x 32.0, y 69.5, w 41.3, h 1.6: #000000
- fill at x 17.0, y 22.2, w 66.8, h 6.4: #2BB673
- fill at x 3.2, y 87.9, w 68.4, h 5.3: #FFFFFF
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 81.6, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Decreased GluSphLevels in Plasma Confirm Target
- text at x 3.9, y 12.3, w 74.9, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Engagement in GLP Tox Study in Healthy NHPs
- text at x 34.0, y 24.4, w 32.8, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Plasma GluSph in NHP GLP Tox Study
- text at x 38.3, y 33.5, w 4.0, h 3.0 [Montserrat Medium; font size 2.96; #000000]: --29%
- text at x 39.0, y 33.5, w 3.4, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 29%
- text at x 50.5, y 33.5, w 3.3, h 3.0 [Montserrat Medium; font size 2.96; #000000]: --11%
- text at x 51.2, y 33.5, w 2.6, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 11%
- text at x 62.9, y 33.5, w 3.9, h 3.0 [Montserrat Medium; font size 2.96; #000000]: --32%
- text at x 63.5, y 33.5, w 3.3, h 3.0 [Montserrat Medium; font size 2.96; #000000]: 32%
- text at x 30.4, y 37.4, w 0.7, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: 0
- text at x 27.2, y 41.1, w 1.3, h 0.8 [ArialMT; font size 2.37; #000000]: )
- text at x 27.2, y 41.9, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: e
- text at x 27.2, y 43.7, w 1.3, h 1.2 [ArialMT; font size 2.37; #000000]: c
- text at x 27.2, y 43.2, w 1.3, h 0.5 [ArialMT; font size 2.37; #000000]: l
- text at x 25.7, y 44.7, w 2.9, h 1.3 [ArialMT; font size 2.37; #000000]: ai
- text at x 29.2, y 43.7, w 1.9, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: -10
- text at x 27.2, y 45.4, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: h
- text at x 25.7, y 46.0, w 2.9, h 2.1 [ArialMT; font size 2.37; #000000]: me
- text at x 25.7, y 48.0, w 2.9, h 1.7 [ArialMT; font size 2.37; #000000]: sV
- text at x 25.7, y 49.2, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: a
- text at x 25.7, y 50.3, w 2.9, h 2.0 [ArialMT; font size 2.37; #000000]: lm
- text at x 29.2, y 49.9, w 1.9, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: -20
- text at x 25.7, y 51.0, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: p
- text at x 25.7, y 52.3, w 2.9, h 2.0 [ArialMT; font size 2.37; #000000]: no
- text at x 25.7, y 54.3, w 2.9, h 0.7 [ArialMT; font size 2.37; #000000]: if
- text at x 27.2, y 53.6, w 1.3, h 0.8 [ArialMT; font size 2.37; #000000]: r
- text at x 25.7, y 55.5, w 2.9, h 1.5 [ArialMT; font size 2.37; #000000]: he
- text at x 25.7, y 56.8, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: p
- text at x 29.2, y 56.2, w 1.9, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: -30
- text at x 27.2, y 57.0, w 1.3, h 1.3 [ArialMT; font size 2.37; #000000]: g
- text at x 25.7, y 58.2, w 2.9, h 1.6 [ArialMT; font size 2.37; #000000]: Sn
- text at x 25.7, y 59.6, w 2.9, h 1.4 [ArialMT; font size 2.37; #000000]: ua
- text at x 25.7, y 61.0, w 2.9, h 1.3 [ArialMT; font size 2.37; #000000]: lh
- text at x 25.7, y 61.6, w 2.9, h 1.9 [ArialMT; font size 2.37; #000000]: Gc
- text at x 29.2, y 62.4, w 1.9, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: -40
- text at x 27.2, y 64.1, w 1.3, h 2.1 [ArialMT; font size 2.37; #000000]: %
- text at x 27.2, y 66.2, w 1.3, h 0.8 [ArialMT; font size 2.37; #000000]: (
- text at x 29.2, y 68.7, w 1.9, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: -50
- text at x 37.5, y 71.7, w 5.5, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: CAP-003
- text at x 49.9, y 71.7, w 5.5, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: CAP-003
- text at x 62.2, y 71.7, w 5.5, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: CAP-003
- text at x 36.2, y 74.5, w 8.1, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: 9.8E12 vg/kg
- text at x 48.6, y 74.5, w 8.1, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: 3.1E13 vg/kg
- text at x 61.4, y 74.5, w 7.0, h 2.4 [ARIAL,Bold; font size 2.38; #000000]: 5E13 vg/kg
- text at x 4.1, y 88.7, w 15.7, h 1.8 [Montserrat; font size 1.84; #000000]: GluSph = Glucosylsphingosine
- text at x 4.1, y 90.7, w 14.6, h 1.8 [Montserrat; font size 1.85; #000000]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.0, y 95.8, w 0.9, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 18

### Slide 19

**Text**

GLP Tox Data Demonstrate CAP-003 is Substantially Detargeted
from Liver and DRGs in NHPs Compared to AAV9
Liver DNA
DRG RNA
18X lower at double the dose
3X lower at double the dose
DNA biodistribution
(WPRE copies/µg DNA)
10^8
10^7
10^6
RNA biodistribution
(WPRE copies/µg RNA)
10^7
10^6
10^5
AAV9*
2.5E13 vg/kg
CAP-003
5E13 vg/kg
AAV9*
2.5E13 vg/kg
CAP-003
5E13 vg/kg
Well-tolerated safety profile with no adverse histopathological findings
*Historical IV-delivered AAV9 2.5E13 vg/kg (non-GBA cargo control)
NHP = non-human primate
GLP Tox Study
In-life: 3 months
Species: Cynomolgus macaques (n=3/grp)
19

**Layout**

Two-line left-aligned title at top. Two equal side-by-side chart panels with green header tabs in the middle, a full-width gradient banner below, footnotes at bottom left, study details right-aligned at bottom right, thin teal rule above a footer with logo at bottom left and page number at bottom right.

**Visuals**

Two bar charts on log scales, each in a white panel with thin teal outline and green rounded-top header. Left chart (Liver DNA): y-axis 10^6 to 10^8, label 'DNA biodistribution (WPRE copies/µg DNA)'. Grey bar AAV9* 2.5E13 vg/kg reaches about 7x10^7 with a tiny error bar. Dark green bar CAP-003 5E13 vg/kg reaches about 4x10^6 with an upper error bar to about 5x10^6. Green bracket line from the top of the AAV9 bar down to the CAP-003 bar, annotated '18X lower at double the dose'. Right chart (DRG RNA): y-axis 10^5 to 10^7, label 'RNA biodistribution (WPRE copies/µg RNA)'. Grey AAV9* bar reaches about 3x10^6 with an error bar up to about 5x10^6. Dark green CAP-003 bar reaches about 9x10^5 with an error bar to about 1.1x10^6. Green bracket annotated '3X lower at double the dose'. Black axes with tick marks. A blue-to-teal gradient rounded banner holds white text. The Capsida Biotherapeutics logo (teal text with a hexagonal icon) sits at bottom left. A thin teal horizontal line spans the full width above the footer.

**Design**

Background: Solid white #FFFFFF. White background. Title in charcoal #252524 Montserrat SemiBold, about 5.2% of slide height. Panel headers in green #2BB673 with white Montserrat Bold text. Annotations in green #2BB673 bold. Bars grey #A0A0A4 and dark green #208856. Chart labels in black Arial Bold. Banner gradient from blue #0088BB on the left to teal #04AD9F on the right with rounded corners, white bold Montserrat text. Footnotes in Montserrat regular, charcoal. Panel headers have rounded top corners; panel outlines are thin teal.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 87.4, h 10.8 [Montserrat SemiBold; font size 5.18% of slide height; #252524; left aligned]: GLP Tox Data Demonstrate CAP-003 is Substantially Detargeted / from Liver and DRGs in NHPs Compared to AAV9 (two lines, tight line spacing)
- shape at x 4.2, y 22.1, w 44.5, h 6.4 [#2BB673]: Green header tab for left panel, rounded top corners (white panel body with thin teal outline below, spanning to about y 72.7)
- shape at x 51.4, y 22.1, w 44.5, h 6.4 [#2BB673]: Green header tab for right panel, rounded top corners (white panel body with thin teal outline below, spanning to about y 72.7)
- caption at x 22, y 24.3, w 8.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Liver DNA
- caption at x 69.5, y 24.3, w 8.2, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: DRG RNA
- caption at x 16.7, y 33.1, w 22.1, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #2BB673; center aligned]: 18X lower at double the dose
- caption at x 64, y 33.3, w 21.4, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #2BB673; center aligned]: 3X lower at double the dose
- chart at x 6.7, y 35.6, w 37.1, h 33 [#A0A0A4]: Left bar chart: grey AAV9* bar and dark green CAP-003 bar on log y-axis 10^6 to 10^8, error bars, green bracket (grey bar x16.7 y38.8 w8.9 h24.0; green bar #208856 x30.2 y55.1 w8.9 h7.6; black x-axis x12.1 y62.5 w31.7 h1.4; bracket in green line about 1.5px)
- chart at x 53.5, y 35.6, w 37.5, h 33 [#A0A0A4]: Right bar chart: grey AAV9* bar and dark green CAP-003 bar on log y-axis 10^5 to 10^7, error bars, green bracket (grey bar x63.6 y43.3 w9.0 h19.4; green bar #208856 x77.3 y50.3 w9.0 h12.4; black x-axis x59.0 y62.5 w32.0 h1.4)
- caption at x 6.7, y 39.2, w 4.3, h 15 [Arial; font size 1.97% of slide height; #000000; center aligned]: DNA biodistribution / (WPRE copies/µg DNA) (rotated 90 degrees counter-clockwise)
- caption at x 53.5, y 38.9, w 4.3, h 15 [Arial; font size 1.98% of slide height; #000000; center aligned]: RNA biodistribution / (WPRE copies/µg RNA) (rotated 90 degrees counter-clockwise)
- caption at x 9.6, y 35.8, w 2, h 28.1 [Arial Bold; font size 1.97% of slide height; #000000; right aligned]: 10^8 / 10^7 / 10^6 (left chart y-axis ticks) (ticks at y about 36.9, 49.8, 62.9)
- caption at x 56.5, y 35.6, w 1.8, h 28.2 [Arial Bold; font size 1.99% of slide height; #000000; right aligned]: 10^7 / 10^6 / 10^5 (right chart y-axis ticks) (ticks at y about 36.6, 49.7, 62.8)
- caption at x 17.8, y 64.3, w 6.7, h 4.3 [Arial Bold; font size 1.97% of slide height; #000000; center aligned]: AAV9* / 2.5E13 vg/kg
- caption at x 31.8, y 64.3, w 5.8, h 4.3 [Arial Bold; font size 1.97% of slide height; #000000; center aligned]: CAP-003 / 5E13 vg/kg
- caption at x 64.7, y 64.3, w 6.8, h 4.3 [Arial Bold; font size 1.99% of slide height; #000000; center aligned]: AAV9* / 2.5E13 vg/kg
- caption at x 78.8, y 64.3, w 5.8, h 4.3 [Arial Bold; font size 1.99% of slide height; #000000; center aligned]: CAP-003 / 5E13 vg/kg
- shape at x 4.1, y 76.7, w 91.9, h 8 [#0795B8]: Gradient rounded banner, blue to teal (horizontal gradient from #0088BB to #04AD9F, rounded corners)
- caption at x 11.6, y 79, w 78.8, h 3.7 [Montserrat Bold; font size 3.71% of slide height; #FFFFFF; center aligned]: Well-tolerated safety profile with no adverse histopathological findings (on gradient banner)
- caption at x 3.9, y 88.5, w 34.5, h 3.8 [Montserrat; font size 1.84% of slide height; #252524; left aligned]: *Historical IV-delivered AAV9 2.5E13 vg/kg (non-GBA cargo control) / NHP = non-human primate
- caption at x 75.3, y 86.7, w 19.8, h 5.7 [Montserrat; labels bold; font size 1.67% of slide height; #252524; right aligned]: GLP Tox Study / In-life: 3 months / Species: Cynomolgus macaques (n=3/grp) ('GLP Tox Study', 'In-life:' and 'Species:' in bold; values regular)
- line at x 0, y 93.3, w 100, h 0.4 [#04AD9F]: Thin teal horizontal rule across full width
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#04AD9F]: Capsida Biotherapeutics logo (teal wordmark with hexagonal icon)
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 19

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 30.2, y 55.1, w 8.9, h 7.6: #208856
- fill at x 16.7, y 38.8, w 8.9, h 24.0: #A0A0A4
- fill at x 12.1, y 62.5, w 31.7, h 1.4: #000000
- fill at x 77.3, y 50.3, w 9.0, h 12.4: #208856
- fill at x 63.6, y 43.3, w 9.0, h 19.4: #A0A0A4
- fill at x 59.0, y 62.5, w 32.0, h 1.4: #000000
- fill at x 4.2, y 22.1, w 44.5, h 6.4: #2BB673
- fill at x 51.4, y 22.1, w 44.5, h 6.4: #2BB673
- image at x 4.1, y 76.7, w 91.9, h 8.0: 882 by 43 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 87.4, h 5.2 [Montserrat SemiBold; font size 5.18; #252524]: GLP Tox Data Demonstrate CAP-003 is Substantially Detargeted
- text at x 3.9, y 11.5, w 66.9, h 5.2 [Montserrat SemiBold; font size 5.18; #252524]: from Liver and DRGs in NHPs Compared to AAV9
- text at x 22.0, y 24.3, w 8.7, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Liver DNA
- text at x 69.5, y 24.3, w 8.2, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: DRG RNA
- text at x 16.7, y 33.1, w 22.1, h 2.6 [Montserrat,Bold; font size 2.60; #2BB673]: 18X lower at double the dose
- text at x 64.0, y 33.3, w 21.4, h 2.6 [Montserrat,Bold; font size 2.60; #2BB673]: 3X lower at double the dose
- text at x 9.6, y 35.9, w 1.2, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: 10
- text at x 56.5, y 35.6, w 1.2, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: 10
- text at x 7.9, y 39.2, w 1.1, h 0.7 [ArialMT; font size 1.97; #000000]: )
- text at x 54.8, y 38.9, w 1.1, h 0.7 [ArialMT; font size 1.98; #000000]: )
- text at x 7.9, y 39.8, w 1.1, h 1.3 [ArialMT; font size 1.97; #000000]: A
- text at x 54.8, y 39.6, w 1.1, h 1.3 [ArialMT; font size 1.98; #000000]: A
- text at x 6.7, y 41.3, w 1.1, h 1.1 [ArialMT; font size 1.97; #000000]: n
- text at x 53.5, y 40.9, w 2.4, h 1.4 [ArialMT; font size 1.98; #000000]: nN
- text at x 7.9, y 41.2, w 1.1, h 1.4 [ArialMT; font size 1.97; #000000]: N
- text at x 53.5, y 42.2, w 2.4, h 1.7 [ArialMT; font size 1.98; #000000]: oR
- text at x 6.7, y 42.4, w 1.1, h 1.1 [ArialMT; font size 1.97; #000000]: o
- text at x 6.7, y 42.6, w 2.4, h 1.4 [ArialMT; font size 1.97; #000000]: iD
- text at x 11.6, y 79.0, w 78.8, h 3.7 [Montserrat,Bold; font size 3.71; #FFFFFF]: Well-tolerated safety profile with no adverse histopathological findings
- text at x 53.5, y 43.7, w 1.1, h 0.6 [ArialMT; font size 1.98; #000000]: t
- text at x 53.5, y 43.3, w 1.1, h 0.4 [ArialMT; font size 1.98; #000000]: i
- text at x 6.7, y 43.9, w 1.1, h 0.5 [ArialMT; font size 1.97; #000000]: t
- text at x 53.5, y 44.3, w 2.4, h 1.2 [ArialMT; font size 1.98; #000000]: ug
- text at x 6.7, y 44.4, w 2.4, h 1.2 [ArialMT; font size 1.97; #000000]: ug
- text at x 53.5, y 45.4, w 2.4, h 1.3 [ArialMT; font size 1.98; #000000]: bμ
- text at x 6.7, y 45.6, w 2.4, h 1.2 [ArialMT; font size 1.97; #000000]: bμ
- text at x 53.5, y 46.5, w 2.4, h 0.7 [ArialMT; font size 1.98; #000000]: i/
- text at x 6.7, y 47.1, w 1.1, h 0.7 [ArialMT; font size 1.97; #000000]: r
- text at x 6.7, y 46.6, w 2.4, h 0.7 [ArialMT; font size 1.97; #000000]: i/
- text at x 53.5, y 47.6, w 1.1, h 0.6 [ArialMT; font size 1.98; #000000]: t
- text at x 53.5, y 46.9, w 2.4, h 1.3 [ArialMT; font size 1.98; #000000]: rs
- text at x 6.7, y 47.4, w 2.4, h 1.0 [ArialMT; font size 1.97; #000000]: ts
- text at x 53.5, y 48.1, w 2.4, h 1.2 [ArialMT; font size 1.98; #000000]: se
- text at x 6.7, y 49.3, w 1.1, h 0.4 [ArialMT; font size 1.97; #000000]: i
- text at x 6.7, y 48.3, w 1.1, h 1.0 [ArialMT; font size 1.97; #000000]: s
- text at x 7.9, y 49.5, w 1.1, h 0.4 [ArialMT; font size 1.97; #000000]: i
- text at x 7.9, y 48.4, w 1.1, h 1.1 [ArialMT; font size 1.97; #000000]: e
- text at x 53.5, y 49.1, w 2.4, h 0.6 [ArialMT; font size 1.98; #000000]: ii
- text at x 56.5, y 48.7, w 1.2, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: 10
- text at x 6.7, y 49.7, w 2.4, h 1.3 [ArialMT; font size 1.97; #000000]: dp
- text at x 9.6, y 48.9, w 1.2, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: 10
- text at x 53.5, y 49.5, w 2.4, h 1.3 [ArialMT; font size 1.98; #000000]: dp
- text at x 6.7, y 50.8, w 2.4, h 1.3 [ArialMT; font size 1.97; #000000]: oo
- text at x 53.5, y 51.8, w 1.1, h 0.4 [ArialMT; font size 1.98; #000000]: i
- text at x 53.5, y 50.7, w 2.4, h 1.3 [ArialMT; font size 1.98; #000000]: oo
- text at x 6.7, y 51.9, w 2.4, h 1.2 [ArialMT; font size 1.97; #000000]: ic
- text at x 53.5, y 52.0, w 2.4, h 1.3 [ArialMT; font size 1.98; #000000]: bc
- text at x 6.7, y 52.3, w 1.1, h 1.1 [ArialMT; font size 1.97; #000000]: b
- text at x 57.9, y 35.6, w 0.4, h 1.3 [ARIAL,Bold; font size 1.33; #000000]: 7
- text at x 7.9, y 53.7, w 1.1, h 1.3 [ArialMT; font size 1.97; #000000]: E
- text at x 11.0, y 35.8, w 0.4, h 1.3 [ARIAL,Bold; font size 1.32; #000000]: 8
- text at x 53.5, y 53.5, w 2.4, h 1.6 [ArialMT; font size 1.98; #000000]: AE
- text at x 6.7, y 54.0, w 1.1, h 1.3 [ArialMT; font size 1.97; #000000]: A
- text at x 53.5, y 54.9, w 2.4, h 1.7 [ArialMT; font size 1.98; #000000]: NR
- text at x 6.7, y 55.0, w 2.4, h 1.7 [ArialMT; font size 1.97; #000000]: NR
- text at x 54.8, y 56.3, w 1.1, h 1.3 [ArialMT; font size 1.98; #000000]: P
- text at x 6.7, y 56.4, w 2.4, h 1.7 [ArialMT; font size 1.97; #000000]: DP
- text at x 53.5, y 56.6, w 1.1, h 1.4 [ArialMT; font size 1.98; #000000]: R
- text at x 54.8, y 57.7, w 1.1, h 1.9 [ArialMT; font size 1.98; #000000]: W
- text at x 7.9, y 57.7, w 1.1, h 1.9 [ArialMT; font size 1.97; #000000]: W
- text at x 54.8, y 59.5, w 1.1, h 0.7 [ArialMT; font size 1.98; #000000]: (
- text at x 7.9, y 59.6, w 1.1, h 0.7 [ArialMT; font size 1.97; #000000]: (
- text at x 56.5, y 61.8, w 1.2, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: 10
- text at x 9.6, y 61.9, w 1.2, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: 10
- text at x 19.5, y 64.4, w 3.4, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: AAV9*
- text at x 32.4, y 64.4, w 4.6, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: CAP-003
- text at x 66.4, y 64.3, w 3.4, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: AAV9*
- text at x 79.4, y 64.3, w 4.6, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: CAP-003
- text at x 64.7, y 66.6, w 6.8, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: 2.5E13 vg/kg
- text at x 78.8, y 66.6, w 5.8, h 2.0 [ARIAL,Bold; font size 1.99; #000000]: 5E13 vg/kg
- text at x 17.8, y 66.6, w 6.7, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: 2.5E13 vg/kg
- text at x 31.8, y 66.6, w 5.8, h 2.0 [ARIAL,Bold; font size 1.97; #000000]: 5E13 vg/kg
- text at x 57.9, y 48.6, w 0.4, h 1.3 [ARIAL,Bold; font size 1.33; #000000]: 6
- text at x 11.0, y 48.8, w 0.4, h 1.3 [ARIAL,Bold; font size 1.32; #000000]: 7
- text at x 57.9, y 61.7, w 0.4, h 1.3 [ARIAL,Bold; font size 1.33; #000000]: 5
- text at x 11.0, y 61.8, w 0.4, h 1.3 [ARIAL,Bold; font size 1.32; #000000]: 6
- text at x 3.9, y 88.5, w 34.5, h 1.8 [Montserrat; font size 1.84; #252524]: *Historical IV-delivered AAV9 2.5E13 vg/kg (non-GBA cargo control)
- text at x 3.9, y 90.5, w 14.3, h 1.8 [Montserrat; font size 1.84; #252524]: NHP = non-human primate
- text at x 88.0, y 86.7, w 7.1, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: GLP Tox Study
- text at x 87.3, y 88.7, w 3.4, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: In-life:
- text at x 90.7, y 88.7, w 4.5, h 1.7 [Montserrat; font size 1.67; #252524]: 3 months
- text at x 75.3, y 90.7, w 4.3, h 1.7 [Montserrat,Bold; font size 1.67; #252524]: Species:
- text at x 79.5, y 90.7, w 15.6, h 1.7 [Montserrat; font size 1.67; #252524]: Cynomolgus macaques (n=3/grp)
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 19

### Slide 20

**Review notes**

- Suggested repair: Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

**Text**

CAP-003 (PD-GBA) Phase 1/2 Clinical Plan
Clinical Ph1/2
Planning
Population
» Ages 21-75 years
» PD Hoehn & Yahr
Stage 1-3
» Ph1: 6 patients
Key Measurements
» Safety
» Biomarkers (e.g., GCase, GluSph, & GluCer)
» 1 & 2-year efficacy (e.g., MDS-UPDRS, cognition, etc.)
2025
2026
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
IND-Enabling
Clinical Ph1/2
CAP-003
(PD-GBA)
Program
Overview
IND Clearance
Projected 1st Patient Dosed
Projected 1st Patient Biomarkers
Projected 1st Patient Efficacy (1 yr)
Projected FDA Meeting
For more information about the Phase 1/2 trial, please visit www.clinicaltrials.gov and search for NCT07011771
GluSph = glucosylsphingosine; GluCer = glucosylceramide;
MDS-UPDRS = Unified Parkinson's Disease Rating Scale
20

**Layout**

Title top-left. Below it a wide rounded grey panel with a mint label block at its left holding the heading, and two text columns (Population, Key Measurements). Below that a Gantt-style timeline: left grey label column, green year header row, grey quarter row, mint phase bars, milestone rows with arrows. A full-width green rounded banner follows, then a two-line footnote, a thin teal rule, a logo bottom-left and the page number bottom-right.

**Visuals**

Gantt timeline with 2025 and 2026 headers and Q1-Q4 each, with faint vertical grey quarter dividers and a light teal divider at the year boundary. Mint pill bars: IND-Enabling spans 2025 Q1 to mid Q2, Clinical Ph1/2 spans from late Q2 2025 to end of 2026 Q4. Green six-pointed star markers precede the milestones. IND Clearance has a star and a black checkmark at about Q2/Q3 2025. Projected 1st Patient Dosed has a star at about 2025 Q3 and a green arrow running to about 2026 Q1. Projected 1st Patient Biomarkers has a star at about 2025 Q4 and an arrow to about 2026 Q2. Projected 1st Patient Efficacy (1 yr) has a star at about 2026 Q3 and an arrow to the right end of 2026 Q4. Projected FDA Meeting has a green diamond at about 2026 Q2/Q3. Capsida Biotherapeutics logo at bottom-left, with teal text and a teal and green geometric mark. Thin teal horizontal line above the footer.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524, Montserrat SemiBold, large. Panel headings in black Montserrat Bold. Body text in black Montserrat Medium. Accent green #2BB673 for the header bars and banner, mint #D1F4E3 for the label block and phase bars, light grey #F2F2F2 for the panel, quarter row and left label column. The banner has white Montserrat Medium text. Panel has a thin grey outline and large rounded corners on the right side. The mint block has a thin teal outline and rounded corners. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 65.1, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: CAP-003 (PD-GBA) Phase 1/2 Clinical Plan
- shape at x 4.7, y 13.8, w 91.1, h 25.8 [#F2F2F2]: Light grey rounded rectangle panel behind the population and measurements text (Thin grey outline, large corner radius on the right side)
- shape at x 4.2, y 13.7, w 12.8, h 25.9 [#D1F4E3]: Mint rounded block at the left of the panel (Thin teal outline, rounded corners)
- caption at x 5.2, y 24, w 10.5, h 5.7 [Montserrat Bold; font size 2.6% of slide height; #000000; left aligned]: Clinical Ph1/2 / Planning
- body at x 19.8, y 16.6, w 8.4, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #000000; left aligned]: Population
- bullet list at x 20.5, y 20.7, w 13.2, h 12.5 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: » Ages 21-75 years / » PD Hoehn & Yahr / Stage 1-3 / » Ph1: 6 patients (Bullets are » characters; second line of PD Hoehn & Yahr is indented)
- body at x 40.8, y 16.6, w 14.7, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #000000; left aligned]: Key Measurements
- bullet list at x 41.6, y 20.7, w 34.7, h 9.8 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: » Safety / » Biomarkers (e.g., GCase, GluSph, & GluCer) / » 1 & 2-year efficacy (e.g., MDS-UPDRS, cognition, etc.) (Bullets are » characters)
- shape at x 14.8, y 42.9, w 80.5, h 4.5 [#2BB673]: Green year header bars 2025 and 2026 (2025 spans x 14.8 to 55.7; 2026 spans x 55.7 to 95.3; thin teal divider between)
- caption at x 33.7, y 44.2, w 3.1, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; center aligned]: 2025
- caption at x 74, y 44.2, w 3.1, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; center aligned]: 2026
- shape at x 14.8, y 47.4, w 80.5, h 4.2 [#F2F2F2]: Grey quarter label row with eight cells Q1-Q4 2025 and Q1-Q4 2026 (Cells separated by thin lines)
- caption at x 19.8, y 48.7, w 72, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #252524; center aligned]: Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 (Eight labels centred in their quarter cells)
- shape at x 3.5, y 51.6, w 11.3, h 29.3 [#F2F2F2]: Grey left label column for the program overview
- caption at x 4.3, y 61.3, w 6.6, h 10.2 [Montserrat Bold; font size 2.22% of slide height; #252524; left aligned]: CAP-003 / (PD-GBA) / Program / Overview
- shape at x 14.9, y 52.7, w 15.6, h 3.8 [#D1F4E3]: Mint pill bar IND-Enabling (Fully rounded ends)
- caption at x 19, y 53.7, w 7.5, h 2 [Montserrat Medium; font size 1.96% of slide height; #000000; center aligned]: IND-Enabling
- shape at x 30.8, y 52.7, w 64.6, h 3.8 [#D1F4E3]: Mint pill bar Clinical Ph1/2 (Fully rounded ends)
- caption at x 59.4, y 53.7, w 7.3, h 2 [Montserrat Medium; font size 1.96% of slide height; #000000; center aligned]: Clinical Ph1/2
- line at x 25.9, y 51.6, w 55.5, h 29.3 [#D0D0D0]: Faint vertical quarter divider lines through the timeline body (Thin grey lines; the year boundary line at x about 55.7 is light teal)
- icon at x 32.2, y 60.8, w 10.4, h 2.8 [#2BB673]: Green six-pointed star marker plus black checkmark beside IND Clearance label (Star at left of label, checkmark at right)
- caption at x 33.7, y 61.4, w 7.6, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: IND Clearance
- caption at x 26.8, y 65.6, w 14.2, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: Projected 1st Patient Dosed ('st' is superscript)
- icon at x 41.5, y 65.3, w 18.7, h 2.4 [#2BB673]: Green star with green arrow pointing right (Star at about x 42; thin line ending in an arrowhead at about x 60)
- caption at x 35.1, y 70.5, w 16.9, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: Projected 1st Patient Biomarkers ('st' is superscript)
- icon at x 52.5, y 70.2, w 19.5, h 2.4 [#2BB673]: Green star with green arrow pointing right (Star at about x 53; arrow ends at about x 72)
- caption at x 62.2, y 73.7, w 17.6, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: Projected 1st Patient Efficacy (1 yr) ('st' is superscript)
- icon at x 80.6, y 73.4, w 14, h 2.4 [#2BB673]: Green star with green arrow pointing right (Star at about x 81; arrow ends at about x 94.5)
- icon at x 74, y 77.9, w 1.4, h 2 [#2BB673]: Green diamond marker
- caption at x 76, y 78, w 12.4, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: Projected FDA Meeting
- shape at x 3.3, y 82.6, w 92.7, h 5.3 [#2BB673]: Green rounded banner (Fully rounded ends)
- caption at x 9.4, y 84.1, w 80.4, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; center aligned]: For more information about the Phase 1/2 trial, please visit www.clinicaltrials.gov and search for NCT07011771
- footer at x 3.8, y 89.1, w 30.3, h 3.8 [Montserrat Regular; font size 1.84% of slide height; #252524; left aligned]: GluSph = glucosylsphingosine; GluCer = glucosylceramide; / MDS-UPDRS = Unified Parkinson's Disease Rating Scale (Tight line spacing)
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Thin teal horizontal rule above the footer (Full width)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#2BB5A5]: Capsida Biotherapeutics logo with teal wordmark and geometric mark
- page number at x 94.8, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 20

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 14.8, y 42.9, w 80.5, h 4.5: #00A79D
- fill at x 14.8, y 42.9, w 41.0, h 4.5: #2BB673
- fill at x 55.7, y 42.9, w 39.6, h 4.5: #2BB673
- fill at x 14.8, y 47.4, w 11.3, h 4.2: #F2F2F2
- fill at x 26.0, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 35.9, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 45.8, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 55.7, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 65.6, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 75.5, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 85.4, y 47.4, w 9.9, h 4.2: #F2F2F2
- fill at x 3.5, y 51.6, w 11.3, h 29.3: #F2F2F2
- fill at x 14.9, y 52.7, w 15.6, h 3.8: #D1F4E3
- fill at x 30.8, y 52.7, w 64.6, h 3.8: #D1F4E3
- fill at x 4.7, y 13.8, w 91.1, h 25.8: #F2F2F2
- fill at x 4.2, y 13.7, w 12.8, h 25.9: #D1F4E3
- fill at x 3.3, y 82.6, w 92.7, h 5.3: #2BB673
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 65.1, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-003 (PD-GBA) Phase 1/2 Clinical Plan
- text at x 19.8, y 16.6, w 8.4, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Population
- text at x 40.8, y 16.6, w 14.7, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Key Measurements
- text at x 5.2, y 24.0, w 10.5, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Clinical Ph1/2
- text at x 20.5, y 20.7, w 12.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Ages 21-75 years
- text at x 41.6, y 20.7, w 5.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Safety
- text at x 5.2, y 27.1, w 6.9, h 2.6 [Montserrat,Bold; font size 2.60; #000000]: Planning
- text at x 20.5, y 24.5, w 13.2, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » PD Hoehn & Yahr
- text at x 41.6, y 24.5, w 28.6, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Biomarkers (e.g., GCase, GluSph, & GluCer)
- text at x 22.4, y 27.2, w 5.7, h 2.2 [Montserrat Medium; font size 2.23; #000000]: Stage 1-3
- text at x 41.6, y 28.3, w 34.7, h 2.2 [Montserrat Medium; font size 2.23; #000000]: » 1 & 2-year efficacy (e.g., MDS-UPDRS, cognition, etc.)
- text at x 20.5, y 31.0, w 11.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: » Ph1: 6 patients
- text at x 33.7, y 44.2, w 3.1, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: 2025
- text at x 74.0, y 44.2, w 3.1, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: 2026
- text at x 19.8, y 48.7, w 1.3, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q1
- text at x 30.2, y 48.7, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q2
- text at x 40.1, y 48.7, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q3
- text at x 50.0, y 48.7, w 1.6, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q4
- text at x 60.0, y 48.7, w 1.3, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q1
- text at x 69.8, y 48.7, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q2
- text at x 79.8, y 48.7, w 1.5, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q3
- text at x 89.6, y 48.7, w 1.6, h 1.8 [Montserrat Medium; font size 1.84; #252524]: Q4
- text at x 4.3, y 61.3, w 6.1, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: CAP-003
- text at x 19.0, y 53.7, w 7.5, h 2.0 [Montserrat Medium; font size 1.96; #000000]: IND-Enabling
- text at x 59.4, y 53.7, w 7.3, h 2.0 [Montserrat Medium; font size 1.96; #000000]: Clinical Ph1/2
- text at x 4.3, y 63.9, w 6.6, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: (PD-GBA)
- text at x 4.3, y 66.6, w 6.1, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: Program
- text at x 4.3, y 69.3, w 6.2, h 2.2 [Montserrat,Bold; font size 2.22; #252524]: Overview
- text at x 9.4, y 84.1, w 80.4, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: For more information about the Phase 1/2 trial, please visit www.clinicaltrials.gov and search for NCT07011771
- text at x 33.7, y 61.4, w 7.6, h 1.8 [Montserrat Medium; font size 1.84; #000000]: IND Clearance
- text at x 26.8, y 65.6, w 14.2, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected 1 Patient Dosed
- text at x 35.1, y 70.5, w 16.9, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected 1 Patient Biomarkers
- text at x 62.2, y 73.7, w 17.6, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected 1 Patient Efficacy (1 yr)
- text at x 76.0, y 78.0, w 12.4, h 1.8 [Montserrat Medium; font size 1.84; #000000]: Projected FDA Meeting
- text at x 3.8, y 89.1, w 30.3, h 1.8 [Montserrat; font size 1.84; #252524]: GluSph = glucosylsphingosine; GluCer = glucosylceramide;
- text at x 3.8, y 91.1, w 28.9, h 1.8 [Montserrat; font size 1.84; #252524]: MDS-UPDRS = Unified Parkinson's Disease Rating Scale
- text at x 32.6, y 65.5, w 0.6, h 1.2 [Montserrat Medium; font size 1.24; #000000]: st
- text at x 40.9, y 70.5, w 0.6, h 1.2 [Montserrat Medium; font size 1.24; #000000]: st
- text at x 68.0, y 73.7, w 0.6, h 1.2 [Montserrat Medium; font size 1.24; #000000]: st
- text at x 94.8, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 20

### Slide 21

**Review notes**

- Suggested repair: Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

**Text**

CAP-003  Phase 1/2 Study (NCT07011771)
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
ClinicalTrials.gov ID NCT07011771
Sponsor Capsida Biotherapeutics, Inc.
Ph1
Dose escalation
N=6
Ph2 (single dose)
N=25
Primary endpoints:
• Safety
Efficacy (secondary endpoints)
• CSF and plasma glucosylsphingosine (GluSph) biomarker change
• CSF and plasma β-Glucocerebrosidase (GCase) biomarker change
• MDS-UPDRS disease rating change
“We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial for CAP-003 with the aim of dosing the first patient in the third quarter of this year,” –
Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics
See clinicaltrials.gov for full list of clinician & caregiver secondary endpoints
21

**Layout**

Large left-aligned title at top. Below it a bold subtitle, then two label/value lines (ClinicalTrials.gov ID, Sponsor). The middle has two side-by-side blocks: a left outlined box with two stacked green rounded boxes and a right solid green rounded box with endpoints. A full-width pale green quote box sits below. A thin teal rule, logo, link footnote and page number form the footer.

**Visuals**

Left: a white rounded rectangle with a green (#2BB673) outline containing two green rounded rectangles with dark navy outlines (Ph1 Dose escalation N=6, Ph2 single dose N=25). Right: a solid green rounded rectangle with white bullet text. A pale mint quote box with a subtle drop shadow. Two small navy circled 'i' info icons next to the labels. A thin teal horizontal line across the slide above the footer. A Capsida Biotherapeutics logo at bottom left (small teal geometric emblem with blue 'CAPSIDA' wordmark).

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524 Montserrat SemiBold, about 6% of slide height. Subtitle in dark grey Roboto bold, about 3%. Labels in blue #1F4E9C bold Roboto, values in black Roboto. Green #2BB673 fills with white Montserrat Medium text; pale green #D1F4E3 quote box with black italic Montserrat Medium text and a bold italic attribution. Footer link in teal #467886 underlined. Rounded corners on the boxes, soft shadow on the quote box.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 3.8, w 62.6, h 5.9 [Montserrat SemiBold; font size 5.94% of slide height; #252524; left aligned]: CAP-003 Phase 1/2 Study (NCT07011771)
- subtitle at x 4.3, y 11.4, w 74.5, h 9 [Roboto Bold; font size 3.1% of slide height; #333333; left aligned]: A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's / Disease (Image-rendered text, wraps onto two lines)
- body at x 4.3, y 22.5, w 22, h 3.5 [Roboto, label bold; font size 2.3% of slide height; #1F4E9C; left aligned]: ClinicalTrials.gov ID (i) NCT07011771 (Label blue bold, value black regular, navy circled info icon between)
- body at x 4.3, y 27.5, w 23.5, h 3.5 [Roboto, label bold; font size 2.3% of slide height; #1F4E9C; left aligned]: Sponsor (i) Capsida Biotherapeutics, Inc. (Label blue bold, value black regular, navy circled info icon between)
- shape at x 9.4, y 38, w 35.3, h 26.6 [#FFFFFF]: Left outline container, white fill with green outline (Green #2BB673 stroke about 0.2% wide, rounded corners)
- shape at x 10.4, y 39.7, w 33.6, h 11.8 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; center aligned]: Ph1 / Dose escalation / N=6 (Green #2BB673 rounded rectangle with dark navy outline; three centered lines)
- shape at x 10.4, y 53.9, w 33.6, h 7.5 [Montserrat Medium; font size 2.6% of slide height; #FFFFFF; center aligned]: Ph2 (single dose) / N=25 (Green #2BB673 rounded rectangle with dark navy outline; two centered lines)
- shape at x 55.3, y 38, w 35.3, h 26.6 [Montserrat Medium; font size 2.1% of slide height; #FFFFFF; left aligned]: Primary endpoints: / • Safety / Efficacy (secondary endpoints) / • CSF and plasma glucosylsphingosine (GluSph) / biomarker change / • CSF and plasma β-Glucocerebrosidase (GCase) / biomarker change / • MDS-UPDRS disease rating change (Green #2BB673 rounded rectangle; bullets are round dots with hanging indent; headings 2.22 em, bullets 2.04 em)
- body at x 9.4, y 68.9, w 81.2, h 9.4 [Montserrat Medium Italic; last line bold italic; font size 2.22% of slide height; #000000; left aligned]: “We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial / for CAP-003 with the aim of dosing the first patient in the third quarter of this year,” – / Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics (On pale green #D1F4E3 box with soft drop shadow)
- line at x 0, y 93.3, w 100, h 0.4 [#1A8A8A]: Thin teal horizontal rule above footer (full width)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#2A7FB0]: Capsida Biotherapeutics logo (Blue wordmark with teal geometric emblem)
- footer at x 11.8, y 95.6, w 39.8, h 1.8 [Montserrat Medium; font size 1.84% of slide height; #000000; left aligned]: See clinicaltrials.gov for full list of clinician & caregiver secondary endpoints ('clinicaltrials.gov' is underlined in teal #467886)
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 21

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 55.3, y 38.0, w 35.3, h 26.6: #2BB673
- fill at x 10.4, y 39.7, w 33.6, h 11.8: #2BB673
- fill at x 10.4, y 53.9, w 33.6, h 7.5: #2BB673
- fill at x 9.4, y 68.9, w 81.2, h 9.4: #D1F4E3
- image at x 3.2, y 11.4, w 79.6, h 19.7: 1792 by 250 pixels
- image at x 9.2, y 68.5, w 81.8, h 11.5: 1091 by 87 pixels
- image at x 9.2, y 68.5, w 82.0, h 10.9: 1094 by 82 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 3.8, w 62.6, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: CAP-003 Phase 1/2 Study (NCT07011771)
- text at x 25.9, y 41.3, w 2.6, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Ph1
- text at x 21.3, y 44.4, w 11.7, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Dose escalation
- text at x 56.3, y 39.5, w 12.1, h 2.2 [Montserrat Medium; font size 2.22; #FFFFFF]: Primary endpoints:
- text at x 25.7, y 47.6, w 2.9, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: N=6
- text at x 56.3, y 42.1, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 58.6, y 42.1, w 3.6, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: Safety
- text at x 20.9, y 54.9, w 12.6, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: Ph2 (single dose)
- text at x 56.3, y 47.0, w 19.5, h 2.2 [Montserrat Medium; font size 2.22; #FFFFFF]: Efficacy (secondary endpoints)
- text at x 25.3, y 58.0, w 3.7, h 2.6 [Montserrat Medium; font size 2.60; #FFFFFF]: N=25
- text at x 56.3, y 49.7, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 58.6, y 49.7, w 27.4, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: CSF and plasma glucosylsphingosine (GluSph)
- text at x 58.6, y 52.1, w 10.8, h 2.0 [Montserrat Medium; font size 2.05; #FFFFFF]: biomarker change
- text at x 56.3, y 54.6, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 58.6, y 54.6, w 9.7, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: CSF and plasma
- text at x 68.4, y 54.6, w 0.6, h 2.0 [Cambria; font size 2.04; #FFFFFF]: β
- text at x 69.0, y 54.6, w 17.1, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: -Glucocerebrosidase (GCase)
- text at x 58.6, y 57.0, w 10.8, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: biomarker change
- text at x 56.3, y 59.4, w 0.4, h 2.0 [ArialMT; font size 2.04; #FFFFFF]: •
- text at x 58.6, y 59.4, w 20.7, h 2.0 [Montserrat Medium; font size 2.04; #FFFFFF]: MDS-UPDRS disease rating change
- text at x 10.2, y 69.9, w 79.1, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: “We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial
- text at x 10.2, y 72.5, w 54.5, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: for CAP-003 with the aim of dosing the first patient in the third quarter of this year,” –
- text at x 10.2, y 75.2, w 41.0, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics
- text at x 10.2, y 75.2, w 41.0, h 2.2 [Montserrat Medium,Italic; font size 2.22; #000000]: Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics
- text at x 11.8, y 95.6, w 2.2, h 1.8 [Montserrat Medium; font size 1.84; #000000]: See
- text at x 14.0, y 95.6, w 8.7, h 1.8 [Montserrat Medium; font size 1.84; #467886]: clinicaltrials.gov
- text at x 22.8, y 95.6, w 28.8, h 1.8 [Montserrat Medium; font size 1.84; #000000]: for full list of clinician & caregiver secondary endpoints
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 21

### Slide 22

**Text**

CAP-004: FA
Friedreich’s ataxia

**Layout**

Full-bleed illustration occupies the left ~40% of the slide; title and subtitle are left-aligned in a text block at the right of centre (x about 47.5%), vertically at about 55–68%. A thin horizontal line runs from the figure's right edge to the slide's right edge at about 80% height. No footer or slide number.

**Visuals**

Full-slide pale gradient background. On the left, a 3D medical illustration of a translucent blue-grey human torso and head in profile facing right, cropped at the waist by the bottom edge. Inside it are visible organs: a green-tinted brain in the head, lungs, a heart, kidneys and vessels, in muted blues. Soft studio lighting with a transparent, glassy look. Behind the figure's shoulder and upper left are clusters of dark grey metallic spheres forming molecular or protein structures that trail diagonally from the top centre-left down to the shoulder. They fade into white at the left. A thin light-blue horizontal line extends from the torso to the right edge.

**Design**

Background is a soft gradient from white at the top left to pale blue #DCE9F6 at the right and bottom. Title and subtitle are in dark charcoal #252524, Montserrat SemiBold, sans-serif. The title is about 5.9% of slide height and the subtitle about 4.4%. The accent line is light blue #A9CBEF, about 1px. The figure is slate blue #3B5575 with the brain in muted green #6F9A8A. No shadows or rounded shapes.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- photo at x 0, y 0, w 100, h 100: Full-slide pale blue-white gradient background image (Covers the whole slide, white to pale blue)
- illustration at x 0, y 0, w 42.8, h 81.6: Clusters of dark grey metallic spheres forming molecular or protein structures, trailing diagonally behind the figure's shoulder and head (Spheres are grey #555555, fading to white at left)
- illustration at x 1.4, y 7.3, w 40.1, h 92.7: Translucent blue human torso and head in profile facing right, with green brain, heart, lungs, kidneys and vessels visible (Cropped at the bottom edge; slate blue #3B5575 with green brain #6F9A8A)
- line at x 38, y 80, w 62, h 0.1 [#A9CBEF]: Thin horizontal light-blue line from the torso's right edge to the slide's right edge (About 1px stroke)
- title at x 47.5, y 55.1, w 21.7, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: CAP-004: FA
- subtitle at x 47.5, y 63.4, w 23.5, h 4.4 [Montserrat SemiBold; font size 4.44% of slide height; #252524; left aligned]: Friedreich’s ataxia

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.9, y 2.6, w 6.0, h 29.6: #FFFFFF
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 42.8, h 81.6: 844 by 1000 pixels
- image at x 1.4, y 7.3, w 40.1, h 92.7: 613 by 798 pixels
- text at x 47.5, y 55.1, w 21.7, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: CAP-004: FA
- text at x 47.5, y 63.4, w 23.5, h 4.4 [Montserrat SemiBold; font size 4.44; #252524]: Friedreich’s ataxia

### Slide 23

**Text**

Friedreich’s Ataxia
Opportunity
CNS, cardiac, and sensory / manifestations
~5,000 patients in the US and / 15,000 worldwide
Genetic validation and potential / for FDA approval after Ph2
>$1B peak year sales
CAP-004
Best in class IV-administered program
Industry-leading frataxin protein expression in all / relevant tissues
Potential for correction of CNS, cardiac, and / sensory manifestations
Safety demonstrated in NHPs, including liver and DRGs
IND-enabling studies ongoing, incl. self-regulating cargo
2H 2026 IND Filing
23

**Layout**

Title top-left. Two rounded cards side by side below the title: a narrower grey-headed 'Opportunity' card on the left and a wider teal-headed 'CAP-004' card on the right. Each card has a bulleted list with thin divider lines. A thin teal rule runs across the slide bottom, with a logo at bottom-left and page number at bottom-right.

**Visuals**

Left card: white body with light grey outline, rounded corners, grey header band, four grey circle bullets, thin grey divider lines between items. Right card: pale cyan body with thin green outline and rounded corners, teal header band, five green filled circles with white checkmarks and one empty green outlined circle for the last item, thin light-teal divider lines between items. Thin teal horizontal line across the full width near the bottom. Capsida Biotherapeutics logo (teal text with a teal and green geometric polyhedron mark and a script wordmark) at bottom-left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524 Montserrat SemiBold, about 5.9% of slide height. Card headers in Montserrat Bold about 3% height: black on grey #DCDDDE, white on teal #00A79D. Body text Montserrat Medium about 2.6% height in #252524. Accents: green #2DB56E check bullets, grey #C8C8CC bullets, teal #00A79D rule. Cards have rounded corners about 1.5% radius, no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 29, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Friedreich’s Ataxia
- shape at x 4.2, y 27.1, w 31.2, h 55.1 [#FFFFFF]: Left card body, white with light grey outline, rounded corners (light grey outline, rounded bottom corners)
- shape at x 4.2, y 18.3, w 31.3, h 9.3 [#DCDDDE]: Left card header band (rounded top corners)
- shape at x 44, y 27.1, w 51.8, h 55.1 [#E1FFFE]: Right card body, pale cyan with green outline (thin green outline, rounded bottom corners)
- shape at x 43.9, y 18.3, w 51.9, h 9.3 [#00A79D]: Right card header band (rounded top corners)
- subtitle at x 5.9, y 21.7, w 10.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #000000; left aligned]: Opportunity
- subtitle at x 45.7, y 21.7, w 7.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: CAP-004
- bullet list at x 6, y 30.5, w 24, h 7.5 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: CNS, cardiac, and sensory / manifestations (grey circle bullet at left, divider line below)
- bullet list at x 6, y 42.4, w 26, h 7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: ~5,000 patients in the US and / 15,000 worldwide (grey circle bullet, divider line below)
- bullet list at x 6, y 54.2, w 28, h 7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Genetic validation and potential / for FDA approval after Ph2 (grey circle bullet, divider line below)
- bullet list at x 6, y 65.2, w 18, h 3.5 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: >$1B peak year sales (grey circle bullet)
- bullet list at x 45.6, y 30.5, w 32, h 3.5 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Best in class IV-administered program (green check circle bullet, divider line below)
- bullet list at x 45.6, y 37.8, w 39.5, h 7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Industry-leading frataxin protein expression in all / relevant tissues (green check circle bullet, divider line below)
- bullet list at x 45.6, y 46.8, w 35, h 7 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Potential for correction of CNS, cardiac, and / sensory manifestations (green check circle bullet, divider line below)
- bullet list at x 45.6, y 57.4, w 43.5, h 3.5 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Safety demonstrated in NHPs, including liver and DRGs (green check circle bullet, divider line below)
- bullet list at x 45.6, y 66.4, w 44.5, h 3.5 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: IND-enabling studies ongoing, incl. self-regulating cargo (green check circle bullet, divider line below)
- bullet list at x 45.6, y 75.4, w 16.2, h 3.5 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: 2H 2026 IND Filing (empty green outlined circle bullet)
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Thin teal horizontal rule across bottom
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#00A79D]: Capsida Biotherapeutics logo
- page number at x 94.9, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 23

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.2, y 27.1, w 31.2, h 55.1: #FFFFFF
- fill at x 4.2, y 18.3, w 31.3, h 9.3: #DCDDDE
- fill at x 44.0, y 27.1, w 51.8, h 55.1: #E1FFFE
- fill at x 43.9, y 18.3, w 51.9, h 9.3: #00A79D
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 29.0, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Friedreich’s Ataxia
- text at x 5.9, y 21.7, w 10.7, h 3.0 [Montserrat,Bold; font size 2.96; #000000]: Opportunity
- text at x 45.7, y 21.7, w 7.7, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: CAP-004
- text at x 8.4, y 31.1, w 19.3, h 2.6 [Montserrat Medium; font size 2.60; #252524]: CNS, cardiac, and sensory
- text at x 48.2, y 31.0, w 28.8, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Best in class IV-administered program
- text at x 8.4, y 34.2, w 11.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: manifestations
- text at x 48.2, y 38.4, w 36.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Industry-leading frataxin protein expression in all
- text at x 48.2, y 41.6, w 11.6, h 2.6 [Montserrat Medium; font size 2.60; #252524]: relevant tissues
- text at x 8.4, y 43.0, w 22.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: ~5,000 patients in the US and
- text at x 8.4, y 46.1, w 12.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: 15,000 worldwide
- text at x 48.2, y 47.4, w 32.6, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Potential for correction of CNS, cardiac, and
- text at x 48.2, y 50.6, w 17.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: sensory manifestations
- text at x 8.4, y 54.8, w 24.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Genetic validation and potential
- text at x 8.4, y 57.9, w 19.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: for FDA approval after Ph2
- text at x 48.2, y 58.0, w 40.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Safety demonstrated in NHPs, including liver and DRGs
- text at x 8.4, y 65.8, w 15.5, h 2.6 [Montserrat Medium; font size 2.60; #252524]: >$1B peak year sales
- text at x 48.2, y 67.0, w 41.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: IND-enabling studies ongoing, incl. self-regulating cargo
- text at x 48.2, y 76.0, w 13.8, h 2.6 [Montserrat Medium; font size 2.60; #252524]: 2H 2026 IND Filing
- text at x 94.9, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 23

### Slide 24

**Text**

IV CAP-004 Achieves Therapeutically Meaningful RNA Expression
Levels in Key FA Tissues While Detargeting Liver
Brain FXN in NHPs
Spinal Cord & Sensory
Neuron FXN in NHPs
Liver FXN in NHPs
>750X
>600X
>13X
<6X
>14X
WPRE copies/ug RNA
10^8
10^7
10^6
10^5
10^4
10^3
Motor Cortex
Cerebellum
SC
DRG
Retina
Liver
AAV9 2.5E13 vg/kg1
CAP-004 2.5E13 vg/kg
FXN = Frataxin
1 AAV9 data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but different therapeutic cargo
24

**Layout**

Two-line left-aligned title across the top. Three equal-width boxed chart panels in a row below, each with a teal header band holding a centered title. A centered legend row sits beneath the panels, then footnotes at bottom left. A thin teal rule above the footer, with a Capsida logo at bottom left and the slide number at bottom right.

**Visuals**

Three log-scale bar charts, each in a white panel with a thin teal outline and a teal header with rounded top corners. All three y-axes read 'WPRE copies/ug RNA' with ticks 10^3, 10^4, 10^5, 10^6, 10^7, 10^8. Grey bars are AAV9 and teal bars are CAP-004, with black error bars. Values below are estimates.

Chart 1, Brain FXN in NHPs, x categories Motor Cortex and Cerebellum. Motor Cortex: AAV9 about 8x10^3 (error about 5x10^3 to 1.1x10^4), CAP-004 about 6x10^6 (error about 1.5x10^6 to 1.1x10^7). Cerebellum: AAV9 about 1.4x10^4 (error about 1x10^4 to 2x10^4), CAP-004 about 8x10^6 (error about 6x10^6 to 1.1x10^7). Teal bracket lines link the grey and teal bars of each category, labelled >750X over Motor Cortex and >600X over Cerebellum.

Chart 2, Spinal Cord & Sensory Neuron FXN in NHPs, categories SC, DRG, Retina. SC: AAV9 about 6x10^5 (error about 2x10^5 to 1x10^6), CAP-004 about 7x10^6 (error about 3x10^6 to 1.2x10^7). DRG: AAV9 about 3x10^6 (error about 1.5x10^6 to 5x10^6), CAP-004 about 5x10^5 (error about 3x10^5 to 7x10^5). Retina: no AAV9 bar, CAP-004 about 1.7x10^6 (error about 1.3x10^6 to 2.2x10^6). Teal brackets are labelled >13X over SC and <6X over DRG.

Chart 3, Liver FXN in NHPs, one category Liver. AAV9 about 4.5x10^5 (error about 2.5x10^5 to 6x10^5), CAP-004 about 3x10^4 (error about 2x10^4 to 4x10^4). A teal bracket labelled >14X joins the two bars.

Legend: grey square labelled AAV9 2.5E13 vg/kg with superscript 1, teal square labelled CAP-004 2.5E13 vg/kg. A thin teal horizontal line spans the slide above the footer. The Capsida Biotherapeutics logo, with a teal and blue faceted gem icon, sits at bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524 Montserrat SemiBold at about 5.2% of slide height. Teal #00A79D panel headers with white Montserrat Bold text at about 3% height. Teal bold callout labels at about 2.6%. Axis text in black Arial at about 2%. Grey #808080 and teal #00A79D bars. Panel outlines are thin teal lines. Footnotes are Montserrat regular at about 1.8% in #252524. No shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 89.8, h 10.8 [Montserrat SemiBold; font size 5.2% of slide height; #252524; left aligned]: IV CAP-004 Achieves Therapeutically Meaningful RNA Expression / Levels in Key FA Tissues While Detargeting Liver (Two lines, tight line spacing)
- shape at x 2.2, y 23.4, w 28.6, h 53 [#00A79D]: Brain panel: white box with thin teal outline and teal header band (Header rounded at top corners; header height about 7.9%)
- caption at x 8.5, y 26.4, w 16.1, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Brain FXN in NHPs
- shape at x 36, y 23.4, w 28.6, h 53 [#00A79D]: Spinal cord panel: white box with thin teal outline and teal header band (Header rounded at top corners)
- caption at x 40.7, y 24.7, w 18.5, h 6.5 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Spinal Cord & Sensory / Neuron FXN in NHPs (Two lines)
- shape at x 68.3, y 23.5, w 28.6, h 53 [#00A79D]: Liver panel: white box with thin teal outline and teal header band (Header rounded at top corners)
- caption at x 74.8, y 26.5, w 15.7, h 3 [Montserrat Bold; font size 3% of slide height; #FFFFFF; center aligned]: Liver FXN in NHPs
- chart at x 4.5, y 33, w 25, h 41 [Arial; font size 2% of slide height; #00A79D]: Brain bar chart: log y-axis 10^3 to 10^8, WPRE copies/ug RNA; Motor Cortex and Cerebellum with AAV9 (grey) and CAP-004 (teal) bars and error bars; labels >750X and >600X with teal brackets (Axis and error bars black; bar tops about 8x10^3, 6x10^6, 1.4x10^4, 8x10^6)
- chart at x 37, y 33, w 25, h 42 [Arial; font size 2% of slide height; #00A79D]: Spinal cord and sensory neuron bar chart: log y-axis 10^3 to 10^8; SC, DRG, Retina categories; labels >13X and <6X with teal brackets (Retina has only a teal bar)
- chart at x 72, y 34, w 24, h 41 [Arial; font size 2% of slide height; #00A79D]: Liver bar chart: log y-axis 10^3 to 10^8; Liver category with AAV9 grey bar and CAP-004 teal bar; label >14X with teal bracket
- shape at x 24.8, y 81.4, w 3, h 4.9 [#808080]: Grey legend swatch (Square)
- caption at x 28.9, y 82.5, w 15.7, h 3 [Montserrat Medium; font size 3% of slide height; #252524; left aligned]: AAV9 2.5E13 vg/kg1 (Superscript 1)
- shape at x 49.4, y 81.4, w 3, h 4.9 [#00A79D]: Teal legend swatch (Square)
- caption at x 54, y 82.6, w 19.2, h 3 [Montserrat Medium; font size 3% of slide height; #252524; left aligned]: CAP-004 2.5E13 vg/kg
- footer at x 3.9, y 89.2, w 76.5, h 3.8 [Montserrat Regular; font size 1.84% of slide height; #252524; left aligned]: FXN = Frataxin / 1 AAV9 data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but different therapeutic cargo (Second line begins with superscript 1)
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Thin teal horizontal rule across slide width
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#00A79D]: Capsida Biotherapeutics logo with teal and blue faceted gem icon
- page number at x 94.8, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.5% of slide height; #252524; right aligned]: 24

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 2.2, y 23.4, w 28.6, h 7.9: #00A79D
- fill at x 26.7, y 81.4, w 20.1, h 4.9: #FFFFFF
- fill at x 51.1, y 81.4, w 24.3, h 4.9: #FFFFFF
- fill at x 36.0, y 23.4, w 28.6, h 7.9: #00A79D
- fill at x 68.3, y 23.5, w 28.6, h 7.9: #00A79D
- fill at x 14.5, y 45.8, w 2.7, h 23.7: #00A79D
- fill at x 25.3, y 44.9, w 2.7, h 24.6: #00A79D
- fill at x 45.2, y 46.1, w 1.8, h 24.3: #00A79D
- fill at x 79.9, y 54.1, w 2.7, h 16.3: #808080
- fill at x 79.7, y 53.9, w 3.0, h 16.5: #808080
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 89.8, h 5.2 [Montserrat SemiBold; font size 5.18; #252524]: IV CAP-004 Achieves Therapeutically Meaningful RNA Expression
- text at x 3.9, y 11.5, w 65.6, h 5.2 [Montserrat SemiBold; font size 5.18; #252524]: Levels in Key FA Tissues While DetargetingLiver
- text at x 40.7, y 24.7, w 19.6, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Spinal Cord & Sensory
- text at x 8.5, y 26.4, w 16.1, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Brain FXN in NHPs
- text at x 74.8, y 26.5, w 15.7, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Liver FXN in NHPs
- text at x 41.3, y 28.2, w 17.9, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Neuron FXN in NHPs
- text at x 10.9, y 35.1, w 4.7, h 2.6 [Montserrat,Bold; font size 2.60; #00A79D]: >750X
- text at x 22.0, y 35.0, w 4.8, h 2.6 [Montserrat,Bold; font size 2.60; #00A79D]: >600X
- text at x 43.0, y 35.5, w 3.4, h 2.6 [Montserrat,Bold; font size 2.60; #00A79D]: >13X
- text at x 50.2, y 35.5, w 2.9, h 2.6 [Montserrat,Bold; font size 2.60; #00A79D]: <6X
- text at x 82.2, y 37.3, w 3.5, h 2.6 [Montserrat,Bold; font size 2.60; #00A79D]: >14X
- text at x 6.6, y 37.2, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 4.7, y 42.7, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: A
- text at x 39.2, y 38.1, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 74.3, y 38.1, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 37.3, y 43.6, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: A
- text at x 72.4, y 43.6, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: A
- text at x 4.7, y 44.2, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: N
- text at x 37.3, y 45.1, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: N
- text at x 72.4, y 45.1, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: N
- text at x 4.7, y 45.8, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: R
- text at x 37.3, y 46.7, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: R
- text at x 72.4, y 46.7, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: R
- text at x 4.7, y 48.0, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: g
- text at x 6.6, y 43.5, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 4.7, y 49.3, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: u
- text at x 37.3, y 48.9, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: g
- text at x 39.2, y 44.3, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 72.4, y 48.9, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: g
- text at x 74.3, y 44.3, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 4.7, y 50.5, w 1.2, h 0.6 [ArialMT; font size 2.22; #000000]: /
- text at x 37.3, y 50.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: u
- text at x 72.4, y 50.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: u
- text at x 4.7, y 51.1, w 1.2, h 1.1 [ArialMT; font size 2.22; #000000]: s
- text at x 37.3, y 52.1, w 1.2, h 1.1 [ArialMT; font size 2.22; #000000]: s
- text at x 37.3, y 51.4, w 1.2, h 0.6 [ArialMT; font size 2.22; #000000]: /
- text at x 72.4, y 52.1, w 1.2, h 1.1 [ArialMT; font size 2.22; #000000]: s
- text at x 72.4, y 51.4, w 1.2, h 0.6 [ArialMT; font size 2.22; #000000]: /
- text at x 4.7, y 53.5, w 1.2, h 0.5 [ArialMT; font size 2.22; #000000]: i
- text at x 4.7, y 52.3, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: e
- text at x 4.7, y 54.0, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: p
- text at x 37.3, y 54.4, w 1.2, h 0.5 [ArialMT; font size 2.22; #000000]: i
- text at x 37.3, y 53.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: e
- text at x 72.4, y 54.4, w 1.2, h 0.5 [ArialMT; font size 2.22; #000000]: i
- text at x 72.4, y 53.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: e
- text at x 4.7, y 55.3, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: o
- text at x 6.6, y 49.7, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 37.3, y 54.9, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: p
- text at x 72.4, y 54.9, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: p
- text at x 4.7, y 56.5, w 1.2, h 1.1 [ArialMT; font size 2.22; #000000]: c
- text at x 37.3, y 56.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: o
- text at x 39.2, y 50.6, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 72.4, y 56.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: o
- text at x 74.3, y 50.6, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 37.3, y 57.4, w 1.2, h 1.1 [ArialMT; font size 2.22; #000000]: c
- text at x 72.4, y 57.4, w 1.2, h 1.1 [ArialMT; font size 2.22; #000000]: c
- text at x 4.7, y 58.2, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: E
- text at x 37.3, y 59.1, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: E
- text at x 72.4, y 59.1, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: E
- text at x 4.7, y 59.7, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: R
- text at x 37.3, y 60.6, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: R
- text at x 72.4, y 60.6, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: R
- text at x 4.7, y 61.3, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: P
- text at x 6.6, y 56.0, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 8.0, y 37.1, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 8
- text at x 28.9, y 82.6, w 15.3, h 3.0 [Montserrat Medium; font size 2.96; #252524]: AAV9 2.5E13 vg/kg
- text at x 37.3, y 62.2, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: P
- text at x 39.2, y 56.9, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 40.5, y 38.0, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 8
- text at x 54.0, y 82.6, w 19.2, h 3.0 [Montserrat Medium; font size 2.96; #252524]: CAP-004 2.5E13 vg/kg
- text at x 72.4, y 62.2, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: P
- text at x 74.3, y 56.9, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 75.6, y 38.0, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 8
- text at x 4.7, y 62.8, w 1.2, h 2.1 [ArialMT; font size 2.22; #000000]: W
- text at x 37.3, y 63.7, w 1.2, h 2.1 [ArialMT; font size 2.22; #000000]: W
- text at x 72.4, y 63.7, w 1.2, h 2.1 [ArialMT; font size 2.22; #000000]: W
- text at x 6.6, y 62.3, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 39.2, y 63.2, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 74.3, y 63.2, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 8.0, y 43.4, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 7
- text at x 40.5, y 44.3, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 7
- text at x 75.6, y 44.3, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 7
- text at x 6.6, y 68.5, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 39.2, y 69.4, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 74.3, y 69.4, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 10.5, y 71.2, w 6.6, h 2.0 [ArialMT; font size 2.02; #000000]: Motor Cortex
- text at x 21.7, y 71.2, w 5.8, h 2.0 [ArialMT; font size 2.02; #000000]: Cerebellum
- text at x 44.0, y 72.1, w 1.6, h 2.0 [ArialMT; font size 2.02; #000000]: SC
- text at x 50.5, y 72.1, w 2.5, h 2.0 [ArialMT; font size 2.02; #000000]: DRG
- text at x 57.1, y 72.1, w 3.3, h 2.0 [ArialMT; font size 2.02; #000000]: Retina
- text at x 82.9, y 72.1, w 2.5, h 2.0 [ArialMT; font size 2.02; #000000]: Liver
- text at x 8.0, y 49.7, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 6
- text at x 40.5, y 50.6, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 6
- text at x 75.6, y 50.6, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 6
- text at x 8.0, y 56.0, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 5
- text at x 44.2, y 82.5, w 0.4, h 2.0 [Montserrat Medium; font size 1.98; #252524]: 1
- text at x 40.5, y 56.8, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 5
- text at x 75.6, y 56.8, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 5
- text at x 8.0, y 62.2, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 4
- text at x 40.5, y 63.1, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 4
- text at x 75.6, y 63.1, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 4
- text at x 3.9, y 89.2, w 7.6, h 1.8 [Montserrat; font size 1.84; #252524]: FXN = Frataxin
- text at x 4.3, y 91.2, w 76.1, h 1.8 [Montserrat; font size 1.84; #252524]: AAV9 data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but different therapeutic cargo
- text at x 8.0, y 68.5, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 3
- text at x 40.5, y 69.4, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 3
- text at x 75.6, y 69.4, w 0.4, h 1.4 [ArialMT; font size 1.35; #000000]: 3
- text at x 94.8, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 24
- text at x 3.9, y 91.1, w 0.4, h 1.2 [Montserrat; font size 1.24; #252524]: 1

### Slide 25

**Text**

27% Average Transduction of Left Ventricle with CAP-004
Results in >70% Increase in FXN Expression in Heart
Left Ventricle %HA Positive Area in NHPs
Cardiac FXN protein levels increase in NHPs
CAP-004 2.5E13 vg/kg
Untreated
CAP-004 2.5E13 vg/kg
27%
70%
50
40
30
20
10
0
% Area
1000
100
10
1
ng FXN per mg of protein
25

**Layout**

Two-line left-aligned title across the top. Below it, two equal panels side by side, each with a rounded teal header band and a thin teal-outlined body holding a bar chart. A thin teal rule runs across the slide near the bottom, with a logo at bottom left and the page number at bottom right.

**Visuals**

Left panel: bar chart titled 'Left Ventricle %HA Positive Area in NHPs'. Y axis '% Area' from 0 to 50 with ticks every 10. One solid teal bar for CAP-004 2.5E13 vg/kg reaching about 27 (label '27%' in bold black above it). Error bar upper cap at about 36. Three black dots at about 38, 34.5 and 7.5. Legend: teal square with 'CAP-004 2.5E13 vg/kg'. Right panel: bar chart titled 'Cardiac FXN protein levels increase in NHPs'. Y axis 'ng FXN per mg of protein', log scale from 1 to 1000 with ticks at 1, 10, 100, 1000. Two bars: Untreated is white with teal outline, height about 60; CAP-004 2.5E13 vg/kg is solid teal, height about 100. Black dots: one at about 60 on the untreated bar, three on the CAP-004 bar at about 130, 110 and 65. Small error bar cap on the teal bar at about 120. A black bracket joins the two bars, with '70%' in bold black above it. Legend: white square with teal outline 'Untreated' and teal square 'CAP-004 2.5E13 vg/kg'. Thin teal horizontal line at the bottom. Capsida Biotherapeutics logo (small teal text with a green-teal geometric polyhedron icon) at bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in dark charcoal #252524, Montserrat SemiBold, about 6% of slide height. Panel header bands in teal #00A79D with white Montserrat Bold text about 3% of slide height, top corners rounded. Panel bodies have a thin teal outline and white fill. Chart text in Arial black, legend text in Montserrat Medium #252524. Bold black Montserrat value callouts. Flat style with no shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 91.4, h 12.3 [Montserrat SemiBold; font size 5.9% of slide height; #252524; left aligned]: 27% Average Transduction of Left Ventricle with CAP-004 / Results in >70% Increase in FXN Expression in Heart (two lines)
- shape at x 4.2, y 23.9, w 44.5, h 6.4 [#00A79D]: Left panel header band, teal with rounded top corners (rounded top corners)
- shape at x 51.4, y 23.9, w 44.5, h 6.4 [#00A79D]: Right panel header band, teal with rounded top corners (rounded top corners)
- shape at x 4.2, y 30.3, w 44.5, h 52 [#FFFFFF]: Left panel body, white with thin teal outline (teal 1px outline)
- shape at x 51.4, y 30.3, w 44.5, h 52 [#FFFFFF]: Right panel body, white with thin teal outline (teal 1px outline)
- caption at x 8.5, y 26.1, w 35.8, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Left Ventricle %HA Positive Area in NHPs
- caption at x 54.5, y 26.1, w 38.3, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: Cardiac FXN protein levels increase in NHPs
- shape at x 25.7, y 32.2, w 1.4, h 2.2 [#00A79D]: Legend swatch, solid teal square for left chart
- caption at x 27.9, y 32.2, w 14.1, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: CAP-004 2.5E13 vg/kg
- shape at x 61.7, y 31.8, w 1.6, h 2.6 [#FFFFFF]: Legend swatch, white square with teal outline (Untreated) (teal outline)
- caption at x 64.1, y 32.1, w 6.5, h 2.2 [Montserrat Medium; font size 2.23% of slide height; #252524; left aligned]: Untreated
- shape at x 74.5, y 32, w 1.4, h 2.4 [#00A79D]: Legend swatch, solid teal square for right chart
- caption at x 76.8, y 32.2, w 14.1, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: CAP-004 2.5E13 vg/kg
- chart at x 13.8, y 35.6, w 21.5, h 44.5 [#00A79D]: Bar chart: % Area axis 0 to 50, one teal bar at about 27 with error bar to about 36 and three black dots at about 38, 34.5 and 7.5 (black axes lines, tick labels 0,10,20,30,40,50; y axis title '% Area' rotated; bar spans x 22.7 to 29.9)
- chart at x 62, y 35.6, w 23.5, h 45 [#00A79D]: Log-scale bar chart: ng FXN per mg of protein axis 1 to 1000, white outlined Untreated bar at about 60 and solid teal CAP-004 bar at about 100, dots, error bar and bracket (black axes lines, tick labels 1,10,100,1000; y axis title rotated; bracket in black joins both bars)
- caption at x 24.2, y 39.4, w 4.4, h 3.7 [Montserrat Bold; font size 3.72% of slide height; #000000; center aligned]: 27%
- caption at x 74, y 38.4, w 4.5, h 3.7 [Montserrat Bold; font size 3.71% of slide height; #000000; center aligned]: 70%
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Thin teal horizontal rule near the bottom
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#00A79D]: Capsida Biotherapeutics logo
- page number at x 94.9, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 25

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.2, y 23.9, w 44.5, h 6.4: #00A79D
- fill at x 51.4, y 23.9, w 44.5, h 6.4: #00A79D
- fill at x 75.7, y 31.2, w 16.0, h 4.0: #FFFFFF
- fill at x 26.8, y 31.2, w 16.0, h 4.0: #FFFFFF
- fill at x 22.7, y 56.5, w 7.2, h 22.8: #00A79D
- fill at x 77.6, y 50.8, w 5.2, h 28.6: #00A79D
- fill at x 69.9, y 54.3, w 5.0, h 25.2: #FFFFFF
- fill at x 69.8, y 54.1, w 5.2, h 25.4: #00A79D
- fill at x 72.4, y 43.8, w 7.9, h 7.6: #000000
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 91.4, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: 27% Average Transduction of Left Ventricle with CAP-004
- text at x 3.9, y 12.3, w 81.1, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Results in >70% Increase in FXN Expression in Heart
- text at x 8.5, y 26.1, w 35.8, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Left Ventricle %HA Positive Area in NHPs
- text at x 54.5, y 26.1, w 38.3, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Cardiac FXN protein levels increase in NHPs
- text at x 24.2, y 39.4, w 4.4, h 3.7 [Montserrat,Bold; font size 3.72; #000000]: 27%
- text at x 74.0, y 38.4, w 4.5, h 3.7 [Montserrat,Bold; font size 3.71; #000000]: 70%
- text at x 27.9, y 32.2, w 14.1, h 2.2 [Montserrat Medium; font size 2.22; #252524]: CAP-004 2.5E13 vg/kg
- text at x 64.1, y 32.1, w 6.5, h 2.2 [Montserrat Medium; font size 2.23; #252524]: Untreated
- text at x 76.8, y 32.2, w 14.1, h 2.2 [Montserrat Medium; font size 2.22; #252524]: CAP-004 2.5E13 vg/kg
- text at x 15.7, y 35.6, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 50
- text at x 63.9, y 35.8, w 2.5, h 2.0 [ArialMT; font size 2.02; #000000]: 1000
- text at x 62.2, y 46.8, w 1.2, h 0.5 [ArialMT; font size 2.22; #000000]: i
- text at x 62.2, y 45.6, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: n
- text at x 62.2, y 47.3, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: e
- text at x 62.2, y 48.6, w 1.2, h 0.6 [ArialMT; font size 2.22; #000000]: t
- text at x 15.7, y 44.1, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 40
- text at x 62.2, y 49.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: o
- text at x 62.2, y 50.4, w 1.2, h 0.7 [ArialMT; font size 2.22; #000000]: r
- text at x 62.2, y 51.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: p
- text at x 62.2, y 53.0, w 1.2, h 0.6 [ArialMT; font size 2.22; #000000]: f
- text at x 62.2, y 53.7, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: o
- text at x 14.0, y 54.3, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: a
- text at x 14.0, y 55.5, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: e
- text at x 62.2, y 55.5, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: g
- text at x 64.5, y 50.0, w 1.9, h 2.0 [ArialMT; font size 2.02; #000000]: 100
- text at x 14.0, y 56.8, w 1.2, h 0.7 [ArialMT; font size 2.22; #000000]: r
- text at x 62.2, y 56.7, w 1.2, h 1.8 [ArialMT; font size 2.22; #000000]: m
- text at x 14.0, y 57.5, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: A
- text at x 15.7, y 52.7, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 30
- text at x 62.2, y 59.2, w 1.2, h 0.7 [ArialMT; font size 2.22; #000000]: r
- text at x 14.0, y 59.5, w 1.2, h 2.0 [ArialMT; font size 2.22; #000000]: %
- text at x 62.2, y 59.9, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: e
- text at x 62.2, y 61.2, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: p
- text at x 62.2, y 63.0, w 1.2, h 1.6 [ArialMT; font size 2.22; #000000]: N
- text at x 62.2, y 64.6, w 1.2, h 1.5 [ArialMT; font size 2.22; #000000]: X
- text at x 62.2, y 66.1, w 1.2, h 1.4 [ArialMT; font size 2.22; #000000]: F
- text at x 15.7, y 61.2, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 20
- text at x 62.2, y 68.1, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: g
- text at x 62.2, y 69.3, w 1.2, h 1.2 [ArialMT; font size 2.22; #000000]: n
- text at x 65.2, y 64.3, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 15.7, y 69.8, w 1.3, h 2.0 [ArialMT; font size 2.02; #000000]: 10
- text at x 16.3, y 78.3, w 0.6, h 2.0 [ArialMT; font size 2.02; #000000]: 0
- text at x 65.8, y 78.5, w 0.6, h 2.0 [ArialMT; font size 2.02; #000000]: 1
- text at x 94.9, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 25

### Slide 26

**Text**

Platform and Capabilities

**Layout**

Section divider: a large translucent human figure illustration occupies the left ~40% of the slide, bleeding off the left and bottom edges. The title is a single left-aligned line in the right half, at about 60-66% height. A thin pale-blue horizontal rule runs from the figure's edge to the right edge at about 80% height. No footer or slide number.

**Visuals**

A 3D medical-style illustration of a male figure in profile, facing right, torso cropped at the bottom edge. The body is rendered as a translucent steel-blue (#3A5578) shape with visible internal organs: a green-grey brain (#5B7F78) in the head, heart, lungs, kidneys and blood vessels in lighter blue. Dark grey glossy spheres form clusters of protein or molecular structures that float behind the shoulder and head at the upper left, with a few chains of beads. The figure fades into the pale background with soft edges. A thin light-blue line (#A9CBEE, about 1px) runs horizontally at y≈80% from x≈38% to the right edge. No logos.

**Design**

Background: Gradient from white (#FFFFFF) at upper left to pale blue (#DCE9F6) at right and bottom. Soft white-to-pale-blue diagonal gradient background, white at top left and light blue (#DCE9F6) toward the right and bottom. The title is dark charcoal (#252524) in Montserrat SemiBold, about 6% of slide height. Accent colours are steel blue (#3A5578), grey spheres (#555555) and a thin pale-blue rule (#A9CBEE). No shadows or rounded shapes.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 0, y 0, w 42.8, h 100: Translucent 3D human figure in profile with visible brain, heart, lungs and kidneys, plus clusters of dark grey molecular spheres behind the shoulder (Cropped at left and bottom edges, blends into the gradient background; the molecules sit at upper left, the brain is tinted green-grey)
- line at x 38, y 80, w 62, h 0.1 [#A9CBEE]: Thin pale-blue horizontal rule (1px stroke, runs to the right edge, behind the figure's lower torso)
- title at x 47.2, y 60.1, w 43.7, h 5.9 [Montserrat SemiBold; font size 5.94% of slide height; #252524; left aligned]: Platform and Capabilities (Single line, sentence-style title case)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.9, y 2.6, w 6.0, h 29.6: #FFFFFF
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 42.8, h 81.6: 844 by 1000 pixels
- image at x 1.4, y 7.3, w 40.1, h 92.7: 613 by 798 pixels
- text at x 47.2, y 60.1, w 43.7, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Platform and Capabilities

### Slide 27

**Text**

Capsida – Uniquely Positioned to Lead Gene Therapy
Capsid Engineering Scale
Fully industrialized and / roboticized platform
Screening capabilities across cell / types in NHPs and human cells
CNS Tropism
>99% specific to neurons
>70% neurons transduced
Broad IP capsids and / capsid/cargo
Peripheral Detargeting
>16x liver & >50x DRG detargeted
Superior off-target safety profile
Broad IP protecting detargeting
Therapeutic Expression
Expression in NHPs with / potential for full disease / correction
Industry leading expression / levels across pipeline programs
Clinical Translatability
Identified/patented novel human / receptor with complete homology / in NHPs and humans
Validated expression in NHPs / including primates >20 years old
Manufacturability
In-house process development / and GMP manufacturing
Productivity surpassing AAV9
Quality specifications > FDA / requirements
Only Capsida has created all the capabilities and results needed to / deliver on the promise of gene therapy
27

**Layout**

Title at top left. Below it a 3-column by 2-row grid of six cards, each with a gradient header bar and a white body with a thin teal outline containing two or three bullet-less statements separated by thin gray rules. A full-width rounded gradient banner with centered white text sits beneath the grid. A thin teal rule runs across the slide near the bottom, with the Capsida logo at bottom left and the slide number at bottom right.

**Visuals**

Six cards: each has a header with rounded top corners filled with a horizontal gradient from blue (#0088BB) on the left to teal-green (#00AA9E) on the right, and a white body with a 1px teal outline. Thin light-gray divider lines separate statements within each card. A wide rounded-rectangle banner with the same blue-to-teal gradient spans the lower part. A thin teal horizontal line spans the full slide width above the footer. The Capsida Biotherapeutics logo (blue 'CAPSIDA' wordmark with a small teal and green hexagonal/geometric mark with script text) is at the bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524, Montserrat SemiBold, about 6% of slide height. Card headers in white Montserrat Bold about 3% of height. Body text black #000000 Montserrat Medium about 2.6% of height. Banner text white Montserrat Bold about 4.4% of height. Accent gradient from blue #0088BB to teal #00AA9E. Card headers and the banner have rounded corners, about 1.5% of height radius for the cards and larger for the banner; no shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 83, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Capsida – Uniquely Positioned to Lead Gene Therapy
- shape at x 4.2, y 13.9, w 29.3, h 8.1 [#0088BB]: Card header, gradient blue to teal, rounded top corners, Capsid Engineering Scale (horizontal gradient blue #0088BB to teal #00AA9E)
- shape at x 35.4, y 13.9, w 29.2, h 8.1 [#0099B0]: Card header, CNS Tropism (horizontal gradient blue to teal, rounded top corners)
- shape at x 66.6, y 13.9, w 29.3, h 8.1 [#0099B0]: Card header, Peripheral Detargeting (horizontal gradient blue to teal, rounded top corners)
- shape at x 4.2, y 46.9, w 29.3, h 8.1 [#0088BB]: Card header, Therapeutic Expression (horizontal gradient blue to teal, rounded top corners)
- shape at x 35.4, y 46.9, w 29.2, h 8.1 [#0099B0]: Card header, Clinical Translatability (horizontal gradient blue to teal, rounded top corners)
- shape at x 66.6, y 46.9, w 29.3, h 8.1 [#0099B0]: Card header, Manufacturability (horizontal gradient blue to teal, rounded top corners)
- shape at x 4.2, y 22, w 91.7, h 55.5 [#FFFFFF]: White card bodies with thin teal outline, six cards (3 columns by 2 rows) below the headers (1px teal #00AA9E outline; top row bodies y 22 to 44.6, bottom row bodies y 55 to 77.6)
- heading at x 5.9, y 16.9, w 22.2, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Capsid Engineering Scale
- heading at x 37.1, y 16.9, w 11.2, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: CNS Tropism
- heading at x 68.3, y 16.9, w 20.2, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Peripheral Detargeting
- body at x 6.1, y 24.5, w 17.6, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Fully industrialized and / roboticized platform (followed by thin gray divider rule)
- body at x 6.1, y 34.3, w 24.8, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Screening capabilities across cell / types in NHPs and human cells
- body at x 37.4, y 24.1, w 18.3, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: >99% specific to neurons (followed by thin gray divider rule)
- body at x 37.4, y 29.5, w 19.4, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: >70% neurons transduced (followed by thin gray divider rule)
- body at x 37.4, y 34.9, w 16, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Broad IP capsids and / capsid/cargo
- body at x 68.6, y 24.1, w 24.4, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: >16x liver & >50x DRG detargeted (followed by thin gray divider rule)
- body at x 68.6, y 29.5, w 23.8, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Superior off-target safety profile (followed by thin gray divider rule)
- body at x 68.6, y 34.9, w 23.9, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Broad IP protecting detargeting
- heading at x 5.9, y 49.8, w 20.5, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Therapeutic Expression
- heading at x 37.1, y 49.8, w 19.3, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Clinical Translatability
- heading at x 68.3, y 49.8, w 15.5, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Manufacturability
- body at x 6.1, y 57.9, w 18.5, h 8.8 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Expression in NHPs with / potential for full disease / correction (followed by thin gray divider rule)
- body at x 6.1, y 68.5, w 23.3, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Industry leading expression / levels across pipeline programs
- body at x 37.2, y 57.8, w 25.9, h 8.8 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Identified/patented novel human / receptor with complete homology / in NHPs and humans (followed by thin gray divider rule)
- body at x 37.2, y 68.4, w 24.1, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Validated expression in NHPs / including primates >20 years old
- body at x 68.4, y 57.9, w 23.4, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: In-house process development / and GMP manufacturing (followed by thin gray divider rule)
- body at x 68.4, y 65.4, w 22.3, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Productivity surpassing AAV9 (followed by thin gray divider rule)
- body at x 68.4, y 69.9, w 21.1, h 5.7 [Montserrat Medium; font size 2.6% of slide height; #000000; left aligned]: Quality specifications > FDA / requirements
- shape at x 4.1, y 78.7, w 91.8, h 13.5 [#0088BB]: Full-width rounded banner with gradient from blue to teal (horizontal gradient #0088BB to #00AA9E, large corner radius)
- body at x 6.3, y 80.8, w 87.9, h 9.7 [Montserrat Bold; font size 4.44% of slide height; #FFFFFF; center aligned]: Only Capsida has created all the capabilities and results needed to / deliver on the promise of gene therapy (two centered lines)
- line at x 0, y 93.3, w 100, h 0.4 [#00AA9E]: Thin teal horizontal rule across slide (about 2px)
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#0088BB]: Capsida Biotherapeutics logo: blue CAPSIDA wordmark with small teal/green geometric mark
- page number at x 94.9, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 27

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- image at x 4.1, y 78.7, w 91.8, h 13.5: 881 by 73 pixels
- image at x 4.2, y 13.9, w 29.3, h 8.1: 281 by 44 pixels
- image at x 66.6, y 13.9, w 29.3, h 8.1: 281 by 44 pixels
- image at x 4.2, y 46.9, w 29.3, h 8.1: 281 by 44 pixels
- image at x 66.6, y 46.9, w 29.3, h 8.1: 281 by 44 pixels
- image at x 35.4, y 13.9, w 29.2, h 8.1: 280 by 44 pixels
- image at x 35.4, y 46.9, w 29.2, h 8.1: 280 by 44 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 83.0, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Capsida –Uniquely Positioned to Lead Gene Therapy
- text at x 5.9, y 16.9, w 22.2, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Capsid Engineering Scale
- text at x 37.1, y 16.9, w 11.2, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: CNS Tropism
- text at x 68.3, y 16.9, w 20.2, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Peripheral Detargeting
- text at x 37.4, y 24.1, w 18.3, h 2.6 [Montserrat Medium; font size 2.60; #000000]: >99% specific to neurons
- text at x 68.6, y 24.1, w 24.4, h 2.6 [Montserrat Medium; font size 2.60; #000000]: >16x liver & >50x DRG detargeted
- text at x 6.1, y 24.5, w 17.6, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Fully industrialized and
- text at x 6.1, y 27.6, w 15.2, h 2.6 [Montserrat Medium; font size 2.60; #000000]: roboticized platform
- text at x 37.4, y 29.5, w 19.4, h 2.6 [Montserrat Medium; font size 2.60; #000000]: >70% neurons transduced
- text at x 68.6, y 29.5, w 23.8, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Superior off-target safety profile
- text at x 6.1, y 34.3, w 24.8, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Screening capabilities across cell
- text at x 37.4, y 34.9, w 16.0, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Broad IP capsids and
- text at x 68.6, y 34.9, w 23.9, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Broad IP protecting detargeting
- text at x 6.1, y 37.4, w 23.1, h 2.6 [Montserrat Medium; font size 2.60; #000000]: types in NHPs and human cells
- text at x 37.4, y 38.0, w 10.0, h 2.6 [Montserrat Medium; font size 2.60; #000000]: capsid/cargo
- text at x 5.9, y 49.8, w 20.5, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Therapeutic Expression
- text at x 37.1, y 49.8, w 19.3, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Clinical Translatability
- text at x 68.3, y 49.8, w 15.5, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Manufacturability
- text at x 6.3, y 80.8, w 87.9, h 4.4 [Montserrat,Bold; font size 4.44; #FFFFFF]: Only Capsida has created all the capabilities and results needed to
- text at x 24.4, y 86.1, w 51.1, h 4.4 [Montserrat,Bold; font size 4.45; #FFFFFF]: deliver on the promise of gene therapy
- text at x 37.2, y 57.8, w 25.1, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Identified/patented novel human
- text at x 6.1, y 57.9, w 18.5, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Expression in NHPs with
- text at x 68.4, y 57.9, w 23.4, h 2.6 [Montserrat Medium; font size 2.60; #000000]: In-house process development
- text at x 6.1, y 61.0, w 18.2, h 2.6 [Montserrat Medium; font size 2.60; #000000]: potential for full disease
- text at x 37.2, y 60.9, w 25.9, h 2.6 [Montserrat Medium; font size 2.60; #000000]: receptor with complete homology
- text at x 68.4, y 61.0, w 18.8, h 2.6 [Montserrat Medium; font size 2.60; #000000]: and GMP manufacturing
- text at x 6.1, y 64.1, w 7.6, h 2.6 [Montserrat Medium; font size 2.60; #000000]: correction
- text at x 37.2, y 64.0, w 15.7, h 2.6 [Montserrat Medium; font size 2.60; #000000]: in NHPs and humans
- text at x 68.4, y 65.4, w 22.3, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Productivity surpassing AAV9
- text at x 6.1, y 68.5, w 20.9, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Industry leading expression
- text at x 37.2, y 68.4, w 22.1, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Validated expression in NHPs
- text at x 68.4, y 69.9, w 21.1, h 2.6 [Montserrat Medium; font size 2.60; #000000]: Quality specifications > FDA
- text at x 6.1, y 71.6, w 23.3, h 2.6 [Montserrat Medium; font size 2.60; #000000]: levels across pipeline programs
- text at x 37.2, y 71.5, w 24.1, h 2.6 [Montserrat Medium; font size 2.60; #000000]: including primates >20 years old
- text at x 68.4, y 73.0, w 10.2, h 2.6 [Montserrat Medium; font size 2.60; #000000]: requirements
- text at x 94.9, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 27
- text at x 94.9, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 27

### Slide 28

**Review notes**

- Suggested repair: Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

**Text**

In-house Process & Analytical Development and cGMP Manufacturing
Enables Capsida to control quality, timelines, and costs
Vector
Production
Rapid production of engineered capsids for preclinical studies
Process &
Analytical
Development
Conduct manufacturability assessment in HEK293 suspension process
Up to 50 L bioreactor scale
Develop and optimize key analytical assays
cGMP
Manufacturing
15,000 ft2 cGMP Manufacturing Facility
Leverages single use systems
200L bioreactor scale with ability to significantly expand capacity
Finish – fill operations
Unidirectional flow
In-house QC capabilities for product release
Modular clean rooms
Excellent yields and quality specifications at or above FDA standards
28

**Layout**

Title and subtitle left-aligned at top. Below, a three-row table-like layout: bold teal row labels in a left column, a photo in a middle column, and descriptive text lines in a right column, with thin teal rules between rows and light gray rules between lines. A full-width rounded gradient banner sits near the bottom, followed by a thin footer line with a logo at left and page number at right.

**Visuals**

Three small photographs in the middle column. Top: a woman in a blue lab coat working at a benchtop centrifuge in a lab with shelves. Middle: a man in a blue lab coat working beside a red bioreactor/incubator unit in a lab. Bottom: two people in white cleanroom suits, hoods and green gloves working at a stainless steel bioreactor in a cleanroom. Thin teal horizontal divider lines at about y 33.5%, 53.5% and 81%. Light gray thin lines between bullet rows. A rounded rectangle banner with blue-to-green horizontal gradient. A thin teal footer line across the full width. Capsida Biotherapeutics logo at bottom left (blue wordmark with teal leaf/triangle icon).

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524 Montserrat SemiBold, about 4.8% of slide height. Subtitle in teal-blue #006487 Montserrat SemiBold about 3% height. Row labels bold Montserrat in #006487 (first two rows) and #0086B4 (cGMP Manufacturing). Body text Montserrat Medium #252524 about 2.6% height. Banner text white bold Montserrat about 3.3% height on a gradient from #0086B4 to #00A99D with rounded corners of about 1% of slide width, no shadow. Rules teal #1BA3A0 and light gray #D9D9D9.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 87.6, h 4.8 [Montserrat SemiBold; font size 4.82% of slide height; #252524; left aligned]: In-house Process & Analytical Development and cGMP Manufacturing (tight letter spacing)
- subtitle at x 4, y 13.5, w 47.3, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: Enables Capsida to control quality, timelines, and costs
- body at x 5, y 24.8, w 7.3, h 4.9 [Montserrat Bold; font size 2.22% of slide height; #006487; left aligned]: Vector / Production (two lines)
- photo at x 21.7, y 20.7, w 9.5, h 12.1 [#7A8A9A]: Woman in blue lab coat working at a benchtop centrifuge in a lab (boxed, no border)
- body at x 38.5, y 26, w 45.9, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Rapid production of engineered capsids for preclinical studies
- line at x 4.2, y 33.5, w 91.6, h 0.1 [#1BA3A0]: Teal divider line under first row (thin teal rule)
- body at x 5, y 40.2, w 8.9, h 7.5 [Montserrat Bold; font size 2.22% of slide height; #006487; left aligned]: Process & / Analytical / Development (three lines)
- photo at x 21.7, y 35.7, w 9.5, h 16.9 [#B03030]: Man in blue lab coat working beside a red bioreactor unit in a lab (boxed, no border)
- body at x 38.5, y 36, w 52, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Conduct manufacturability assessment in HEK293 suspension process (light gray rule below)
- body at x 38.5, y 42.7, w 19.7, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Up to 50 L bioreactor scale (light gray rule below)
- body at x 38.5, y 49.3, w 31.9, h 2.6 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: Develop and optimize key analytical assays
- line at x 4.2, y 53.5, w 91.6, h 0.1 [#1BA3A0]: Teal divider line under second row (thin teal rule)
- body at x 5, y 65.2, w 9.8, h 5.2 [Montserrat Bold; font size 2.22% of slide height; #0086B4; left aligned]: cGMP / Manufacturing (two lines)
- photo at x 21.7, y 58.9, w 9.5, h 17.8 [#C8C8C8]: Two people in white cleanroom suits working at a stainless steel bioreactor (boxed, no border)
- bullet list at x 38.5, y 54.6, w 52, h 26.1 [Montserrat Medium; font size 2.6% of slide height; #252524; left aligned]: 15,000 ft2 cGMP Manufacturing Facility / Leverages single use systems / 200L bioreactor scale with ability to significantly expand capacity / Finish – fill operations / Unidirectional flow / In-house QC capabilities for product release / Modular clean rooms (seven rows about 3.9% apart, each separated by thin light gray rules; 2 in ft2 is superscript)
- line at x 4.2, y 81, w 91.6, h 0.1 [#1BA3A0]: Teal divider line under third row (thin teal rule)
- shape at x 4.1, y 85.4, w 91.8, h 6.1 [#0086B4]: Rounded rectangle banner with horizontal gradient from blue to green (gradient #0086B4 to #00A99D, rounded corners)
- caption at x 16, y 86.9, w 67.7, h 3.3 [Montserrat Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: Excellent yields and quality specifications at or above FDA standards (on gradient banner)
- line at x 0, y 93.3, w 100, h 0.4 [#1BA3A0]: Thin teal footer line across slide
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#0086B4]: Capsida Biotherapeutics logo (blue wordmark with teal leaf icon)
- page number at x 94.8, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 28

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- image at x 4.1, y 85.4, w 91.8, h 6.1: 881 by 33 pixels
- image at x 21.7, y 58.9, w 9.5, h 17.8: 253 by 266 pixels
- image at x 21.7, y 35.7, w 9.5, h 16.9: 253 by 253 pixels
- image at x 21.7, y 20.7, w 9.5, h 12.1: 253 by 181 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 87.6, h 4.8 [Montserrat SemiBold; font size 4.82; #252524]: In-house Process & Analytical Development and cGMP Manufacturing
- text at x 4.0, y 13.5, w 47.3, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: Enables Capsida to control quality, timelines, and costs
- text at x 38.5, y 26.0, w 45.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Rapid production of engineered capsids for preclinical studies
- text at x 5.0, y 24.8, w 4.7, h 2.2 [Montserrat,Bold; font size 2.22; #006487]: Vector
- text at x 5.0, y 27.5, w 7.3, h 2.2 [Montserrat,Bold; font size 2.22; #006487]: Production
- text at x 38.5, y 36.0, w 52.0, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Conduct manufacturability assessment in HEK293 suspension process
- text at x 38.5, y 42.7, w 19.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Up to 50 L bioreactor scale
- text at x 5.0, y 40.2, w 6.7, h 2.2 [Montserrat,Bold; font size 2.22; #006487]: Process &
- text at x 38.5, y 49.3, w 31.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Develop and optimize key analytical assays
- text at x 5.0, y 42.8, w 6.9, h 2.2 [Montserrat,Bold; font size 2.22; #006487]: Analytical
- text at x 5.0, y 45.5, w 8.9, h 2.2 [Montserrat,Bold; font size 2.22; #006487]: Development
- text at x 38.5, y 54.6, w 28.6, h 2.6 [Montserrat Medium; font size 2.60; #252524]: 15,000 ft cGMP Manufacturing Facility
- text at x 38.5, y 58.5, w 21.9, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Leverages single use systems
- text at x 38.5, y 62.4, w 48.2, h 2.6 [Montserrat Medium; font size 2.60; #252524]: 200L bioreactor scale with ability to significantly expand capacity
- text at x 38.5, y 66.3, w 16.0, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Finish – fill operations
- text at x 16.0, y 86.9, w 67.7, h 3.3 [Montserrat,Bold; font size 3.33; #FFFFFF]: Excellent yields and quality specifications at or above FDA standards
- text at x 38.5, y 70.3, w 14.1, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Unidirectional flow
- text at x 38.5, y 74.2, w 32.4, h 2.6 [Montserrat Medium; font size 2.60; #252524]: In-house QC capabilities for product release
- text at x 5.0, y 65.2, w 4.2, h 2.2 [Montserrat,Bold; font size 2.22; #0086B4]: cGMP
- text at x 38.5, y 78.1, w 15.7, h 2.6 [Montserrat Medium; font size 2.60; #252524]: Modular clean rooms
- text at x 5.0, y 67.8, w 9.8, h 2.2 [Montserrat,Bold; font size 2.22; #0086B4]: Manufacturing
- text at x 44.7, y 54.5, w 0.6, h 1.7 [Montserrat Medium; font size 1.74; #252524]: 2
- text at x 94.8, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 28

### Slide 29

**Text**

Corporate & Finance

**Layout**

Section divider: a large anatomical figure image occupies the left ~40% of the slide, bleeding off the top, left and bottom edges. The title is left-aligned in the right half at about 60-66% of the slide height; a thin horizontal line runs from the figure to the right edge at about 80% height. No footer or slide number.

**Visuals**

Rendered 3D translucent human torso in profile facing right, in steel blue (#2F4A6E) with a visible green-grey brain (#5F8B80) in the head, heart, lungs, kidneys and vessels showing through the body. The figure is cropped at the waist and the left arm is cut off at the slide edge. Behind the head and shoulders, clusters of grey-black glossy spheres form molecular or protein strands, rising diagonally from the shoulder to the top edge of the slide. They are lit softly, with a white fade on the left. A thin light-blue horizontal line (#A9CBEF, about 1px) extends from the figure's torso to the right edge.

**Design**

Background: Diagonal gradient from white (#FFFFFF) at the top-left to pale blue (#DCE8F6) at the right and bottom. Soft gradient background from white at upper-left to pale blue (#DCE8F6) at the right and bottom. Title in near-black charcoal (#252524), Montserrat SemiBold, about 6% of the slide height. The imagery is blue and grey and the light-blue rule is the only accent. No shadows or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- photo at x 0, y 0, w 42.8, h 100: Translucent 3D human torso in profile with the brain highlighted in green and organs visible, with grey molecular sphere clusters behind the head and shoulder (Bleeds off the left, top and bottom edges; blends into the white-to-blue background; blue figure #2F4A6E, grey spheres #4A4A4A)
- line at x 38.5, y 79.8, w 61.5, h 0.2 [#A9CBEF]: Thin light-blue horizontal rule from the figure's torso to the right edge (About 1px stroke, spans to the right slide edge at about 80% height)
- title at x 47.2, y 59.7, w 35.3, h 5.9 [Montserrat SemiBold; font size 5.94% of slide height; #252524; left aligned]: Corporate & Finance

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 4.9, y 2.6, w 6.0, h 29.6: #FFFFFF
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 0.0, y 0.0, w 42.8, h 81.6: 844 by 1000 pixels
- image at x 1.4, y 7.3, w 40.1, h 92.7: 613 by 798 pixels
- text at x 47.2, y 59.7, w 35.3, h 5.9 [Montserrat SemiBold; font size 5.94; #252524]: Corporate & Finance

### Slide 30

**Text**

Leadership Team and Board of Directors
Decades of Industry Experience and Drug Development Expertise
Leadership
Board Members
Peter Anastasiou
Chief Executive Officer
Nicholas Flytzanis,
PhD
Founder, Chief Research
and Innovation Officer
Swati Tole, MD
Chief Medical
Officer
Clare Ozawa,
PhD
Beth Seidenberg,
MD
Viviana Gradinaru,
PhD
Founder
Julie Hakim
Chief Financial Officer
Bethany Mancilla
Chief Business Officer
Rob Murphy
Chief Manufacturing
and Quality Officer
Rita Balice-Gordon,
PhD
CEO, Muna Tx
Frank Verwiel,
MD
Chairman, Intellia
Peter Anastasiou
Chief Executive Officer
30

**Layout**

Title and subtitle left-aligned at top left. Below, two rounded pill banners: 'Leadership' on the left (about 4%-55% wide) and 'Board Members' on the right (about 59%-96%). Under each, a grid of headshots with name, title and company logos beneath: leadership as 3 columns by 2 rows, board as 3 columns by 2 rows. A thin teal rule runs across the slide near the bottom, with a Capsida logo bottom left and page number bottom right.

**Visuals**

Two horizontal pill-shaped gradient banners (Leadership: teal-blue #0088B8 to green-teal #00A79D; Board Members: darker blue #2060A0 to light blue #0088C0). Twelve rounded-corner square portrait photos on light grey #F2F2F2 backgrounds, each a professional headshot of a person from the chest up, on a neutral grey backdrop. Leadership row 1: bald smiling man in grey blazer and light blue shirt; bearded dark-haired man in dark jacket; smiling woman with long black hair, dark navy top. Leadership row 2: woman with short blond hair and green top; woman with long grey-blonde hair in light blue top; older man with dark grey hair in navy jacket and light blue shirt. Board row 1: woman with black bob hair; woman with long wavy brown-grey hair in black top; woman with brown shoulder-length hair in cream top. Board row 2: woman with dark brown hair in cream top; man in dark suit and white shirt with short hair; bald smiling man in grey blazer. Small white rounded-rectangle logo chips with thin grey border beneath each person: Peter Anastasiou (CEO): Lundbeck with red starfish, Lilly script logo. Nicholas Flytzanis: Caltech. Swati Tole: Genentech. Clare Ozawa: Versant Ventures, Novartis. Beth Seidenberg: Westlake BioPartners, Kleiner Perkins. Viviana Gradinaru: Caltech. Julie Hakim: Lundbeck, Sequoia Vaccines. Bethany Mancilla: Amgen, Micromet. Rob Murphy: Amgen. Rita Balice-Gordon: Muna Therapeutics, Sanofi. Frank Verwiel: Avexis, Intellia Therapeutics. Peter Anastasiou (second): Lundbeck, Lilly. Thin teal horizontal line near the bottom; Capsida Biotherapeutics logo with teal-green geometric mark at bottom left.

**Design**

Background: Solid white #FFFFFF. White background; large title in dark charcoal #252524 Montserrat SemiBold at about 5.9% of slide height; subtitle in teal-blue #006487 Montserrat SemiBold about 3%. Banner labels white Montserrat SemiBold about 2.6%. Names in Montserrat Bold about 1.84% in #252524; titles in Montserrat Medium about 1.67% in #252524. Photo tiles have rounded corners about 10% of tile size; logo chips have small rounded corners and thin light grey outlines; banners fully rounded ends. No shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 63.7, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Leadership Team and Board of Directors
- subtitle at x 3.9, y 14.1, w 56.6, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: Decades of Industry Experience and Drug Development Expertise
- shape at x 4, y 20.7, w 51.1, h 5.4 [#0088B8]: Leadership banner pill, gradient teal-blue to green-teal (Fully rounded ends, horizontal gradient to #00A79D)
- shape at x 59.4, y 20.7, w 36.2, h 5.4 [#2060A0]: Board Members banner pill, gradient dark blue to light blue (Fully rounded ends, horizontal gradient to #0088C0)
- caption at x 25.4, y 22.3, w 8.4, h 2.6 [Montserrat SemiBold; font size 2.6% of slide height; #FFFFFF; center aligned]: Leadership
- caption at x 71.5, y 22.3, w 12.1, h 2.6 [Montserrat SemiBold; font size 2.6% of slide height; #FFFFFF; center aligned]: Board Members
- photo at x 11.4, y 28.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Peter Anastasiou, bald smiling man in grey blazer (Rounded corners, grey tile)
- photo at x 25.4, y 28.9, w 8, h 14.1 [#F2F2F2]: Headshot of Nicholas Flytzanis, bearded man in dark jacket (Rounded corners)
- photo at x 39.7, y 29, w 7.9, h 14.1 [#F2F2F2]: Headshot of Swati Tole, woman with long black hair (Rounded corners)
- photo at x 59.7, y 28.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Clare Ozawa, woman with black bob (Rounded corners)
- photo at x 72.1, y 28.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Beth Seidenberg, woman with wavy brown-grey hair (Rounded corners)
- photo at x 84.9, y 28.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Viviana Gradinaru, woman with brown hair (Rounded corners)
- body at x 11.4, y 43.7, w 9.3, h 1.8 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Peter Anastasiou
- body at x 11.4, y 45.9, w 10.8, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chief Executive Officer
- body at x 25.4, y 43.9, w 10.4, h 4 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Nicholas Flytzanis, / PhD
- body at x 25.4, y 48.3, w 11.9, h 3.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Founder, Chief Research / and Innovation Officer
- body at x 39.7, y 44, w 8, h 1.8 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Swati Tole, MD
- body at x 39.7, y 46.2, w 6.7, h 3.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chief Medical / Officer
- body at x 59.7, y 43.7, w 7.4, h 4 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Clare Ozawa, / PhD
- body at x 72.1, y 43.7, w 9.7, h 4 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Beth Seidenberg, / MD
- body at x 84.9, y 43.7, w 10.3, h 4 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Viviana Gradinaru, / PhD
- body at x 84.9, y 48.1, w 4.1, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Founder
- logo at x 20, y 52.5, w 0, h 0: Lundbeck logo chip and Lilly logo chip (Peter Anastasiou) (Placeholder grouping; see individual logos)
- logo at x 11.4, y 52.5, w 4.6, h 4.4 [#FFFFFF]: Lundbeck (with red starfish) logo chip (White chip, thin grey border)
- logo at x 16.8, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Lilly logo chip, red script (White chip, thin grey border)
- logo at x 25.4, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Caltech logo chip (Nicholas Flytzanis) (Orange icon and text)
- logo at x 39.7, y 51.2, w 6.9, h 4.4 [#FFFFFF]: Genentech logo chip (Blue wordmark)
- logo at x 59.7, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Versant Ventures logo chip
- logo at x 65.2, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Novartis logo chip
- logo at x 72, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Westlake BioPartners logo chip
- logo at x 77.5, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Kleiner Perkins logo chip
- logo at x 84.9, y 52.5, w 5.2, h 4.4 [#FFFFFF]: Caltech logo chip (Viviana Gradinaru)
- photo at x 11.4, y 61.9, w 7.9, h 14.1 [#F2F2F2]: Headshot of Julie Hakim, woman with short blond hair, green top (Rounded corners)
- photo at x 25.4, y 61.9, w 7.9, h 14.1 [#F2F2F2]: Headshot of Bethany Mancilla, woman with long grey-blonde hair (Rounded corners)
- photo at x 39.7, y 61.8, w 8, h 14.1 [#F2F2F2]: Headshot of Rob Murphy, older man in navy jacket (Rounded corners)
- photo at x 59.7, y 61.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Rita Balice-Gordon, woman with dark hair, cream top (Rounded corners)
- photo at x 72.1, y 61.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Frank Verwiel, man in dark suit and white shirt (Rounded corners)
- photo at x 84.7, y 61.8, w 7.9, h 14.1 [#F2F2F2]: Headshot of Peter Anastasiou, bald smiling man in grey blazer (Rounded corners)
- body at x 11.4, y 76.7, w 6.4, h 1.8 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Julie Hakim
- body at x 11.4, y 78.9, w 10.5, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chief Financial Officer
- body at x 25.4, y 76.7, w 9.4, h 1.8 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Bethany Mancilla
- body at x 25.4, y 78.9, w 10.6, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chief Business Officer
- body at x 39.7, y 76.8, w 6.7, h 1.8 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Rob Murphy
- body at x 39.7, y 79, w 10.1, h 3.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chief Manufacturing / and Quality Officer
- body at x 59.7, y 76.8, w 10.8, h 4 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Rita Balice-Gordon, / PhD
- body at x 59.7, y 81.2, w 6.6, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: CEO, Muna Tx
- body at x 72.1, y 76.8, w 8.1, h 4 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Frank Verwiel, / MD
- body at x 72.1, y 81.2, w 8.4, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chairman, Intellia
- body at x 84.8, y 76.8, w 9.3, h 1.8 [Montserrat Bold; font size 1.84% of slide height; #252524; left aligned]: Peter Anastasiou
- body at x 84.8, y 79, w 10.8, h 1.7 [Montserrat Medium; font size 1.67% of slide height; #252524; left aligned]: Chief Executive Officer
- logo at x 11.4, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Lundbeck logo chip (Julie Hakim)
- logo at x 17, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Sequoia Vaccines logo chip
- logo at x 25.4, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Amgen logo chip (Bethany Mancilla) (Blue wordmark)
- logo at x 31, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Micromet logo chip
- logo at x 39.7, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Amgen logo chip (Rob Murphy) (Blue wordmark)
- logo at x 59.7, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Muna Therapeutics logo chip
- logo at x 65.2, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Sanofi logo chip
- logo at x 72.1, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Avexis logo chip
- logo at x 77.7, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Intellia Therapeutics logo chip
- logo at x 84.7, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Lundbeck logo chip (Peter Anastasiou)
- logo at x 90.3, y 84.6, w 5.2, h 4.4 [#FFFFFF]: Lilly logo chip (Peter Anastasiou)
- line at x 0, y 93.3, w 100, h 0.4 [#00A29A]: Thin teal horizontal rule across slide bottom
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#0088B8]: Capsida Biotherapeutics logo with teal-green geometric mark
- page number at x 94.8, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 30

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 84.9, y 28.8, w 7.9, h 14.1: #F2F2F2
- fill at x 59.7, y 28.8, w 7.9, h 14.1: #F2F2F2
- fill at x 72.1, y 28.8, w 7.9, h 14.1: #F2F2F2
- fill at x 84.7, y 61.8, w 7.9, h 14.1: #F2F2F2
- fill at x 72.1, y 61.8, w 7.9, h 14.1: #F2F2F2
- fill at x 59.7, y 61.8, w 7.9, h 14.1: #F2F2F2
- fill at x 25.4, y 28.9, w 8.0, h 14.1: #F2F2F2
- fill at x 39.7, y 61.8, w 8.0, h 14.1: #F2F2F2
- fill at x 39.7, y 29.0, w 7.9, h 14.1: #F2F2F2
- fill at x 11.4, y 61.8, w 8.0, h 14.1: #F2F2F2
- fill at x 25.4, y 61.9, w 7.9, h 14.1: #F2F2F2
- fill at x 11.4, y 28.8, w 7.9, h 14.1: #F2F2F2
- image at x 4.0, y 20.7, w 51.1, h 5.4: 491 by 29 pixels
- image at x 59.4, y 20.7, w 36.2, h 5.4: 348 by 29 pixels
- image at x 25.4, y 28.9, w 8.0, h 14.1: 284 by 284 pixels
- image at x 39.7, y 61.8, w 8.0, h 14.1: 212 by 211 pixels
- image at x 11.4, y 61.9, w 7.9, h 14.1: 211 by 211 pixels
- image at x 25.4, y 61.9, w 7.9, h 14.1: 211 by 211 pixels
- image at x 84.9, y 28.8, w 7.9, h 14.1: 211 by 211 pixels
- image at x 59.7, y 28.8, w 7.9, h 14.1: 211 by 211 pixels
- image at x 72.1, y 28.8, w 7.9, h 14.1: 211 by 211 pixels
- image at x 84.7, y 61.8, w 7.9, h 14.1: 211 by 211 pixels
- image at x 72.1, y 61.8, w 7.9, h 14.1: 211 by 211 pixels
- image at x 59.7, y 61.8, w 7.9, h 14.1: 278 by 278 pixels
- image at x 39.7, y 29.0, w 7.9, h 14.1: 211 by 211 pixels
- image at x 11.4, y 28.8, w 7.9, h 14.1: 211 by 211 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- image at x 78.0, y 84.6, w 4.5, h 4.0: 121 by 60 pixels
- image at x 72.2, y 53.3, w 5.3, h 3.2: 139 by 48 pixels
- image at x 72.6, y 84.8, w 4.1, h 3.6: 109 by 54 pixels
- image at x 59.8, y 85.2, w 5.0, h 3.0: 133 by 44 pixels
- image at x 65.5, y 85.2, w 4.8, h 2.9: 127 by 43 pixels
- image at x 78.0, y 53.5, w 4.5, h 2.7: 119 by 40 pixels
- image at x 25.7, y 53.9, w 4.6, h 2.1: 122 by 31 pixels
- image at x 85.2, y 53.8, w 4.6, h 2.1: 122 by 31 pixels
- image at x 31.3, y 85.7, w 4.7, h 1.9: 124 by 27 pixels
- image at x 40.2, y 85.7, w 4.3, h 2.0: 113 by 29 pixels
- image at x 25.8, y 85.7, w 4.3, h 2.0: 113 by 29 pixels
- image at x 60.0, y 54.0, w 4.6, h 1.7: 122 by 25 pixels
- image at x 65.7, y 54.3, w 4.4, h 1.3: 116 by 18 pixels
- text at x 3.9, y 5.9, w 63.7, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Leadership Team and Board of Directors
- text at x 3.9, y 14.1, w 56.6, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: Decades of Industry Experience and Drug Development Expertise
- text at x 25.4, y 22.3, w 8.4, h 2.6 [Montserrat SemiBold; font size 2.60; #FFFFFF]: Leadership
- text at x 71.5, y 22.3, w 12.1, h 2.6 [Montserrat SemiBold; font size 2.60; #FFFFFF]: Board Members
- text at x 11.4, y 43.7, w 9.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Peter Anastasiou
- text at x 59.7, y 43.7, w 7.4, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Clare Ozawa,
- text at x 72.1, y 43.7, w 9.7, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Beth Seidenberg,
- text at x 84.9, y 43.7, w 10.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Viviana Gradinaru,
- text at x 25.4, y 43.9, w 10.4, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Nicholas Flytzanis,
- text at x 39.7, y 44.0, w 8.0, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Swati Tole, MD
- text at x 25.4, y 46.1, w 2.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: PhD
- text at x 59.7, y 45.9, w 2.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: PhD
- text at x 72.1, y 45.9, w 1.8, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: MD
- text at x 84.9, y 45.9, w 2.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: PhD
- text at x 11.4, y 45.9, w 10.8, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chief Executive Officer
- text at x 39.7, y 46.2, w 6.7, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chief Medical
- text at x 25.4, y 48.3, w 11.9, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Founder, Chief Research
- text at x 39.7, y 48.2, w 3.2, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Officer
- text at x 84.9, y 48.1, w 4.1, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Founder
- text at x 25.4, y 50.3, w 10.7, h 1.7 [Montserrat Medium; font size 1.67; #252524]: and Innovation Officer
- text at x 11.4, y 76.7, w 6.4, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Julie Hakim
- text at x 25.4, y 76.7, w 9.4, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Bethany Mancilla
- text at x 39.7, y 76.8, w 6.7, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Rob Murphy
- text at x 59.7, y 76.8, w 10.8, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Rita Balice-Gordon,
- text at x 72.1, y 76.8, w 8.1, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Frank Verwiel,
- text at x 84.8, y 76.8, w 9.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: Peter Anastasiou
- text at x 59.7, y 79.0, w 2.3, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: PhD
- text at x 72.1, y 79.0, w 1.8, h 1.8 [Montserrat,Bold; font size 1.84; #252524]: MD
- text at x 11.4, y 78.9, w 10.5, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chief Financial Officer
- text at x 25.4, y 78.9, w 10.6, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chief Business Officer
- text at x 39.7, y 79.0, w 10.1, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chief Manufacturing
- text at x 84.8, y 79.0, w 10.8, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chief Executive Officer
- text at x 39.7, y 81.0, w 8.9, h 1.7 [Montserrat Medium; font size 1.67; #252524]: and Quality Officer
- text at x 59.7, y 81.2, w 6.6, h 1.7 [Montserrat Medium; font size 1.67; #252524]: CEO, Muna Tx
- text at x 72.1, y 81.2, w 8.4, h 1.7 [Montserrat Medium; font size 1.67; #252524]: Chairman, Intellia
- text at x 94.8, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 30

### Slide 31

**Text**

>$300M Funding to Date
2019
2021
2023
2025
$50M Series A
CNS $90M
CNS $55M
Ophthalmology $70M
Contract manufacturing
$12M convertible note
AbbVie opt-in ($40M)
Potential additional milestones
Series B (TBD)
31

**Layout**

Title top-left. A horizontal timeline of four pill-shaped year labels at the same height (2019, 2021, 2023, 2025) joined by a thin teal line. Under each year is a left-aligned column of logo cards with captions. The 2025 column sits inside a large light-blue rounded panel on the right. A thin teal footer rule runs across the bottom, with a small logo at the bottom-left and the slide number at the bottom-right.

**Visuals**

Four gradient pill labels (blue to teal; the 2025 pill is a darker blue) on a thin teal horizontal line. White rounded-corner logo cards with light grey borders. 2019 column: Versant Ventures logo (grey-teal V mark with VERSANT ventures wordmark), Westlake BioPartners logo (blue wave mark with blue text). 2021 column: AbbVie logo (navy lowercase wordmark). 2023 column: Lilly logo (red script), AbbVie logo, KATE Therapeutics logo (green and grey chevron mark, dark KATE lettering, 'A Novartis Company' tagline), NEURO.VC logo (dark navy bold condensed text with a small box). 2025 column, inside a pale blue rounded rectangle with a teal outline: AbbVie logo, a second AbbVie logo, Lilly logo, and Capsida Biotherapeutics logo (blue CAPSIDA text with teal and green geometric mark). A small Capsida logo sits bottom-left in the footer. A thin teal line spans the full width above the footer.

**Design**

Background: Solid white #FFFFFF. White background. Title in Montserrat SemiBold, dark charcoal #252524, about 5.9% of slide height. Body captions in Montserrat Medium with bold amounts, black #000000, about 2.2% of slide height. Year labels in white Montserrat Bold, about 3% of slide height, on pill shapes with a gradient from blue #0088B8 to teal #00A99D. The 2025 pill has a darker blue gradient #2060A0 to #1A75BB. Teal connector line and footer rule about #00A9A0. The panel fill is #E5F8FF with a thin light-cyan outline and large rounded corners. Logo cards are white with thin grey borders and small corner radii. No shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 39.5, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: >$300M Funding to Date
- line at x 14.6, y 11.2, w 65, h 0.2 [#00A9A0]: Thin teal horizontal timeline line running behind the year pills from 2019 to 2025 (about 1px stroke)
- shape at x 74.9, y 20.2, w 19.6, h 66.6 [#E5F8FF]: Light-blue rounded rectangle panel behind the 2025 column (cyan outline, large corner radius)
- shape at x 3.9, y 17.4, w 10.8, h 5.9 [#0A8DBE]: Pill label 2019 (fully rounded ends, gradient blue to teal)
- shape at x 25, y 17.4, w 10.8, h 5.9 [#0A8DBE]: Pill label 2021 (fully rounded ends, gradient blue to teal)
- shape at x 46, y 17.4, w 10.8, h 5.9 [#00A99D]: Pill label 2023 (fully rounded ends, gradient blue to teal)
- shape at x 79.3, y 17.4, w 10.8, h 5.9 [#1F5FA0]: Pill label 2025 (fully rounded ends, darker blue gradient)
- title at x 7.4, y 19, w 3.8, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: 2019
- title at x 28.5, y 19, w 3.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: 2021
- title at x 49.5, y 19, w 4.1, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: 2023
- title at x 82.7, y 19, w 4.1, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; center aligned]: 2025
- logo at x 3.9, y 26.9, w 10.8, h 6.7 [#FFFFFF]: Versant Ventures logo card (white card with grey border; grey-teal V mark and VERSANT ventures wordmark)
- logo at x 3.9, y 34.6, w 10.8, h 6.7 [#FFFFFF]: Westlake BioPartners logo card (white card with grey border; blue wave W mark and Westlake BioPartners text)
- caption at x 3.9, y 43.2, w 9.4, h 2.2 [Montserrat Bold / Medium; font size 2.22% of slide height; #000000; left aligned]: $50M Series A ($50M bold, Series A medium)
- logo at x 25, y 27, w 10.8, h 6.7 [#FFFFFF]: AbbVie logo card (2021) (white card with grey border; navy abbvie wordmark)
- caption at x 25.6, y 34.8, w 6.6, h 2.2 [Montserrat Medium / Bold; font size 2.22% of slide height; #000000; left aligned]: CNS $90M ($90M bold)
- logo at x 46, y 27, w 10.8, h 6.7 [#FFFFFF]: Lilly logo card (2023) (white card with grey border; red script Lilly)
- caption at x 46.1, y 34.8, w 6.6, h 2.2 [Montserrat Medium / Bold; font size 2.22% of slide height; #000000; left aligned]: CNS $55M ($55M bold)
- logo at x 46, y 43.2, w 10.8, h 6.7 [#FFFFFF]: AbbVie logo card (2023) (white card with grey border; navy abbvie wordmark)
- caption at x 46.1, y 51.4, w 14, h 2.2 [Montserrat Medium / Bold; font size 2.22% of slide height; #000000; left aligned]: Ophthalmology $70M ($70M bold)
- logo at x 46, y 59.6, w 10.8, h 6.7 [#FFFFFF]: KATE Therapeutics logo card (white card with grey border; green and grey chevron mark, KATE THERAPEUTICS, A Novartis Company)
- caption at x 46.1, y 68, w 15.8, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Contract manufacturing
- logo at x 46, y 76.7, w 10.8, h 6.7 [#FFFFFF]: NEURO.VC logo card (white card with grey border; navy bold condensed NEURO.VC)
- caption at x 46.1, y 84.5, w 14, h 2.2 [Montserrat Bold / Medium; font size 2.22% of slide height; #000000; left aligned]: $12M convertible note ($12M bold)
- logo at x 78.1, y 27, w 10.7, h 6.7 [#FFFFFF]: AbbVie logo card (2025, top) (white card on light-blue panel; navy abbvie wordmark)
- caption at x 78.1, y 34.8, w 13.7, h 2.2 [Montserrat Medium / Bold; font size 2.22% of slide height; #000000; left aligned]: AbbVie opt-in ($40M) (($40M) bold)
- logo at x 78.1, y 41.6, w 10.7, h 6.7 [#FFFFFF]: AbbVie logo card (2025, second) (white card; navy abbvie wordmark)
- logo at x 78.1, y 49.5, w 10.7, h 6.7 [#FFFFFF]: Lilly logo card (2025) (white card stacked directly under the AbbVie card; red script Lilly)
- caption at x 78.4, y 57.7, w 12.9, h 5 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Potential additional / milestones (two lines)
- logo at x 78.1, y 68, w 10.7, h 6.7 [#FFFFFF]: Capsida Biotherapeutics logo card (white card; blue CAPSIDA text with teal and green geometric mark)
- caption at x 78.4, y 75.9, w 9.3, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #000000; left aligned]: Series B (TBD)
- line at x 0, y 93.3, w 100, h 0.4 [#00A9A0]: Thin teal footer rule across full width
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#1A9AC0]: Small Capsida Biotherapeutics logo in footer (blue text with teal and green mark)
- page number at x 95, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 31

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 74.9, y 20.2, w 19.6, h 66.6: #E5F8FF
- fill at x 78.1, y 27.0, w 10.7, h 6.7: #FFFFFF
- fill at x 78.1, y 68.0, w 10.7, h 6.7: #FFFFFF
- fill at x 78.1, y 41.6, w 10.7, h 6.7: #FFFFFF
- fill at x 78.1, y 49.5, w 10.7, h 6.7: #FFFFFF
- image at x 3.9, y 17.4, w 10.8, h 5.9: 104 by 32 pixels
- image at x 79.3, y 17.4, w 10.8, h 5.9: 104 by 32 pixels
- image at x 25.0, y 17.4, w 10.8, h 5.9: 104 by 32 pixels
- image at x 46.0, y 17.4, w 10.8, h 5.9: 104 by 32 pixels
- image at x 79.6, y 68.9, w 7.7, h 5.3: 204 by 79 pixels
- image at x 4.7, y 35.9, w 9.2, h 4.3: 246 by 64 pixels
- image at x 80.2, y 50.0, w 6.5, h 6.1: 172 by 91 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 48.2, y 27.7, w 6.1, h 5.8: 172 by 91 pixels
- image at x 4.5, y 28.6, w 9.6, h 3.5: 329 by 67 pixels
- image at x 26.3, y 28.7, w 9.2, h 3.3: 246 by 49 pixels
- image at x 46.9, y 45.3, w 9.2, h 3.3: 246 by 49 pixels
- image at x 78.8, y 28.7, w 9.2, h 3.3: 246 by 49 pixels
- image at x 78.8, y 43.3, w 9.2, h 3.3: 246 by 49 pixels
- image at x 47.7, y 78.7, w 7.0, h 3.4: 187 by 50 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 39.5, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: >$300M Funding to Date
- text at x 7.4, y 19.0, w 3.8, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: 2019
- text at x 28.5, y 19.0, w 3.7, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: 2021
- text at x 49.5, y 19.0, w 4.1, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: 2023
- text at x 82.7, y 19.0, w 4.1, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: 2025
- text at x 25.6, y 34.8, w 2.7, h 2.2 [Montserrat Medium; font size 2.22; #000000]: CNS
- text at x 28.6, y 34.8, w 3.6, h 2.2 [Montserrat,Bold; font size 2.22; #000000]: $90M
- text at x 46.1, y 34.8, w 2.7, h 2.2 [Montserrat Medium; font size 2.22; #000000]: CNS
- text at x 49.2, y 34.8, w 3.5, h 2.2 [Montserrat,Bold; font size 2.22; #000000]: $55M
- text at x 78.1, y 34.8, w 9.1, h 2.2 [Montserrat Medium; font size 2.22; #000000]: AbbVie opt-in
- text at x 87.2, y 34.8, w 4.6, h 2.2 [Montserrat,Bold; font size 2.22; #000000]: ($40M)
- text at x 3.9, y 43.2, w 4.0, h 2.2 [Montserrat,Bold; font size 2.22; #000000]: $50M
- text at x 7.9, y 43.2, w 5.4, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Series A
- text at x 46.1, y 51.4, w 10.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Ophthalmology
- text at x 56.5, y 51.4, w 3.6, h 2.2 [Montserrat,Bold; font size 2.22; #000000]: $70M
- text at x 78.4, y 57.7, w 12.9, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Potential additional
- text at x 78.4, y 60.3, w 7.0, h 2.2 [Montserrat Medium; font size 2.22; #000000]: milestones
- text at x 46.1, y 68.0, w 15.8, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Contract manufacturing
- text at x 78.4, y 75.9, w 9.3, h 2.2 [Montserrat Medium; font size 2.22; #000000]: Series B (TBD)
- text at x 46.1, y 84.5, w 3.6, h 2.2 [Montserrat,Bold; font size 2.22; #000000]: $12M
- text at x 49.7, y 84.5, w 10.4, h 2.2 [Montserrat Medium; font size 2.22; #000000]: convertible note
- text at x 95.0, y 95.8, w 0.8, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 31

### Slide 32

**Review notes**

- Review: Slide 32 repeats slide 3 almost exactly and the closing does not drive to a clear takeaway, while the decorative body-figure dividers (5, 12, 22, 26, 29) add little.
- What would change the score: Replace the duplicate slide 32 with a closing summary that states the key milestones to watch, and cut or shrink the divider slides that carry only a stock figure.

**Text**

Next-generation Genetic Medicines Company
Unlocking the full potential of gene therapy for all
Wholly-owned Pipeline
Fully-integrated Capabilities
External Validation
Two clinical programs in 2025
CAP-002: STXBP1-DEE
IND clearance
ODD granted
Fast Track granted
CAP-003: PD-GBA
IND clearance
Human POC in Q4
Third clinical program in 2026
CAP-004: Friedreich’s ataxia
» Capsid engineering
» Cargo optimization
» Clinical development
» In-house manufacturing
» Protected by expansive IP portfolio
Strategic partnerships
abbvie » 1st AbbVie opt-in ($40M) achieved
Contract manufacturing
>$300M funding to date, including $50M Series A
32

**Layout**

White slide with a large left-aligned title and teal subtitle at top. Three outlined columns with gradient header bars sit side by side below (left pipeline, middle capabilities, right external validation). A grey rounded funding bar with two investor logo boxes spans the lower area, a thin teal rule sits above the footer, with the company logo bottom left and page number bottom right.

**Visuals**

Three column cards with a thin teal outline and a blue-to-teal gradient header band. Left column holds three rounded pill shapes: blue (CAP-002) with three white check-circle icons, green (CAP-003) with one check-circle icon and a white bullet, and teal (CAP-004). Middle column has » chevron bullets. Right column has logo boxes with thin light-grey rounded borders: abbvie wordmark in dark blue with a » chevron beside it, Lilly red script logo, CRISPR Therapeutics black-framed logo, KATE Therapeutics (a Novartis company) logo with green/grey chevron mark. Bottom: Versant Ventures logo (teal V mark and grey text) and Westlake BioPartners logo (dark blue W mark, blue text) in white rounded boxes overlapping the right end of the grey bar. Thin teal horizontal line above the footer. Small Capsida Biotherapeutics logo bottom left.

**Design**

Background: Solid white #FFFFFF. White background. Title in near-black #252524 Montserrat SemiBold, about 6% of slide height. Subtitle teal-blue #006487 Montserrat SemiBold about 3%. Column headers white Montserrat Bold about 3% on a gradient from #0086B4 to #00A79D. Body text Montserrat Bold #252524 about 2.6%. Pill text white Montserrat, titles bold, about 2.2%. Pills fully rounded, colours #0086B4, #2BB673, #00A79D. Grey funding bar #EDEEEE with rounded left end. No shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- title at x 3.9, y 5.9, w 72.3, h 5.9 [Montserrat SemiBold; font size 5.93% of slide height; #252524; left aligned]: Next-generation Genetic Medicines Company
- subtitle at x 3.9, y 14.1, w 43, h 3 [Montserrat SemiBold; font size 2.96% of slide height; #006487; left aligned]: Unlocking the full potential of gene therapy for all
- shape at x 3.4, y 19.3, w 28, h 59.5 [#FFFFFF]: Left column card with thin teal outline and white fill (1px teal outline #00A79D)
- shape at x 34.4, y 19.3, w 27.9, h 59.5 [#FFFFFF]: Middle column card with thin teal outline and white fill (1px teal outline #00A79D)
- shape at x 64.6, y 19.3, w 31, h 59.5 [#FFFFFF]: Right column card with thin teal outline and white fill (1px teal outline #00A79D)
- shape at x 3.3, y 19.3, w 28.1, h 8.1 [#0086B4]: Gradient header band for Wholly-owned Pipeline (gradient blue to teal, rounded top-left corner)
- shape at x 34.4, y 19.3, w 27.9, h 8.1 [#0086B4]: Gradient header band for Fully-integrated Capabilities (gradient blue to teal, rounded top-left corner)
- shape at x 64.6, y 19.3, w 31, h 8.1 [#0086B4]: Gradient header band for External Validation (gradient blue to teal, rounded top-right corner)
- title at x 5.2, y 22.4, w 20.4, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Wholly-owned Pipeline
- title at x 36.2, y 22.4, w 24.9, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: Fully-integrated Capabilities
- title at x 66.4, y 22.4, w 16.7, h 3 [Montserrat Bold; font size 2.96% of slide height; #FFFFFF; left aligned]: External Validation
- body at x 6.1, y 28.4, w 22.7, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Two clinical programs in 2025
- shape at x 5.9, y 32.9, w 21.4, h 14.4 [#0086B4]: Blue rounded pill for CAP-002 (large corner radius)
- body at x 7.6, y 35.2, w 14.4, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: CAP-002: STXBP1-DEE
- icon at x 6.8, y 37.5, w 1.4, h 7.5 [#FFFFFF]: Three white check-circle icons beside the CAP-002 lines
- body at x 8.6, y 37.8, w 9.1, h 2.2 [Montserrat; font size 2.22% of slide height; #FFFFFF; left aligned]: IND clearance
- body at x 8.6, y 40.5, w 8.5, h 2.2 [Montserrat; font size 2.22% of slide height; #FFFFFF; left aligned]: ODD granted
- body at x 8.6, y 43.2, w 11.8, h 2.2 [Montserrat; font size 2.22% of slide height; #FFFFFF; left aligned]: Fast Track granted
- shape at x 5.9, y 49.5, w 21.4, h 10.6 [#2BB673]: Green rounded pill for CAP-003 (large corner radius)
- body at x 7.5, y 51.2, w 11.7, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: CAP-003: PD-GBA
- icon at x 7, y 53.7, w 1.4, h 2.2 [#FFFFFF]: White check-circle icon beside IND clearance
- body at x 8.9, y 53.9, w 8.8, h 2.2 [Montserrat; font size 2.22% of slide height; #FFFFFF; left aligned]: IND clearance
- body at x 7.5, y 56.5, w 0.4, h 2.2 [Arial; font size 2.22% of slide height; #FFFFFF; left aligned]: •
- body at x 8.9, y 56.5, w 11.7, h 2.2 [Montserrat; font size 2.22% of slide height; #FFFFFF; left aligned]: Human POC in Q4
- body at x 6.1, y 64.9, w 22.8, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Third clinical program in 2026
- shape at x 5.9, y 68.8, w 21.4, h 5.3 [#00A79D]: Teal rounded pill for CAP-004 (fully rounded ends)
- body at x 7.1, y 70.4, w 18.5, h 2.2 [Montserrat Bold; font size 2.22% of slide height; #FFFFFF; left aligned]: CAP-004: Friedreich’s ataxia
- bullet list at x 37.1, y 30.7, w 22, h 25.5 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: » Capsid engineering / » Cargo optimization / » Clinical development / » In-house manufacturing / » Protected by expansive IP / portfolio (» chevron bullets in regular weight; items spaced about 5% apart; last item wraps to two lines)
- body at x 66.4, y 30.7, w 17.1, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Strategic partnerships
- logo at x 67.4, y 37.4, w 8.8, h 3.1 [#1D2D8F]: abbvie wordmark in dark blue (inside white rounded box with thin grey border, x 66.4 y 35.4 w 27.3 h 7.0)
- icon at x 77.5, y 37.5, w 1.5, h 3 [#252524]: » chevron arrow
- body at x 80.2, y 36.6, w 11.1, h 4.6 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: 1st AbbVie opt-in / ($40M) achieved
- logo at x 68.9, y 49, w 5.9, h 5.5 [#D52B1E]: Lilly red script logo (inside white rounded box with thin grey border, about x 66.5 y 45.2 w 9.9 h 12.9)
- logo at x 86.1, y 46.2, w 5.2, h 10.1 [#000000]: CRISPR Therapeutics logo, black square frame with CRISPR text and THERAPEUTICS band (inside white rounded box with thin grey border, about x 83.8 y 44.7 w 9.9 h 12.9)
- line at x 66.4, y 59.5, w 27.3, h 0.1 [#D9D9D9]: Thin light grey divider
- body at x 66.4, y 62.4, w 18.6, h 2.6 [Montserrat Bold; font size 2.6% of slide height; #252524; left aligned]: Contract manufacturing
- logo at x 66.3, y 66, w 9.9, h 8 [#252524]: KATE Therapeutics, a Novartis company logo (green and grey chevron mark with KATE lettering, in white rounded box with thin grey border)
- shape at x 13.5, y 81.6, w 72.4, h 7.4 [#EDEEEE]: Grey funding bar (rounded left end)
- body at x 16.2, y 84, w 43.4, h 3 [Montserrat Bold; font size 2.96% of slide height; #252524; left aligned]: >$300M funding to date, including $50M Series A
- shape at x 61, y 81.4, w 12.4, h 7.8 [#FFFFFF]: White rounded box holding Versant logo (thin light border)
- logo at x 61.7, y 83.3, w 11.1, h 4 [#7A8A94]: VERSANT ventures logo with teal V mark
- shape at x 74.1, y 81.4, w 12.5, h 7.8 [#FFFFFF]: White rounded box holding Westlake logo (thin light border)
- logo at x 74.9, y 82.8, w 10.7, h 5 [#1B3A8A]: Westlake BioPartners logo with dark blue W mark
- line at x 0, y 93.3, w 100, h 0.4 [#00A79D]: Thin teal horizontal rule above footer, full width
- logo at x 4.2, y 94.7, w 5.2, h 3.6 [#00A79D]: Capsida Biotherapeutics logo with teal geometric mark
- page number at x 94.9, y 95.8, w 1, h 1.5 [Montserrat Medium; font size 1.49% of slide height; #252524; right aligned]: 32

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 13.5, y 81.6, w 72.4, h 7.4: #EDEEEE
- fill at x 61.0, y 81.4, w 12.4, h 7.8: #FFFFFF
- fill at x 74.1, y 81.4, w 12.5, h 7.8: #FFFFFF
- fill at x 5.9, y 32.9, w 21.4, h 14.4: #0086B4
- fill at x 5.9, y 68.8, w 21.4, h 5.3: #00A79D
- fill at x 5.9, y 49.5, w 21.4, h 10.6: #2BB673
- image at x 64.6, y 19.3, w 31.0, h 8.1: 298 by 44 pixels
- image at x 3.3, y 19.3, w 28.1, h 8.1: 270 by 44 pixels
- image at x 34.4, y 19.3, w 27.9, h 8.1: 268 by 44 pixels
- image at x 74.9, y 82.8, w 10.7, h 5.0: 286 by 75 pixels
- image at x 86.1, y 46.2, w 5.2, h 10.1: 138 by 151 pixels
- image at x 61.7, y 83.3, w 11.1, h 4.0: 329 by 67 pixels
- image at x 0.0, y 93.3, w 100.0, h 0.4: 960 by 2 pixels
- image at x 68.9, y 49.0, w 5.9, h 5.5: 157 by 81 pixels
- image at x 67.4, y 37.4, w 8.8, h 3.1: 246 by 49 pixels
- image at x 4.2, y 94.7, w 5.2, h 3.6: 137 by 53 pixels
- text at x 3.9, y 5.9, w 72.3, h 5.9 [Montserrat SemiBold; font size 5.93; #252524]: Next-generation Genetic Medicines Company
- text at x 3.9, y 14.1, w 43.0, h 3.0 [Montserrat SemiBold; font size 2.96; #006487]: Unlocking the full potential of gene therapy for all
- text at x 5.2, y 22.4, w 20.4, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Wholly-owned Pipeline
- text at x 36.2, y 22.4, w 24.9, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: Fully-integrated Capabilities
- text at x 66.4, y 22.4, w 16.7, h 3.0 [Montserrat,Bold; font size 2.96; #FFFFFF]: External Validation
- text at x 6.1, y 28.4, w 22.7, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Two clinical programs in 2025
- text at x 37.1, y 30.7, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 30.7, w 15.0, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Capsid engineering
- text at x 66.4, y 30.7, w 17.1, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Strategic partnerships
- text at x 37.1, y 35.7, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 35.7, w 14.7, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Cargo optimization
- text at x 37.1, y 40.7, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 40.7, w 16.3, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Clinical development
- text at x 7.6, y 35.2, w 14.4, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: CAP-002: STXBP1-DEE
- text at x 80.2, y 36.6, w 11.1, h 2.2 [Montserrat Medium; font size 2.22; #252524]: 1st AbbVie opt-in
- text at x 8.6, y 37.8, w 9.1, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: IND clearance
- text at x 37.1, y 45.8, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 45.8, w 19.0, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: In-house manufacturing
- text at x 80.2, y 39.0, w 10.6, h 2.2 [Montserrat Medium; font size 2.22; #252524]: ($40M) achieved
- text at x 8.6, y 40.5, w 8.5, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: ODD granted
- text at x 8.6, y 43.2, w 11.8, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: Fast Track granted
- text at x 37.1, y 50.8, w 0.7, h 2.6 [Montserrat; font size 2.60; #252524]: »
- text at x 38.6, y 50.8, w 20.4, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Protected by expansive IP
- text at x 38.6, y 53.6, w 6.6, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: portfolio
- text at x 7.5, y 51.2, w 11.7, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: CAP-003: PD-GBA
- text at x 7.5, y 53.9, w 0.4, h 2.2 [ArialMT; font size 2.22; #FFFFFF]: •
- text at x 8.9, y 53.9, w 8.8, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: IND clearance
- text at x 66.4, y 62.4, w 18.6, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Contract manufacturing
- text at x 6.1, y 64.9, w 22.8, h 2.6 [Montserrat,Bold; font size 2.60; #252524]: Third clinical program in 2026
- text at x 7.5, y 56.5, w 0.4, h 2.2 [ArialMT; font size 2.22; #FFFFFF]: •
- text at x 8.9, y 56.5, w 11.7, h 2.2 [Montserrat; font size 2.22; #FFFFFF]: Human POC in Q4
- text at x 16.2, y 84.0, w 43.4, h 3.0 [Montserrat,Bold; font size 2.96; #252524]: >$300M funding to date, including $50M Series A
- text at x 7.1, y 70.4, w 18.5, h 2.2 [Montserrat,Bold; font size 2.22; #FFFFFF]: CAP-004: Friedreich’s ataxia
- text at x 94.9, y 95.8, w 1.0, h 1.5 [Montserrat Medium; font size 1.49; #252524]: 32

### Slide 33

**Text**

Our Pipeline is Making the
Impossible Possible
info@capsida.com
1300 Rancho Conejo Blvd
Thousand Oaks, California
www.capsida.com

**Layout**

Left-aligned closing slide. Logo sits top-left, a two-line title is at left-middle, and a thin divider with three contact rows (icon plus text) is at lower left. A large DNA helix graphic fills the right side, bleeding off the top, right and bottom edges.

**Visuals**

Capsida Biotherapeutics logo at top left: 'CAPSIDA' in blue outlined geometric capitals, 'BIOTHERAPEUTICS' in grey letter-spaced capitals below it, and a blue-to-green faceted polyhedron/capsid shape with a small teal DNA strand curling over it. A large DNA double helix made of grey-blue dots (about #8FA9B8) spans the right 56% of the slide, running diagonally from top centre to bottom right, cropped at the edges. A thin light grey horizontal line runs across the lower left at about 70% of the slide height, ending at about 71% of the width. Three thin black outline icons: an envelope beside the email, a map pin beside the address, and a browser window with cursor beside the website.

**Design**

Background: Gradient from pale blue (#DCE9F7) at top left to white (#FFFFFF) toward the centre and right. Soft gradient background, pale blue at top left fading to white. Title line 1 is dark charcoal #252524 and line 2 is green #2BB673, both Montserrat SemiBold at about 7.4% of slide height. Contact text is Montserrat Medium, charcoal #252524, about 2.2% of slide height. Icons are thin line style. No shadows or rounded shapes.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- logo at x 4.2, y 7.6, w 21.8, h 15.4: Capsida Biotherapeutics logo: CAPSIDA wordmark, BIOTHERAPEUTICS, faceted blue-green polyhedron with DNA strand (Wordmark blue #0E80B0, subtext grey #7A8590, polyhedron gradient blue to green #2BB673)
- illustration at x 43.7, y 0, w 56.3, h 100 [#8FA9B8]: Large DNA double helix made of grey-blue dots, running diagonally and cropped by the top, right and bottom edges (Dotted rungs between two dotted strands, with two visible twists)
- line at x 0, y 69.7, w 71.5, h 0.1 [#D9DDE0]: Thin light grey horizontal divider (Hairline stroke about 1px)
- title at x 3.9, y 37.9, w 53.9, h 16.3 [Montserrat SemiBold; font size 7.4% of slide height; #252524; left aligned]: Our Pipeline is Making the / Impossible Possible (Line 1 charcoal #252524; line 2 'Impossible Possible' green #2BB673; line spacing about 1.35)
- icon at x 4.2, y 73.8, w 1.8, h 2.2 [#252524]: Envelope icon (Thin outline)
- body at x 7.2, y 73.8, w 11.7, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: info@capsida.com
- icon at x 4.2, y 79.8, w 1.6, h 3.4 [#252524]: Map pin icon (Thin outline)
- body at x 7.2, y 79.8, w 16.5, h 4.9 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: 1300 Rancho Conejo Blvd / Thousand Oaks, California
- icon at x 4.2, y 87.8, w 1.8, h 3.2 [#252524]: Browser window with cursor icon (Thin outline)
- body at x 7.2, y 88.5, w 11.7, h 2.2 [Montserrat Medium; font size 2.22% of slide height; #252524; left aligned]: www.capsida.com

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- image at x 0.0, y 0.0, w 100.0, h 100.0: 960 by 540 pixels (covers the slide)
- image at x 43.7, y 0.0, w 56.3, h 100.0: 899 by 897 pixels
- image at x 4.2, y 7.6, w 21.8, h 15.4: 600 by 239 pixels
- text at x 3.9, y 37.9, w 53.9, h 7.4 [Montserrat SemiBold; font size 7.40; #252524]: Our Pipeline is Making the
- text at x 3.9, y 46.8, w 39.6, h 7.4 [Montserrat SemiBold; font size 7.40; #2BB673]: ImpossiblePossible
- text at x 7.2, y 73.8, w 11.7, h 2.2 [Montserrat Medium; font size 2.22; #252524]: info@capsida.com
- text at x 7.2, y 79.8, w 16.4, h 2.2 [Montserrat Medium; font size 2.22; #252524]: 1300 Rancho Conejo Blvd
- text at x 7.2, y 82.5, w 16.5, h 2.2 [Montserrat Medium; font size 2.23; #252524]: Thousand Oaks, California
- text at x 7.2, y 88.5, w 11.7, h 2.2 [Montserrat Medium; font size 2.22; #252524]: www.capsida.com
